JP5744288B2 - キノキサリン誘導体 - Google Patents
キノキサリン誘導体 Download PDFInfo
- Publication number
- JP5744288B2 JP5744288B2 JP2014115951A JP2014115951A JP5744288B2 JP 5744288 B2 JP5744288 B2 JP 5744288B2 JP 2014115951 A JP2014115951 A JP 2014115951A JP 2014115951 A JP2014115951 A JP 2014115951A JP 5744288 B2 JP5744288 B2 JP 5744288B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- oxo
- dihydroimidazo
- quinoxaline
- cyclohexyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000001567 quinoxalinyl group Chemical class N1=C(C=NC2=CC=CC=C12)* 0.000 title claims 8
- 125000005843 halogen group Chemical group 0.000 claims description 93
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 61
- -1 quinoxalin-1-yl Chemical group 0.000 claims description 56
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 47
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 42
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 41
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 38
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 23
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 230000027939 micturition Effects 0.000 claims description 7
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims description 6
- 206010013990 dysuria Diseases 0.000 claims description 6
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 4
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- ZKGGCZGXEZKASH-ZZXKWVIFSA-N (e)-3-[4-oxo-7-(trifluoromethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]prop-2-enoic acid Chemical compound C1=C(C(F)(F)F)C=C2NC(=O)C3=CC=C(/C=C/C(=O)O)N3C2=C1 ZKGGCZGXEZKASH-ZZXKWVIFSA-N 0.000 claims description 3
- RTNMQAHLXOOBDK-UHFFFAOYSA-N 2-methyl-3-[4-oxo-7-(trifluoromethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound C1=C(C(F)(F)F)C=C2NC(=O)C3=CC=C(CC(C)C(O)=O)N3C2=C1 RTNMQAHLXOOBDK-UHFFFAOYSA-N 0.000 claims description 3
- YBSQAHXPNXLNJY-UHFFFAOYSA-N 3-[2-methyl-4-oxo-7-(trifluoromethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound C1=C(C(F)(F)F)C=C2NC(=O)C3=CC(C)=C(CCC(O)=O)N3C2=C1 YBSQAHXPNXLNJY-UHFFFAOYSA-N 0.000 claims description 3
- ZFYOIMAIQWMZNM-UHFFFAOYSA-N 3-[4-oxo-7-(trifluoromethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound C1=C(C(F)(F)F)C=C2NC(=O)C3=CC=C(CCC(=O)O)N3C2=C1 ZFYOIMAIQWMZNM-UHFFFAOYSA-N 0.000 claims description 3
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 3
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 3
- 229940076380 PDE9 inhibitor Drugs 0.000 claims description 3
- 206010046543 Urinary incontinence Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- RVEJWGYZBXCGGM-DNVCBOLYSA-N chembl2179094 Chemical compound C([C@H]([C@@H](C1)C=2NC(=O)C=3C=NN(C=3N=2)C2CCOCC2)C)N1CC1=CC=CC=C1 RVEJWGYZBXCGGM-DNVCBOLYSA-N 0.000 claims description 3
- 208000020629 overactive bladder Diseases 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims description 2
- 206010029279 Neurogenic bladder Diseases 0.000 claims description 2
- 208000009911 Urinary Calculi Diseases 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 409
- 238000005160 1H NMR spectroscopy Methods 0.000 description 312
- 238000004519 manufacturing process Methods 0.000 description 280
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 120
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 80
- 239000000203 mixture Substances 0.000 description 59
- 239000000243 solution Substances 0.000 description 56
- 239000002904 solvent Substances 0.000 description 56
- 125000003277 amino group Chemical group 0.000 description 53
- 125000002837 carbocyclic group Chemical group 0.000 description 53
- 125000000623 heterocyclic group Chemical group 0.000 description 53
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 51
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 50
- 239000002585 base Substances 0.000 description 50
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- 238000006243 chemical reaction Methods 0.000 description 39
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 39
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 38
- 125000002252 acyl group Chemical group 0.000 description 38
- 125000003368 amide group Chemical group 0.000 description 38
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 37
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- 238000000034 method Methods 0.000 description 33
- 238000010992 reflux Methods 0.000 description 33
- 238000001914 filtration Methods 0.000 description 30
- 239000012044 organic layer Substances 0.000 description 30
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 29
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 28
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 26
- 230000002401 inhibitory effect Effects 0.000 description 26
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 239000013078 crystal Substances 0.000 description 24
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 24
- 235000019341 magnesium sulphate Nutrition 0.000 description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- UOOUOMSISGMWDC-UHFFFAOYSA-N 1-cyclohexyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxylic acid Chemical compound N12C3=CC(C(=O)O)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 UOOUOMSISGMWDC-UHFFFAOYSA-N 0.000 description 23
- 230000002829 reductive effect Effects 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000012299 nitrogen atmosphere Substances 0.000 description 21
- OZPARFAOVUKJKX-UHFFFAOYSA-N 8-chloro-1-cyclohexyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxylic acid Chemical compound N12C=3C=C(Cl)C(C(=O)O)=CC=3NC(=O)C2=CN=C1C1CCCCC1 OZPARFAOVUKJKX-UHFFFAOYSA-N 0.000 description 19
- 238000001035 drying Methods 0.000 description 19
- 239000011541 reaction mixture Substances 0.000 description 19
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 18
- 125000004043 oxo group Chemical group O=* 0.000 description 18
- 125000001424 substituent group Chemical group 0.000 description 18
- 235000002639 sodium chloride Nutrition 0.000 description 17
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
- 235000019441 ethanol Nutrition 0.000 description 16
- UIZFRJXCOYRCKT-UHFFFAOYSA-N 8-chloro-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxylic acid Chemical compound ClC1=C(C(O)=O)C=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 UIZFRJXCOYRCKT-UHFFFAOYSA-N 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 235000011054 acetic acid Nutrition 0.000 description 15
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- FKRCODPIKNYEAC-UHFFFAOYSA-N propionic acid ethyl ester Natural products CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- 238000010438 heat treatment Methods 0.000 description 13
- 229910000027 potassium carbonate Inorganic materials 0.000 description 13
- 235000017557 sodium bicarbonate Nutrition 0.000 description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 13
- YWVMWOAJAYEWEU-UHFFFAOYSA-N 1-cyclohexyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxylic acid Chemical compound C=1C(C(=O)O)=CC=C(N23)C=1NC(=O)C3=CN=C2C1CCCCC1 YWVMWOAJAYEWEU-UHFFFAOYSA-N 0.000 description 12
- SHKDGDDHUKQFOP-UHFFFAOYSA-N 8-methoxy-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxylic acid Chemical compound COC1=C(C(O)=O)C=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 SHKDGDDHUKQFOP-UHFFFAOYSA-N 0.000 description 12
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- KYGSMOZMYHBDBV-UHFFFAOYSA-N 4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 KYGSMOZMYHBDBV-UHFFFAOYSA-N 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 10
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 9
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 9
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 9
- 235000019345 sodium thiosulphate Nutrition 0.000 description 9
- QOROFIYAFQSVLX-UHFFFAOYSA-N 1-cyclohexyl-8-methoxy-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxylic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(N23)=C1NC(=O)C3=CN=C2C1CCCCC1 QOROFIYAFQSVLX-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 150000003252 quinoxalines Chemical class 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 210000003932 urinary bladder Anatomy 0.000 description 8
- 238000009423 ventilation Methods 0.000 description 8
- QXQMLFRQWFJGAA-UHFFFAOYSA-N 1-cyclopentyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxylic acid Chemical compound N12C3=CC(C(=O)O)=CC=C3NC(=O)C2=CN=C1C1CCCC1 QXQMLFRQWFJGAA-UHFFFAOYSA-N 0.000 description 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 206010046555 Urinary retention Diseases 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 5
- HKESOTAQVZHJQQ-UHFFFAOYSA-N C1=NN=C2N1C1=CC(=CC=C1N=C2)C(=O)N Chemical compound C1=NN=C2N1C1=CC(=CC=C1N=C2)C(=O)N HKESOTAQVZHJQQ-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 150000001408 amides Chemical group 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- KQIXNQRMDCPWIH-UHFFFAOYSA-N ethyl 3-(1h-imidazol-2-yl)propanoate Chemical compound CCOC(=O)CCC1=NC=CN1 KQIXNQRMDCPWIH-UHFFFAOYSA-N 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 238000007363 ring formation reaction Methods 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- AAVLNFKHCHLSHO-UHFFFAOYSA-N 3-(7-butyl-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl)propanoic acid Chemical compound N1C(=O)C2=CC=C(CCC(O)=O)N2C2=CC=C(CCCC)C=C21 AAVLNFKHCHLSHO-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 4
- YTGLEVHXHYUPMX-UHFFFAOYSA-N 7-chloro-1-cyclohexyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxylic acid Chemical compound C1=C(Cl)C(C(=O)O)=CC(N23)=C1NC(=O)C3=CN=C2C1CCCCC1 YTGLEVHXHYUPMX-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 208000028938 Urination disease Diseases 0.000 description 4
- OSRCHTRPIOGYBD-UHFFFAOYSA-N [1,2,4]triazolo[4,3-a]quinoxaline-7-carboxamide Chemical compound C1=NN=C2N1C1=CC=C(C=C1N=C2)C(=O)N OSRCHTRPIOGYBD-UHFFFAOYSA-N 0.000 description 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 4
- 230000003222 cGMP degradation Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000036724 intravesical pressure Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 4
- 230000036453 micturition reflex Effects 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000011514 reflex Effects 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- SKFGUXVUAAICSR-VQHVLOKHSA-N (e)-3-(1-cyclohexyl-4-oxo-5h-imidazo[1,5-a]quinoxalin-8-yl)prop-2-enoic acid Chemical compound N12C3=CC(/C=C/C(=O)O)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 SKFGUXVUAAICSR-VQHVLOKHSA-N 0.000 description 3
- 0 *c1c[n]c(*)n1 Chemical compound *c1c[n]c(*)n1 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- CAWGDJHLJNLXPX-UHFFFAOYSA-N 1-(4-fluoro-2-methoxy-5-nitrophenyl)ethanone Chemical compound COC1=CC(F)=C([N+]([O-])=O)C=C1C(C)=O CAWGDJHLJNLXPX-UHFFFAOYSA-N 0.000 description 3
- YULNFTGJDWYLKN-UHFFFAOYSA-N 1-[4-(2-cyclohexylimidazol-1-yl)-3-nitrophenyl]sulfonyl-4-methylpiperazine Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(N2C(=NC=C2)C2CCCCC2)C([N+]([O-])=O)=C1 YULNFTGJDWYLKN-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 3
- XSJMOLCRLLDSFM-UHFFFAOYSA-N 2h-triazolo[4,5-f]quinoxaline Chemical group C1=CC2=NC=CN=C2C2=NNN=C21 XSJMOLCRLLDSFM-UHFFFAOYSA-N 0.000 description 3
- GACKISMLQFHXIC-UHFFFAOYSA-N 3-(1-cyclohexyl-4-oxo-5h-imidazo[1,5-a]quinoxalin-8-yl)propanoic acid Chemical compound N12C3=CC(CCC(=O)O)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 GACKISMLQFHXIC-UHFFFAOYSA-N 0.000 description 3
- WVZBIQSKLXJFNX-UHFFFAOYSA-N 3-fluoro-4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C(F)=C1 WVZBIQSKLXJFNX-UHFFFAOYSA-N 0.000 description 3
- PQSKYDJMEQKGIB-UHFFFAOYSA-N 5-chloro-2-(2-propan-2-ylimidazol-1-yl)aniline Chemical compound CC(C)C1=NC=CN1C1=CC=C(Cl)C=C1N PQSKYDJMEQKGIB-UHFFFAOYSA-N 0.000 description 3
- VFKOYLVNOIWIIU-UHFFFAOYSA-N 7-bromo-1-cyclohexyl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C=1C(Br)=CC=C(N23)C=1NC(=O)C3=CN=C2C1CCCCC1 VFKOYLVNOIWIIU-UHFFFAOYSA-N 0.000 description 3
- 101100296723 Homo sapiens PDE5A gene Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 3
- NBKSUTBGLQKBDH-UHFFFAOYSA-N ethyl 1-cyclohexyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxylate Chemical compound N12C3=CC(C(=O)OCC)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 NBKSUTBGLQKBDH-UHFFFAOYSA-N 0.000 description 3
- JURJVRQMADFNEZ-UHFFFAOYSA-N ethyl 2-chloro-5-(2-cyclohexylimidazol-1-yl)-4-nitrobenzoate Chemical compound C1=C(Cl)C(C(=O)OCC)=CC(N2C(=NC=C2)C2CCCCC2)=C1[N+]([O-])=O JURJVRQMADFNEZ-UHFFFAOYSA-N 0.000 description 3
- COCQUMPOGYMNLS-UHFFFAOYSA-N ethyl 2-ethoxy-4-fluoro-5-nitrobenzoate Chemical compound CCOC(=O)C1=CC([N+]([O-])=O)=C(F)C=C1OCC COCQUMPOGYMNLS-UHFFFAOYSA-N 0.000 description 3
- YKBLPWTXJMSWRI-UHFFFAOYSA-N ethyl 3-(7-chloro-4-oxo-5h-imidazo[1,5-a]quinoxalin-1-yl)propanoate Chemical compound C1=C(Cl)C=C2NC(=O)C3=CN=C(CCC(=O)OCC)N3C2=C1 YKBLPWTXJMSWRI-UHFFFAOYSA-N 0.000 description 3
- CTNJNPNYQDRWBY-BQYQJAHWSA-N ethyl 5-[(e)-3-ethoxy-3-oxoprop-1-enyl]-3,4-dimethyl-1h-pyrrole-2-carboxylate Chemical compound CCOC(=O)\C=C\C=1NC(C(=O)OCC)=C(C)C=1C CTNJNPNYQDRWBY-BQYQJAHWSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000003708 urethra Anatomy 0.000 description 3
- 239000011345 viscous material Substances 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 2
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 2
- ZKSQQGYKAKTIEX-UHFFFAOYSA-N 1-(3-chlorophenyl)-n,n-dimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C=1C(C(=O)N(C)C)=CC=C(N23)C=1NC(=O)C3=CN=C2C1=CC=CC(Cl)=C1 ZKSQQGYKAKTIEX-UHFFFAOYSA-N 0.000 description 2
- RPYDEHMYZANZPV-UHFFFAOYSA-N 1-(4-bromo-2-nitrophenyl)-2-cyclohexylimidazole Chemical compound [O-][N+](=O)C1=CC(Br)=CC=C1N1C(C2CCCCC2)=NC=C1 RPYDEHMYZANZPV-UHFFFAOYSA-N 0.000 description 2
- DXLJNSYKBPAHRR-UHFFFAOYSA-N 1-(4-chloro-2-nitrophenyl)-2-propan-2-ylimidazole Chemical compound CC(C)C1=NC=CN1C1=CC=C(Cl)C=C1[N+]([O-])=O DXLJNSYKBPAHRR-UHFFFAOYSA-N 0.000 description 2
- QVLBUTWRIIGYFT-UHFFFAOYSA-N 1-(4-chloro-3-nitrophenyl)sulfonyl-4-methylpiperazine Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 QVLBUTWRIIGYFT-UHFFFAOYSA-N 0.000 description 2
- GRSYFWUXYHQMRT-UHFFFAOYSA-N 1-(oxan-4-yl)-7-(trifluoromethyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C=1C(C(F)(F)F)=CC=C(N23)C=1NC(=O)C3=CN=C2C1CCOCC1 GRSYFWUXYHQMRT-UHFFFAOYSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- NDAGFWXBRLFNOP-UHFFFAOYSA-N 1-[2-nitro-4-(trifluoromethyl)phenyl]-2-(oxan-4-yl)imidazole Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC=C1N1C(C2CCOCC2)=NC=C1 NDAGFWXBRLFNOP-UHFFFAOYSA-N 0.000 description 2
- JZWQTCGBHDFHDO-UHFFFAOYSA-N 1-[4-(2-cyclohexylimidazol-1-yl)-2-methoxy-5-nitrophenyl]ethanone Chemical compound C1=C(C(C)=O)C(OC)=CC(N2C(=NC=C2)C2CCCCC2)=C1[N+]([O-])=O JZWQTCGBHDFHDO-UHFFFAOYSA-N 0.000 description 2
- OGCUJTWWKSLJFU-UHFFFAOYSA-N 1-[5-amino-4-(2-cyclohexylimidazol-1-yl)-2-methoxyphenyl]ethanone Chemical compound C1=C(C(C)=O)C(OC)=CC(N2C(=NC=C2)C2CCCCC2)=C1N OGCUJTWWKSLJFU-UHFFFAOYSA-N 0.000 description 2
- VMRJILGKBJGBMY-UHFFFAOYSA-N 1-cyclohexyl-3-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxylic acid Chemical compound O=C1NC2=CC=C(C(O)=O)C=C2N2C1=C(C)N=C2C1CCCCC1 VMRJILGKBJGBMY-UHFFFAOYSA-N 0.000 description 2
- DICNEZNOLPBYMA-UHFFFAOYSA-N 1-cyclohexyl-7-(4-methylpiperazin-1-yl)sulfonyl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C2N3C(C4CCCCC4)=NC=C3C(=O)NC2=C1 DICNEZNOLPBYMA-UHFFFAOYSA-N 0.000 description 2
- XSRDXHWWRPRQRA-UHFFFAOYSA-N 1-cyclohexyl-8-[3-(4-methylpiperazin-1-yl)-3-oxopropyl]-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C1CN(C)CCN1C(=O)CCC1=CC=C(NC(=O)C=2N3C(C4CCCCC4)=NC=2)C3=C1 XSRDXHWWRPRQRA-UHFFFAOYSA-N 0.000 description 2
- WHTHTOGKCBRFBR-UHFFFAOYSA-N 1-cyclohexyl-8-ethoxy-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxylic acid Chemical compound C1=C(C(O)=O)C(OCC)=CC(N23)=C1NC(=O)C3=CN=C2C1CCCCC1 WHTHTOGKCBRFBR-UHFFFAOYSA-N 0.000 description 2
- CUYHZHLYZSFTTP-UHFFFAOYSA-N 1-cyclohexyl-8-methoxy-3-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxylic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(N23)=C1NC(=O)C3=C(C)N=C2C1CCCCC1 CUYHZHLYZSFTTP-UHFFFAOYSA-N 0.000 description 2
- JUVPQJQEAOEDHR-UHFFFAOYSA-N 1-cyclohexyl-n-methoxy-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)OC)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 JUVPQJQEAOEDHR-UHFFFAOYSA-N 0.000 description 2
- HLDFCCHSOZWKAA-UHFFFAOYSA-N 1-fluoro-2-nitro-4-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC=C1F HLDFCCHSOZWKAA-UHFFFAOYSA-N 0.000 description 2
- WJBMLCIHWQXTLL-UHFFFAOYSA-N 1-heptan-4-yl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC(=O)C3=CN=C(C(CCC)CCC)N3C2=C1 WJBMLCIHWQXTLL-UHFFFAOYSA-N 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- NIGTUNKTXWXZGJ-UHFFFAOYSA-N 2-(2-cyclohexylimidazol-1-yl)-5-(4-methylpiperazin-1-yl)sulfonylaniline Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(N2C(=NC=C2)C2CCCCC2)C(N)=C1 NIGTUNKTXWXZGJ-UHFFFAOYSA-N 0.000 description 2
- TVMWYYYSKTWBPB-UHFFFAOYSA-N 2-(oxan-4-yl)-1h-imidazole Chemical compound C1COCCC1C1=NC=CN1 TVMWYYYSKTWBPB-UHFFFAOYSA-N 0.000 description 2
- UUWSBBSXIXWLNG-UHFFFAOYSA-N 2-[2-(oxan-4-yl)imidazol-1-yl]-5-(trifluoromethyl)aniline Chemical compound NC1=CC(C(F)(F)F)=CC=C1N1C(C2CCOCC2)=NC=C1 UUWSBBSXIXWLNG-UHFFFAOYSA-N 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- LNOAAKNOHISOTF-UHFFFAOYSA-N 2-chloro-n,n-dimethyl-5-nitro-4-(2-pentan-3-ylimidazol-1-yl)benzamide Chemical compound CCC(CC)C1=NC=CN1C1=CC(Cl)=C(C(=O)N(C)C)C=C1[N+]([O-])=O LNOAAKNOHISOTF-UHFFFAOYSA-N 0.000 description 2
- UHMINCSUEKRNKZ-UHFFFAOYSA-N 2-cyclohexyl-1h-imidazole Chemical compound C1CCCCC1C1=NC=CN1 UHMINCSUEKRNKZ-UHFFFAOYSA-N 0.000 description 2
- JJKMBDMBSITAQQ-UHFFFAOYSA-N 2-heptan-4-yl-1h-imidazole Chemical compound CCCC(CCC)C1=NC=CN1 JJKMBDMBSITAQQ-UHFFFAOYSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- FUOZJYASZOSONT-UHFFFAOYSA-N 2-propan-2-yl-1h-imidazole Chemical compound CC(C)C1=NC=CN1 FUOZJYASZOSONT-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- LCRYNZVBZZAJCE-UHFFFAOYSA-N 2-thiophen-3-yl-1h-imidazole Chemical compound C1=CNC(C2=CSC=C2)=N1 LCRYNZVBZZAJCE-UHFFFAOYSA-N 0.000 description 2
- UKMGAUCQNCOYDV-UHFFFAOYSA-N 3-(1h-imidazol-2-yl)-2-methylpyridine Chemical compound CC1=NC=CC=C1C1=NC=CN1 UKMGAUCQNCOYDV-UHFFFAOYSA-N 0.000 description 2
- GHGMZSMOUCZMLV-UHFFFAOYSA-N 3-(2-cyclohexylimidazol-1-yl)-n-(2-ethoxyethyl)-4-nitrobenzamide Chemical compound CCOCCNC(=O)C1=CC=C([N+]([O-])=O)C(N2C(=NC=C2)C2CCCCC2)=C1 GHGMZSMOUCZMLV-UHFFFAOYSA-N 0.000 description 2
- ZUQINNTVXRQTIM-UHFFFAOYSA-N 3-(2-cyclohexylimidazol-1-yl)-n-(2-ethoxyethyl)-n-methyl-4-nitrobenzamide Chemical compound CCOCCN(C)C(=O)C1=CC=C([N+]([O-])=O)C(N2C(=NC=C2)C2CCCCC2)=C1 ZUQINNTVXRQTIM-UHFFFAOYSA-N 0.000 description 2
- GBFIVVGIFGCTRY-UHFFFAOYSA-N 3-(2-cyclohexylimidazol-1-yl)-n-(3-methoxypropyl)-4-nitrobenzamide Chemical compound COCCCNC(=O)C1=CC=C([N+]([O-])=O)C(N2C(=NC=C2)C2CCCCC2)=C1 GBFIVVGIFGCTRY-UHFFFAOYSA-N 0.000 description 2
- PINGSSALMBKYBU-UHFFFAOYSA-N 3-(2-cyclohexylimidazol-1-yl)-n-(3-methoxypropyl)-n-methyl-4-nitrobenzamide Chemical compound COCCCN(C)C(=O)C1=CC=C([N+]([O-])=O)C(N2C(=NC=C2)C2CCCCC2)=C1 PINGSSALMBKYBU-UHFFFAOYSA-N 0.000 description 2
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 2
- QDXBEFCQYDXNNK-UHFFFAOYSA-N 3-(7-chloro-2-methyl-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl)propanoic acid Chemical compound C1=C(Cl)C=C2NC(=O)C3=CC(C)=C(CCC(O)=O)N3C2=C1 QDXBEFCQYDXNNK-UHFFFAOYSA-N 0.000 description 2
- BDTIGLRWPUTGJJ-UHFFFAOYSA-N 3-amino-4-(2-cyclohexylimidazol-1-yl)-n,n-dimethylbenzamide Chemical compound NC1=CC(C(=O)N(C)C)=CC=C1N1C(C2CCCCC2)=NC=C1 BDTIGLRWPUTGJJ-UHFFFAOYSA-N 0.000 description 2
- IISKSSDXUBGKKZ-UHFFFAOYSA-N 3-amino-4-(2-cyclohexylimidazol-1-yl)-n,n-dimethylbenzenesulfonamide Chemical compound NC1=CC(S(=O)(=O)N(C)C)=CC=C1N1C(C2CCCCC2)=NC=C1 IISKSSDXUBGKKZ-UHFFFAOYSA-N 0.000 description 2
- OUYQGNFKVPZCLQ-UHFFFAOYSA-N 3-amino-4-(2-cyclohexylimidazol-1-yl)-n-[2-(dimethylamino)ethyl]-n-methylbenzenesulfonamide Chemical compound NC1=CC(S(=O)(=O)N(C)CCN(C)C)=CC=C1N1C(C2CCCCC2)=NC=C1 OUYQGNFKVPZCLQ-UHFFFAOYSA-N 0.000 description 2
- SQYURKANCGWINP-UHFFFAOYSA-N 3-amino-4-(2-cyclohexylimidazol-1-yl)benzonitrile Chemical compound NC1=CC(C#N)=CC=C1N1C(C2CCCCC2)=NC=C1 SQYURKANCGWINP-UHFFFAOYSA-N 0.000 description 2
- UPQCCMXNTYRZLR-UHFFFAOYSA-N 3-amino-4-[2-(3-chlorophenyl)imidazol-1-yl]-n,n-dimethylbenzamide Chemical compound NC1=CC(C(=O)N(C)C)=CC=C1N1C(C=2C=C(Cl)C=CC=2)=NC=C1 UPQCCMXNTYRZLR-UHFFFAOYSA-N 0.000 description 2
- NONILZFZFQGFAX-UHFFFAOYSA-N 3-amino-n,n-dimethyl-4-(2-pentan-3-ylimidazol-1-yl)benzamide Chemical compound CCC(CC)C1=NC=CN1C1=CC=C(C(=O)N(C)C)C=C1N NONILZFZFQGFAX-UHFFFAOYSA-N 0.000 description 2
- LJWSNXGTJMLMAK-UHFFFAOYSA-N 3-amino-n,n-dimethyl-4-(2-thiophen-3-ylimidazol-1-yl)benzamide Chemical compound NC1=CC(C(=O)N(C)C)=CC=C1N1C(C2=CSC=C2)=NC=C1 LJWSNXGTJMLMAK-UHFFFAOYSA-N 0.000 description 2
- ZUXBMDVSUPYQSM-UHFFFAOYSA-N 3-fluoro-4-nitro-n-(pyridin-3-ylmethyl)benzamide Chemical compound C1=C(F)C([N+](=O)[O-])=CC=C1C(=O)NCC1=CC=CN=C1 ZUXBMDVSUPYQSM-UHFFFAOYSA-N 0.000 description 2
- WSVJEBYZLNXQIC-UHFFFAOYSA-N 3-fluoro-n-(3-methoxypropyl)-4-nitrobenzamide Chemical compound COCCCNC(=O)C1=CC=C([N+]([O-])=O)C(F)=C1 WSVJEBYZLNXQIC-UHFFFAOYSA-N 0.000 description 2
- YELMWJNXDALKFE-UHFFFAOYSA-N 3h-imidazo[4,5-f]quinoxaline Chemical group N1=CC=NC2=C(NC=N3)C3=CC=C21 YELMWJNXDALKFE-UHFFFAOYSA-N 0.000 description 2
- CLWBCZMVHTZDCW-UHFFFAOYSA-N 4-(2-cyclohexylimidazol-1-yl)-3-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC(C#N)=CC=C1N1C(C2CCCCC2)=NC=C1 CLWBCZMVHTZDCW-UHFFFAOYSA-N 0.000 description 2
- SVYZCBSDXDPVAG-UHFFFAOYSA-N 4-(2-cyclohexylimidazol-1-yl)-n,n-dimethyl-3-nitrobenzamide Chemical compound [O-][N+](=O)C1=CC(C(=O)N(C)C)=CC=C1N1C(C2CCCCC2)=NC=C1 SVYZCBSDXDPVAG-UHFFFAOYSA-N 0.000 description 2
- REMSROKSQAXZMT-UHFFFAOYSA-N 4-(2-cyclohexylimidazol-1-yl)-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)N(C)C)=CC=C1N1C(C2CCCCC2)=NC=C1 REMSROKSQAXZMT-UHFFFAOYSA-N 0.000 description 2
- DQSJZXGNMRPKFN-UHFFFAOYSA-N 4-(2-cyclohexylimidazol-1-yl)-n-[2-(dimethylamino)ethyl]-n-methyl-3-nitrobenzenesulfonamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)N(C)CCN(C)C)=CC=C1N1C(C2CCCCC2)=NC=C1 DQSJZXGNMRPKFN-UHFFFAOYSA-N 0.000 description 2
- HPZLXYZQFYEHRN-UHFFFAOYSA-N 4-[2-(3-chlorophenyl)imidazol-1-yl]-n,n-dimethyl-3-nitrobenzamide Chemical compound [O-][N+](=O)C1=CC(C(=O)N(C)C)=CC=C1N1C(C=2C=C(Cl)C=CC=2)=NC=C1 HPZLXYZQFYEHRN-UHFFFAOYSA-N 0.000 description 2
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 2
- FUYPUWCYBWUNCJ-UHFFFAOYSA-N 4-[4-oxo-7-(trifluoromethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]butanoic acid Chemical compound C1=C(C(F)(F)F)C=C2NC(=O)C3=CC=C(CCCC(=O)O)N3C2=C1 FUYPUWCYBWUNCJ-UHFFFAOYSA-N 0.000 description 2
- MAZBZHWFKFWJSH-UHFFFAOYSA-N 4-amino-3-(2-cyclohexylimidazol-1-yl)-n-(2-ethoxyethyl)-n-methylbenzamide Chemical compound CCOCCN(C)C(=O)C1=CC=C(N)C(N2C(=NC=C2)C2CCCCC2)=C1 MAZBZHWFKFWJSH-UHFFFAOYSA-N 0.000 description 2
- JFRUJNBHWWIGQB-UHFFFAOYSA-N 4-amino-3-(2-cyclohexylimidazol-1-yl)-n-(3-methoxypropyl)-n-methylbenzamide Chemical compound COCCCN(C)C(=O)C1=CC=C(N)C(N2C(=NC=C2)C2CCCCC2)=C1 JFRUJNBHWWIGQB-UHFFFAOYSA-N 0.000 description 2
- DIAWBHLTWNWYGR-UHFFFAOYSA-N 4-chloro-1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC=C1F DIAWBHLTWNWYGR-UHFFFAOYSA-N 0.000 description 2
- ZPSIPYXUASFMTQ-UHFFFAOYSA-N 4-fluoro-n,n-dimethyl-3-nitrobenzamide Chemical compound CN(C)C(=O)C1=CC=C(F)C([N+]([O-])=O)=C1 ZPSIPYXUASFMTQ-UHFFFAOYSA-N 0.000 description 2
- BXGFYTFNNROIAB-UHFFFAOYSA-N 4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 BXGFYTFNNROIAB-UHFFFAOYSA-N 0.000 description 2
- AFPGCZUGIYQXQJ-UHFFFAOYSA-N 4-oxo-1-propan-2-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2NC(=O)C3=CN=C(C(C)C)N3C2=C1 AFPGCZUGIYQXQJ-UHFFFAOYSA-N 0.000 description 2
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 2
- DHQSWNCNZWINTK-UHFFFAOYSA-N 5-amino-2-chloro-n,n-dimethyl-4-(2-pentan-3-ylimidazol-1-yl)benzamide Chemical compound CCC(CC)C1=NC=CN1C1=CC(Cl)=C(C(=O)N(C)C)C=C1N DHQSWNCNZWINTK-UHFFFAOYSA-N 0.000 description 2
- RKYLGVYRVSKBJM-UHFFFAOYSA-N 5-bromo-2-(2-cyclohexylimidazol-1-yl)aniline Chemical compound NC1=CC(Br)=CC=C1N1C(C2CCCCC2)=NC=C1 RKYLGVYRVSKBJM-UHFFFAOYSA-N 0.000 description 2
- ONGWNGZWVQJUAN-UHFFFAOYSA-N 5-chloro-2-(2-cyclohexylimidazol-1-yl)-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC(Cl)=CN=C1N1C(C2CCCCC2)=NC=C1 ONGWNGZWVQJUAN-UHFFFAOYSA-N 0.000 description 2
- ZGWPORTZIRSHFL-UHFFFAOYSA-N 5-chloro-2-(2-cyclohexylimidazol-1-yl)pyridin-3-amine Chemical compound NC1=CC(Cl)=CN=C1N1C(C2CCCCC2)=NC=C1 ZGWPORTZIRSHFL-UHFFFAOYSA-N 0.000 description 2
- WMOSXRMMUWZZPL-UHFFFAOYSA-N 8-chloro-1-cyclohexyl-n,n-dimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound N12C=3C=C(Cl)C(C(=O)N(C)C)=CC=3NC(=O)C2=CN=C1C1CCCCC1 WMOSXRMMUWZZPL-UHFFFAOYSA-N 0.000 description 2
- NKUQAGLOJOCHQT-UHFFFAOYSA-N 8-chloro-1-cyclohexyl-n-(2-methoxyethyl)-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound N12C=3C=C(Cl)C(C(=O)N(C)CCOC)=CC=3NC(=O)C2=CN=C1C1CCCCC1 NKUQAGLOJOCHQT-UHFFFAOYSA-N 0.000 description 2
- KOUGENICWHDHGG-UHFFFAOYSA-N 8-ethoxy-n,n-dimethyl-4-oxo-1-pyrrolidin-1-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C1=C(C(=O)N(C)C)C(OCC)=CC(N23)=C1NC(=O)C3=CN=C2N1CCCC1 KOUGENICWHDHGG-UHFFFAOYSA-N 0.000 description 2
- PLFUHCNXIDTTEN-UHFFFAOYSA-N 8-methoxy-7-(4-methylpiperazine-1-carbonyl)-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound CCC(CC)C1=NC=C(C(NC2=C3)=O)N1C2=CC(OC)=C3C(=O)N1CCN(C)CC1 PLFUHCNXIDTTEN-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- PVHGBNYTCJASNZ-UHFFFAOYSA-N C1=CNC2=C3C=CN=C3C=CC2=N1 Chemical group C1=CNC2=C3C=CN=C3C=CC2=N1 PVHGBNYTCJASNZ-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000003377 acid catalyst Substances 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N acrylic acid methyl ester Natural products COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 2
- 125000004266 aziridin-1-yl group Chemical group [H]C1([H])N(*)C1([H])[H] 0.000 description 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 2
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 2
- ADHYDMXWJIHWHS-VMPITWQZSA-N ethyl (e)-3-[4-oxo-7-(trifluoromethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]prop-2-enoate Chemical compound C1=C(C(F)(F)F)C=C2NC(=O)C3=CC=C(/C=C/C(=O)OCC)N3C2=C1 ADHYDMXWJIHWHS-VMPITWQZSA-N 0.000 description 2
- VBZGUKPQEPINHB-UHFFFAOYSA-N ethyl 1-cyclohexyl-3-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxylate Chemical compound N12C3=CC(C(=O)OCC)=CC=C3NC(=O)C2=C(C)N=C1C1CCCCC1 VBZGUKPQEPINHB-UHFFFAOYSA-N 0.000 description 2
- UYGJQPFBEFPPFS-UHFFFAOYSA-N ethyl 1-cyclohexyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxylate Chemical compound C=1C(C(=O)OCC)=CC=C(N23)C=1NC(=O)C3=CN=C2C1CCCCC1 UYGJQPFBEFPPFS-UHFFFAOYSA-N 0.000 description 2
- QICZHCMZUJJDTD-UHFFFAOYSA-N ethyl 1-cyclohexyl-8-ethoxy-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxylate Chemical compound N12C=3C=C(OCC)C(C(=O)OCC)=CC=3NC(=O)C2=CN=C1C1CCCCC1 QICZHCMZUJJDTD-UHFFFAOYSA-N 0.000 description 2
- CHYICMDMUZGFTA-UHFFFAOYSA-N ethyl 2-chloro-4-(2-cyclohexylimidazol-1-yl)-5-nitrobenzoate Chemical compound C1=C(Cl)C(C(=O)OCC)=CC([N+]([O-])=O)=C1N1C(C2CCCCC2)=NC=C1 CHYICMDMUZGFTA-UHFFFAOYSA-N 0.000 description 2
- YGEIDBAYKUXAJA-UHFFFAOYSA-N ethyl 2-chloro-5-fluoro-4-nitrobenzoate Chemical compound CCOC(=O)C1=CC(F)=C([N+]([O-])=O)C=C1Cl YGEIDBAYKUXAJA-UHFFFAOYSA-N 0.000 description 2
- OGRVCMCXLJEZNN-UHFFFAOYSA-N ethyl 2-chloro-5-nitro-4-(2-pentan-3-ylimidazol-1-yl)benzoate Chemical compound C1=C(Cl)C(C(=O)OCC)=CC([N+]([O-])=O)=C1N1C(C(CC)CC)=NC=C1 OGRVCMCXLJEZNN-UHFFFAOYSA-N 0.000 description 2
- BXPGPEKCYSSETC-UHFFFAOYSA-N ethyl 2-ethoxy-4-fluorobenzoate Chemical compound CCOC(=O)C1=CC=C(F)C=C1OCC BXPGPEKCYSSETC-UHFFFAOYSA-N 0.000 description 2
- QJEYXUHCMDCFKA-UHFFFAOYSA-N ethyl 3-(2-cyclohexyl-4-methylimidazol-1-yl)-4-nitrobenzoate Chemical compound CCOC(=O)C1=CC=C([N+]([O-])=O)C(N2C(=NC(C)=C2)C2CCCCC2)=C1 QJEYXUHCMDCFKA-UHFFFAOYSA-N 0.000 description 2
- VICKPWWLLVHXHX-UHFFFAOYSA-N ethyl 3-(2-cyclohexylimidazol-1-yl)-4-nitrobenzoate Chemical compound CCOC(=O)C1=CC=C([N+]([O-])=O)C(N2C(=NC=C2)C2CCCCC2)=C1 VICKPWWLLVHXHX-UHFFFAOYSA-N 0.000 description 2
- GIHDJYPCYVNRPM-UHFFFAOYSA-N ethyl 3-(7-acetyl-4-oxo-5h-imidazo[1,5-a]quinoxalin-1-yl)propanoate Chemical compound C1=C(C(C)=O)C=C2NC(=O)C3=CN=C(CCC(=O)OCC)N3C2=C1 GIHDJYPCYVNRPM-UHFFFAOYSA-N 0.000 description 2
- SPYKJKDFKSERMF-UHFFFAOYSA-N ethyl 3-(7-bromo-4-oxo-5h-imidazo[1,5-a]quinoxalin-1-yl)propanoate Chemical compound C1=C(Br)C=C2NC(=O)C3=CN=C(CCC(=O)OCC)N3C2=C1 SPYKJKDFKSERMF-UHFFFAOYSA-N 0.000 description 2
- MVJUYUIBNXKKHM-UHFFFAOYSA-N ethyl 3-(7-fluoro-4-oxo-5h-imidazo[1,5-a]quinoxalin-1-yl)propanoate Chemical compound C1=C(F)C=C2NC(=O)C3=CN=C(CCC(=O)OCC)N3C2=C1 MVJUYUIBNXKKHM-UHFFFAOYSA-N 0.000 description 2
- JYHZZDRQHLTLNT-UHFFFAOYSA-N ethyl 3-[1-(2-amino-4-methylphenyl)imidazol-2-yl]propanoate Chemical compound CCOC(=O)CCC1=NC=CN1C1=CC=C(C)C=C1N JYHZZDRQHLTLNT-UHFFFAOYSA-N 0.000 description 2
- FNBBHCPNILTMGG-UHFFFAOYSA-N ethyl 3-[1-(4-acetyl-2-nitrophenyl)imidazol-2-yl]propanoate Chemical compound CCOC(=O)CCC1=NC=CN1C1=CC=C(C(C)=O)C=C1[N+]([O-])=O FNBBHCPNILTMGG-UHFFFAOYSA-N 0.000 description 2
- PBWBCBFBXWOFRU-UHFFFAOYSA-N ethyl 3-[1-(4-methyl-2-nitrophenyl)imidazol-2-yl]propanoate Chemical compound CCOC(=O)CCC1=NC=CN1C1=CC=C(C)C=C1[N+]([O-])=O PBWBCBFBXWOFRU-UHFFFAOYSA-N 0.000 description 2
- AOVGEWHVLXLDME-UHFFFAOYSA-N ethyl 3-[4-oxo-7-(trifluoromethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoate Chemical compound C1=C(C(F)(F)F)C=C2NC(=O)C3=CC=C(CCC(=O)OCC)N3C2=C1 AOVGEWHVLXLDME-UHFFFAOYSA-N 0.000 description 2
- LJHQPONFCGGGKZ-UHFFFAOYSA-N ethyl 3-amino-4-(2-propan-2-ylimidazol-1-yl)benzoate Chemical compound NC1=CC(C(=O)OCC)=CC=C1N1C(C(C)C)=NC=C1 LJHQPONFCGGGKZ-UHFFFAOYSA-N 0.000 description 2
- BFEJCZKSFRXXDG-UHFFFAOYSA-N ethyl 3-fluoro-4-nitrobenzoate Chemical compound CCOC(=O)C1=CC=C([N+]([O-])=O)C(F)=C1 BFEJCZKSFRXXDG-UHFFFAOYSA-N 0.000 description 2
- UOQDDZYKBHTJPO-UHFFFAOYSA-N ethyl 3-nitro-4-(2-pentan-3-ylimidazol-1-yl)benzoate Chemical compound [O-][N+](=O)C1=CC(C(=O)OCC)=CC=C1N1C(C(CC)CC)=NC=C1 UOQDDZYKBHTJPO-UHFFFAOYSA-N 0.000 description 2
- PQGPRZOFCJHEDG-UHFFFAOYSA-N ethyl 3-nitro-4-(2-propan-2-ylimidazol-1-yl)benzoate Chemical compound [O-][N+](=O)C1=CC(C(=O)OCC)=CC=C1N1C(C(C)C)=NC=C1 PQGPRZOFCJHEDG-UHFFFAOYSA-N 0.000 description 2
- MHGLYEQSPAUGGY-UHFFFAOYSA-N ethyl 4-(2-cyclohexylimidazol-1-yl)-2-ethoxy-5-nitrobenzoate Chemical compound C1=C(OCC)C(C(=O)OCC)=CC([N+]([O-])=O)=C1N1C(C2CCCCC2)=NC=C1 MHGLYEQSPAUGGY-UHFFFAOYSA-N 0.000 description 2
- SDTSGISFTKCYNA-UHFFFAOYSA-N ethyl 4-(2-cyclohexylimidazol-1-yl)-3-nitrobenzoate Chemical compound [O-][N+](=O)C1=CC(C(=O)OCC)=CC=C1N1C(C2CCCCC2)=NC=C1 SDTSGISFTKCYNA-UHFFFAOYSA-N 0.000 description 2
- YONVBKVUSUGBQR-UHFFFAOYSA-N ethyl 4-fluoro-3-nitrobenzoate Chemical compound CCOC(=O)C1=CC=C(F)C([N+]([O-])=O)=C1 YONVBKVUSUGBQR-UHFFFAOYSA-N 0.000 description 2
- NUPBUQYQAKKFPF-UHFFFAOYSA-N ethyl 4-nitro-3-(2-pentan-3-ylimidazol-1-yl)benzoate Chemical compound CCOC(=O)C1=CC=C([N+]([O-])=O)C(N2C(=NC=C2)C(CC)CC)=C1 NUPBUQYQAKKFPF-UHFFFAOYSA-N 0.000 description 2
- VQBXSGPUNMQGOQ-UHFFFAOYSA-N ethyl 4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxylate Chemical compound N1C(=O)C2=CN=C(C(CC)CC)N2C2=CC=C(C(=O)OCC)C=C21 VQBXSGPUNMQGOQ-UHFFFAOYSA-N 0.000 description 2
- VQQISVHOJRNAOW-UHFFFAOYSA-N ethyl 4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxylate Chemical compound N1C(=O)C2=CN=C(C(CC)CC)N2C2=CC(C(=O)OCC)=CC=C21 VQQISVHOJRNAOW-UHFFFAOYSA-N 0.000 description 2
- WEANEKULPISPFW-UHFFFAOYSA-N ethyl 4-oxo-1-propan-2-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxylate Chemical compound N1C(=O)C2=CN=C(C(C)C)N2C2=CC=C(C(=O)OCC)C=C21 WEANEKULPISPFW-UHFFFAOYSA-N 0.000 description 2
- YUIDQWIJZPETPI-VOTSOKGWSA-N ethyl 5-[(e)-3-ethoxy-3-oxoprop-1-enyl]-3-methyl-1h-pyrrole-2-carboxylate Chemical compound CCOC(=O)\C=C\C1=CC(C)=C(C(=O)OCC)N1 YUIDQWIJZPETPI-VOTSOKGWSA-N 0.000 description 2
- ZKJLPXKUYQMELR-UHFFFAOYSA-N ethyl 5-amino-4-(2-cyclohexylimidazol-1-yl)-2-ethoxybenzoate Chemical compound C1=C(OCC)C(C(=O)OCC)=CC(N)=C1N1C(C2CCCCC2)=NC=C1 ZKJLPXKUYQMELR-UHFFFAOYSA-N 0.000 description 2
- JITSPDJIAQAZRX-UHFFFAOYSA-N ethyl 7-chloro-1-cyclohexyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxylate Chemical compound C1=C(Cl)C(C(=O)OCC)=CC(N23)=C1NC(=O)C3=CN=C2C1CCCCC1 JITSPDJIAQAZRX-UHFFFAOYSA-N 0.000 description 2
- HYUOEFNKJQDMAI-UHFFFAOYSA-N ethyl 8-chloro-1-cyclohexyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxylate Chemical compound N12C=3C=C(Cl)C(C(=O)OCC)=CC=3NC(=O)C2=CN=C1C1CCCCC1 HYUOEFNKJQDMAI-UHFFFAOYSA-N 0.000 description 2
- JHGLWBRODYDXQO-UHFFFAOYSA-N ethyl 8-chloro-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxylate Chemical compound N1C(=O)C2=CN=C(C(CC)CC)N2C2=C1C=C(C(=O)OCC)C(Cl)=C2 JHGLWBRODYDXQO-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- YESJNPNPRWCJIM-CSKARUKUSA-N methyl (e)-3-(1-cyclohexyl-4-oxo-5h-imidazo[1,5-a]quinoxalin-8-yl)prop-2-enoate Chemical compound N12C3=CC(/C=C/C(=O)OC)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 YESJNPNPRWCJIM-CSKARUKUSA-N 0.000 description 2
- UMDQBOFZNLBHPF-UHFFFAOYSA-N methyl 1-cyclohexyl-8-methoxy-3-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxylate Chemical compound N12C=3C=C(OC)C(C(=O)OC)=CC=3NC(=O)C2=C(C)N=C1C1CCCCC1 UMDQBOFZNLBHPF-UHFFFAOYSA-N 0.000 description 2
- RTNDHOFRJIGBBI-UHFFFAOYSA-N methyl 1-cyclohexyl-8-methoxy-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxylate Chemical compound N12C=3C=C(OC)C(C(=O)OC)=CC=3NC(=O)C2=CN=C1C1CCCCC1 RTNDHOFRJIGBBI-UHFFFAOYSA-N 0.000 description 2
- SSOAUAOBKUGBHX-UHFFFAOYSA-N methyl 2-methoxy-5-nitro-4-(2-pentan-3-ylimidazol-1-yl)benzoate Chemical compound CCC(CC)C1=NC=CN1C1=CC(OC)=C(C(=O)OC)C=C1[N+]([O-])=O SSOAUAOBKUGBHX-UHFFFAOYSA-N 0.000 description 2
- CPDTWQPNIPZOIP-UHFFFAOYSA-N methyl 3-(1-cyclohexyl-4-oxo-5h-imidazo[1,5-a]quinoxalin-8-yl)propanoate Chemical compound N12C3=CC(CCC(=O)OC)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 CPDTWQPNIPZOIP-UHFFFAOYSA-N 0.000 description 2
- TWHIOIPCJOHSPH-UHFFFAOYSA-N methyl 3-(2-cyclopentylimidazol-1-yl)-4-nitrobenzoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)C(N2C(=NC=C2)C2CCCC2)=C1 TWHIOIPCJOHSPH-UHFFFAOYSA-N 0.000 description 2
- ZPYWUMYDFXTTIJ-UHFFFAOYSA-N methyl 4-(2-cyclohexyl-4-methylimidazol-1-yl)-2-methoxy-5-nitrobenzoate Chemical compound C1=C(OC)C(C(=O)OC)=CC([N+]([O-])=O)=C1N1C(C2CCCCC2)=NC(C)=C1 ZPYWUMYDFXTTIJ-UHFFFAOYSA-N 0.000 description 2
- LBEIKGNOYOWAJX-UHFFFAOYSA-N methyl 4-(2-cyclohexylimidazol-1-yl)-2-methoxy-5-nitrobenzoate Chemical compound C1=C(OC)C(C(=O)OC)=CC([N+]([O-])=O)=C1N1C(C2CCCCC2)=NC=C1 LBEIKGNOYOWAJX-UHFFFAOYSA-N 0.000 description 2
- RBTRHHXVJWTUFN-UHFFFAOYSA-N methyl 5-amino-2-methoxy-4-(2-pentan-3-ylimidazol-1-yl)benzoate Chemical compound CCC(CC)C1=NC=CN1C1=CC(OC)=C(C(=O)OC)C=C1N RBTRHHXVJWTUFN-UHFFFAOYSA-N 0.000 description 2
- ZRNBDLJWDMYZQK-UHFFFAOYSA-N methyl 5-amino-4-(2-cyclohexyl-4-methylimidazol-1-yl)-2-methoxybenzoate Chemical compound C1=C(OC)C(C(=O)OC)=CC(N)=C1N1C(C2CCCCC2)=NC(C)=C1 ZRNBDLJWDMYZQK-UHFFFAOYSA-N 0.000 description 2
- SEYDXZLVIINESO-UHFFFAOYSA-N methyl 5-amino-4-(2-cyclohexylimidazol-1-yl)-2-methoxybenzoate Chemical compound C1=C(OC)C(C(=O)OC)=CC(N)=C1N1C(C2CCCCC2)=NC=C1 SEYDXZLVIINESO-UHFFFAOYSA-N 0.000 description 2
- 125000005322 morpholin-1-yl group Chemical group 0.000 description 2
- DXGXVTQDZOLGAN-UHFFFAOYSA-N n,n-dimethyl-3-nitro-4-(2-pentan-3-ylimidazol-1-yl)benzamide Chemical compound CCC(CC)C1=NC=CN1C1=CC=C(C(=O)N(C)C)C=C1[N+]([O-])=O DXGXVTQDZOLGAN-UHFFFAOYSA-N 0.000 description 2
- IENCLNQKDJCHHR-UHFFFAOYSA-N n,n-dimethyl-3-nitro-4-(2-thiophen-3-ylimidazol-1-yl)benzamide Chemical compound [O-][N+](=O)C1=CC(C(=O)N(C)C)=CC=C1N1C(C2=CSC=C2)=NC=C1 IENCLNQKDJCHHR-UHFFFAOYSA-N 0.000 description 2
- GEVUHWKYEWTTMW-UHFFFAOYSA-N n,n-dimethylacetamide;methanol Chemical compound OC.CN(C)C(C)=O GEVUHWKYEWTTMW-UHFFFAOYSA-N 0.000 description 2
- VWIXAZZWUZDTKL-UHFFFAOYSA-N n-(2-ethoxyethyl)-3-fluoro-4-nitrobenzamide Chemical compound CCOCCNC(=O)C1=CC=C([N+]([O-])=O)C(F)=C1 VWIXAZZWUZDTKL-UHFFFAOYSA-N 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 108010091212 pepstatin Proteins 0.000 description 2
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 201000004240 prostatic hypertrophy Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- AZIURDYOVNCNHO-VQHVLOKHSA-N (e)-3-(1-cyclohexyl-4-oxo-5h-imidazo[1,5-a]quinoxalin-7-yl)prop-2-enoic acid Chemical compound C=1C(/C=C/C(=O)O)=CC=C(N23)C=1NC(=O)C3=CN=C2C1CCCCC1 AZIURDYOVNCNHO-VQHVLOKHSA-N 0.000 description 1
- KKWXNXIYOIYXFM-PKNBQFBNSA-N (e)-3-(1-cyclohexyl-4-oxo-5h-imidazo[1,5-a]quinoxalin-8-yl)-n,n-dimethylprop-2-enamide Chemical compound N12C3=CC(/C=C/C(=O)N(C)C)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 KKWXNXIYOIYXFM-PKNBQFBNSA-N 0.000 description 1
- UJNCIEWHRFRITD-CSKARUKUSA-N (e)-3-(1-cyclohexyl-4-oxo-5h-imidazo[1,5-a]quinoxalin-8-yl)-n-methylprop-2-enamide Chemical compound N12C3=CC(/C=C/C(=O)NC)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 UJNCIEWHRFRITD-CSKARUKUSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 1
- XNJAYQHWXYJBBD-UHFFFAOYSA-N 1,4-difluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(F)=CC=C1F XNJAYQHWXYJBBD-UHFFFAOYSA-N 0.000 description 1
- YOXBPWVWNQROBJ-UHFFFAOYSA-N 1-(4-fluoro-2-methoxyphenyl)ethanone Chemical compound COC1=CC(F)=CC=C1C(C)=O YOXBPWVWNQROBJ-UHFFFAOYSA-N 0.000 description 1
- PTCNZDJJIOLIKQ-UHFFFAOYSA-N 1-(4-fluoro-3-nitrophenyl)ethanone Chemical compound CC(=O)C1=CC=C(F)C([N+]([O-])=O)=C1 PTCNZDJJIOLIKQ-UHFFFAOYSA-N 0.000 description 1
- XQSWUBGBODXNCU-UHFFFAOYSA-N 1-(azepin-1-yl)-7-(trifluoromethyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C=1C(C(F)(F)F)=CC=C(N23)C=1NC(=O)C3=CN=C2N1C=CC=CC=C1 XQSWUBGBODXNCU-UHFFFAOYSA-N 0.000 description 1
- PAJXYORDYSQUFH-UHFFFAOYSA-N 1-(azepin-1-yl)-7-methoxy-n,n-dimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C=3C=C(C(=O)N(C)C)C(OC)=CC=3NC(=O)C2=CN=C1N1C=CC=CC=C1 PAJXYORDYSQUFH-UHFFFAOYSA-N 0.000 description 1
- FSCGIBXQUPQMHL-UHFFFAOYSA-N 1-(azepin-1-yl)-8-(trifluoromethyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N12C3=CC(C(F)(F)F)=CC=C3NC(=O)C2=CN=C1N1C=CC=CC=C1 FSCGIBXQUPQMHL-UHFFFAOYSA-N 0.000 description 1
- BLSDEVBZTZGDQT-UHFFFAOYSA-N 1-(azepin-1-yl)-8-chloro-n,n-dimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound N12C=3C=C(Cl)C(C(=O)N(C)C)=CC=3NC(=O)C2=CN=C1N1C=CC=CC=C1 BLSDEVBZTZGDQT-UHFFFAOYSA-N 0.000 description 1
- DZTQOKDZMRTFIC-UHFFFAOYSA-N 1-(azepin-1-yl)-8-ethoxy-n,n-dimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C1=C(C(=O)N(C)C)C(OCC)=CC(N23)=C1NC(=O)C3=CN=C2N1C=CC=CC=C1 DZTQOKDZMRTFIC-UHFFFAOYSA-N 0.000 description 1
- WLJRWZULOHTIAK-UHFFFAOYSA-N 1-(azepin-1-yl)-8-methoxy-n,n,3-trimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C1=C(C(=O)N(C)C)C(OC)=CC(N23)=C1NC(=O)C3=C(C)N=C2N1C=CC=CC=C1 WLJRWZULOHTIAK-UHFFFAOYSA-N 0.000 description 1
- JYANJSQSVHVOJS-UHFFFAOYSA-N 1-(azepin-1-yl)-8-methoxy-n,n-dimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C1=C(C(=O)N(C)C)C(OC)=CC(N23)=C1NC(=O)C3=CN=C2N1C=CC=CC=C1 JYANJSQSVHVOJS-UHFFFAOYSA-N 0.000 description 1
- FNJSNFZAHGRWBT-UHFFFAOYSA-N 1-(azepin-1-yl)-8-methylsulfonyl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N12C3=CC(S(=O)(=O)C)=CC=C3NC(=O)C2=CN=C1N1C=CC=CC=C1 FNJSNFZAHGRWBT-UHFFFAOYSA-N 0.000 description 1
- FUBYWDISZVOQSY-UHFFFAOYSA-N 1-(azepin-1-yl)-n,n,3-trimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)C)=CC=C3NC(=O)C2=C(C)N=C1N1C=CC=CC=C1 FUBYWDISZVOQSY-UHFFFAOYSA-N 0.000 description 1
- SRKFGEMWVXHVBW-UHFFFAOYSA-N 1-(azepin-1-yl)-n,n-dimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)C)=CC=C3NC(=O)C2=CN=C1N1C=CC=CC=C1 SRKFGEMWVXHVBW-UHFFFAOYSA-N 0.000 description 1
- UHWYHNHNSFXZQI-UHFFFAOYSA-N 1-(azepin-1-yl)-n-(2-methoxyethyl)-n,3-dimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)CCOC)=CC=C3NC(=O)C2=C(C)N=C1N1C=CC=CC=C1 UHWYHNHNSFXZQI-UHFFFAOYSA-N 0.000 description 1
- PNGYKVANTDDXJQ-UHFFFAOYSA-N 1-(azepin-1-yl)-n-(2-methoxyethyl)-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)CCOC)=CC=C3NC(=O)C2=CN=C1N1C=CC=CC=C1 PNGYKVANTDDXJQ-UHFFFAOYSA-N 0.000 description 1
- FLFMDRKJWCTHNX-UHFFFAOYSA-N 1-(oxan-4-yl)-8-(trifluoromethyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N12C3=CC(C(F)(F)F)=CC=C3NC(=O)C2=CN=C1C1CCOCC1 FLFMDRKJWCTHNX-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- GYLSNZTWXYVOCL-UHFFFAOYSA-N 1-cyclohexyl-4-oxo-5h-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxylic acid Chemical compound N12C3=CC(C(=O)O)=CC=C3NC(=O)C2=NN=C1C1CCCCC1 GYLSNZTWXYVOCL-UHFFFAOYSA-N 0.000 description 1
- VJYPJFMVKPZRQP-UHFFFAOYSA-N 1-cyclohexyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carbonitrile Chemical compound N=1C=C2C(=O)NC3=CC(C#N)=CC=C3N2C=1C1CCCCC1 VJYPJFMVKPZRQP-UHFFFAOYSA-N 0.000 description 1
- QMCKJSZNWYRBIO-UHFFFAOYSA-N 1-cyclohexyl-4-oxo-n,n-bis(trifluoromethyl)-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C(F)(F)F)C(F)(F)F)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 QMCKJSZNWYRBIO-UHFFFAOYSA-N 0.000 description 1
- PJSOJZWGGASNGB-UHFFFAOYSA-N 1-cyclohexyl-4-oxo-n-(pyridin-2-ylmethyl)-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound C=1C=C2NC(=O)C3=CN=C(C4CCCCC4)N3C2=CC=1C(=O)NCC1=CC=CC=N1 PJSOJZWGGASNGB-UHFFFAOYSA-N 0.000 description 1
- NETWWTLJZCQMOQ-UHFFFAOYSA-N 1-cyclohexyl-4-oxo-n-(pyridin-3-ylmethyl)-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound C=1C=C2NC(=O)C3=CN=C(C4CCCCC4)N3C2=CC=1C(=O)NCC1=CC=CN=C1 NETWWTLJZCQMOQ-UHFFFAOYSA-N 0.000 description 1
- RIDOUXCBWYUTRD-UHFFFAOYSA-N 1-cyclohexyl-4-oxo-n-pyridin-2-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound C=1C=C2NC(=O)C3=CN=C(C4CCCCC4)N3C2=CC=1C(=O)NC1=CC=CC=N1 RIDOUXCBWYUTRD-UHFFFAOYSA-N 0.000 description 1
- AEAZGZWAFGVOLO-UHFFFAOYSA-N 1-cyclohexyl-4-oxo-n-pyridin-3-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound C=1C=C2NC(=O)C3=CN=C(C4CCCCC4)N3C2=CC=1C(=O)NC1=CC=CN=C1 AEAZGZWAFGVOLO-UHFFFAOYSA-N 0.000 description 1
- KBTXNDHQNLHSTE-UHFFFAOYSA-N 1-cyclohexyl-7-(3,5-dimethylpyrazol-1-yl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N1=C(C)C=C(C)N1C1=CC=C2N3C(C4CCCCC4)=NC=C3C(=O)NC2=C1 KBTXNDHQNLHSTE-UHFFFAOYSA-N 0.000 description 1
- IZUOOAPOGUPDIR-UHFFFAOYSA-N 1-cyclohexyl-7-(3,5-dimethylpyrazole-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N1=C(C)C=C(C)N1C(=O)C1=CC=C2N3C(C4CCCCC4)=NC=C3C(=O)NC2=C1 IZUOOAPOGUPDIR-UHFFFAOYSA-N 0.000 description 1
- IOJFKCSDCPRJEG-UHFFFAOYSA-N 1-cyclohexyl-7-(3-methyl-1,2,4-oxadiazol-5-yl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound CC1=NOC(C=2C=C3C(N4C(C5CCCCC5)=NC=C4C(=O)N3)=CC=2)=N1 IOJFKCSDCPRJEG-UHFFFAOYSA-N 0.000 description 1
- ALGWZNWERMQQEJ-UHFFFAOYSA-N 1-cyclohexyl-7-(4-methylpiperazine-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C1CN(C)CCN1C(=O)C1=CC=C2N3C(C4CCCCC4)=NC=C3C(=O)NC2=C1 ALGWZNWERMQQEJ-UHFFFAOYSA-N 0.000 description 1
- GAQIBEGLDZTXMK-UHFFFAOYSA-N 1-cyclohexyl-7-(morpholine-4-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C=1C=C(N2C(C3CCCCC3)=NC=C2C(=O)N2)C2=CC=1C(=O)N1CCOCC1 GAQIBEGLDZTXMK-UHFFFAOYSA-N 0.000 description 1
- QKCXVYVYSNFNOX-UHFFFAOYSA-N 1-cyclohexyl-7-(piperidine-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C=1C=C(N2C(C3CCCCC3)=NC=C2C(=O)N2)C2=CC=1C(=O)N1CCCCC1 QKCXVYVYSNFNOX-UHFFFAOYSA-N 0.000 description 1
- BPKXBRFEXGQAQD-UHFFFAOYSA-N 1-cyclohexyl-7-(pyrrolidine-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C=1C=C(N2C(C3CCCCC3)=NC=C2C(=O)N2)C2=CC=1C(=O)N1CCCC1 BPKXBRFEXGQAQD-UHFFFAOYSA-N 0.000 description 1
- OHSFGGAJEZUFPZ-UHFFFAOYSA-N 1-cyclohexyl-7-methoxy-n,n-dimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C=3C=C(C(=O)N(C)C)C(OC)=CC=3NC(=O)C2=CN=C1C1CCCCC1 OHSFGGAJEZUFPZ-UHFFFAOYSA-N 0.000 description 1
- IPQPJECQTMVHNM-UHFFFAOYSA-N 1-cyclohexyl-7-pyrazol-1-yl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N=1C=C2C(=O)NC3=CC(N4N=CC=C4)=CC=C3N2C=1C1CCCCC1 IPQPJECQTMVHNM-UHFFFAOYSA-N 0.000 description 1
- PXDLFTJPBCDHNQ-UHFFFAOYSA-N 1-cyclohexyl-8-(2-hydroxypropan-2-yl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N12C3=CC(C(C)(O)C)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 PXDLFTJPBCDHNQ-UHFFFAOYSA-N 0.000 description 1
- ZLUYFQGACSHWQF-UHFFFAOYSA-N 1-cyclohexyl-8-(4-methylpiperazine-1-carbonyl)-5h-[1,2,4]triazolo[4,3-a]quinoxalin-4-one Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(NC(=O)C=2N3C(C4CCCCC4)=NN=2)C3=C1 ZLUYFQGACSHWQF-UHFFFAOYSA-N 0.000 description 1
- VVXNDYHLNRBTQD-UHFFFAOYSA-N 1-cyclohexyl-8-(4-methylpiperazine-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(NC(=O)C=2N3C(C4CCCCC4)=NC=2)C3=C1 VVXNDYHLNRBTQD-UHFFFAOYSA-N 0.000 description 1
- JPRRLJUIBAEHER-UHFFFAOYSA-N 1-cyclohexyl-8-(morpholine-4-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C=1C=C2NC(=O)C3=CN=C(C4CCCCC4)N3C2=CC=1C(=O)N1CCOCC1 JPRRLJUIBAEHER-UHFFFAOYSA-N 0.000 description 1
- MGNDVUDXDUHZFV-UHFFFAOYSA-N 1-cyclohexyl-8-(piperidine-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C=1C=C2NC(=O)C3=CN=C(C4CCCCC4)N3C2=CC=1C(=O)N1CCCCC1 MGNDVUDXDUHZFV-UHFFFAOYSA-N 0.000 description 1
- ZWUJMFBCVVZFDM-UHFFFAOYSA-N 1-cyclohexyl-8-(pyrrolidine-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C=1C=C2NC(=O)C3=CN=C(C4CCCCC4)N3C2=CC=1C(=O)N1CCCC1 ZWUJMFBCVVZFDM-UHFFFAOYSA-N 0.000 description 1
- UZEVBGAPQUKDRC-UHFFFAOYSA-N 1-cyclohexyl-8-[4-(2-hydroxyethyl)piperidine-1-carbonyl]-5h-[1,2,4]triazolo[4,3-a]quinoxalin-4-one Chemical compound C1CC(CCO)CCN1C(=O)C1=CC=C(NC(=O)C=2N3C(C4CCCCC4)=NN=2)C3=C1 UZEVBGAPQUKDRC-UHFFFAOYSA-N 0.000 description 1
- SRLSHMZHRSBSBL-UHFFFAOYSA-N 1-cyclohexyl-8-[4-(2-hydroxyethyl)piperidine-1-carbonyl]-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C1CC(CCO)CCN1C(=O)C1=CC=C(NC(=O)C=2N3C(C4CCCCC4)=NC=2)C3=C1 SRLSHMZHRSBSBL-UHFFFAOYSA-N 0.000 description 1
- UMWUUQQFTIUJRG-UHFFFAOYSA-N 1-cyclohexyl-8-ethoxy-n,n-dimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C1=C(C(=O)N(C)C)C(OCC)=CC(N23)=C1NC(=O)C3=CN=C2C1CCCCC1 UMWUUQQFTIUJRG-UHFFFAOYSA-N 0.000 description 1
- WCMXSYLZCHMBET-UHFFFAOYSA-N 1-cyclohexyl-8-methoxy-7-(piperidine-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound COC1=CC(N2C(C3CCCCC3)=NC=C2C(=O)N2)=C2C=C1C(=O)N1CCCCC1 WCMXSYLZCHMBET-UHFFFAOYSA-N 0.000 description 1
- BJAVEWFOBWRUIH-UHFFFAOYSA-N 1-cyclohexyl-8-methoxy-7-(pyrrolidine-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound COC1=CC(N2C(C3CCCCC3)=NC=C2C(=O)N2)=C2C=C1C(=O)N1CCCC1 BJAVEWFOBWRUIH-UHFFFAOYSA-N 0.000 description 1
- VIPQBHYXLMJZFA-UHFFFAOYSA-N 1-cyclohexyl-8-methoxy-n,n,3-trimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C1=C(C(=O)N(C)C)C(OC)=CC(N23)=C1NC(=O)C3=C(C)N=C2C1CCCCC1 VIPQBHYXLMJZFA-UHFFFAOYSA-N 0.000 description 1
- ZWNYSNVANDAZPD-UHFFFAOYSA-N 1-cyclohexyl-8-methoxy-n,n-dimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C1=C(C(=O)N(C)C)C(OC)=CC(N23)=C1NC(=O)C3=CN=C2C1CCCCC1 ZWNYSNVANDAZPD-UHFFFAOYSA-N 0.000 description 1
- MSYSBXYELRKWKI-UHFFFAOYSA-N 1-cyclohexyl-8-methoxy-n-(2-methoxyethyl)-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound N12C=3C=C(OC)C(C(=O)N(C)CCOC)=CC=3NC(=O)C2=CN=C1C1CCCCC1 MSYSBXYELRKWKI-UHFFFAOYSA-N 0.000 description 1
- GSUUOUKXMGIIEE-UHFFFAOYSA-N 1-cyclohexyl-8-methoxy-n-methyl-4-oxo-n-propyl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound N12C=3C=C(OC)C(C(=O)N(C)CCC)=CC=3NC(=O)C2=CN=C1C1CCCCC1 GSUUOUKXMGIIEE-UHFFFAOYSA-N 0.000 description 1
- HPLOMXMUOFFQHX-UHFFFAOYSA-N 1-cyclohexyl-8-methylsulfonyl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N12C3=CC(S(=O)(=O)C)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 HPLOMXMUOFFQHX-UHFFFAOYSA-N 0.000 description 1
- NFOPVVAVJKNNBQ-UHFFFAOYSA-N 1-cyclohexyl-n,3-dimethyl-4-oxo-n-[2-(trifluoromethoxy)ethyl]-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(CCOC(F)(F)F)C)=CC=C3NC(=O)C2=C(C)N=C1C1CCCCC1 NFOPVVAVJKNNBQ-UHFFFAOYSA-N 0.000 description 1
- FXLPAMJONPYJTK-UHFFFAOYSA-N 1-cyclohexyl-n,n-diethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C=1C(C(=O)N(CC)CC)=CC=C(N23)C=1NC(=O)C3=CN=C2C1CCCCC1 FXLPAMJONPYJTK-UHFFFAOYSA-N 0.000 description 1
- LTPKRWTWGXMNIF-UHFFFAOYSA-N 1-cyclohexyl-n,n-diethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(CC)CC)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 LTPKRWTWGXMNIF-UHFFFAOYSA-N 0.000 description 1
- VZTXOIMRSMUIBW-UHFFFAOYSA-N 1-cyclohexyl-n,n-diethyl-8-methoxy-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound N12C=3C=C(OC)C(C(=O)N(CC)CC)=CC=3NC(=O)C2=CN=C1C1CCCCC1 VZTXOIMRSMUIBW-UHFFFAOYSA-N 0.000 description 1
- YWJDMOAQKZEJSG-UHFFFAOYSA-N 1-cyclohexyl-n,n-dimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C=1C(C(=O)N(C)C)=CC=C(N23)C=1NC(=O)C3=CN=C2C1CCCCC1 YWJDMOAQKZEJSG-UHFFFAOYSA-N 0.000 description 1
- TVUDTEIKDNGHSK-UHFFFAOYSA-N 1-cyclohexyl-n,n-dimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-sulfonamide Chemical compound C=1C(S(=O)(=O)N(C)C)=CC=C(N23)C=1NC(=O)C3=CN=C2C1CCCCC1 TVUDTEIKDNGHSK-UHFFFAOYSA-N 0.000 description 1
- FNAJMFSDFJRQCM-UHFFFAOYSA-N 1-cyclohexyl-n,n-dimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)C)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 FNAJMFSDFJRQCM-UHFFFAOYSA-N 0.000 description 1
- IDXXHKMNWVRELT-UHFFFAOYSA-N 1-cyclohexyl-n,n-dimethyl-4-oxo-8-(trifluoromethoxy)-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound N12C=3C=C(OC(F)(F)F)C(C(=O)N(C)C)=CC=3NC(=O)C2=CN=C1C1CCCCC1 IDXXHKMNWVRELT-UHFFFAOYSA-N 0.000 description 1
- JMIFEYCLFUYNOD-UHFFFAOYSA-N 1-cyclohexyl-n-(2-ethoxyethyl)-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)CCOCC)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 JMIFEYCLFUYNOD-UHFFFAOYSA-N 0.000 description 1
- MCSWEBCEBZADDW-UHFFFAOYSA-N 1-cyclohexyl-n-(2-hydroxyethyl)-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C=1C(C(=O)N(CCO)C)=CC=C(N23)C=1NC(=O)C3=CN=C2C1CCCCC1 MCSWEBCEBZADDW-UHFFFAOYSA-N 0.000 description 1
- WCVLYGHTLUHGHX-UHFFFAOYSA-N 1-cyclohexyl-n-(2-methoxyethyl)-3-methyl-4-oxo-n-(trifluoromethyl)-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(CCOC)C(F)(F)F)=CC=C3NC(=O)C2=C(C)N=C1C1CCCCC1 WCVLYGHTLUHGHX-UHFFFAOYSA-N 0.000 description 1
- QZXIZSHFVHKMKN-UHFFFAOYSA-N 1-cyclohexyl-n-(2-methoxyethyl)-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCCOC)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 QZXIZSHFVHKMKN-UHFFFAOYSA-N 0.000 description 1
- NGHQMYQBEKORRL-UHFFFAOYSA-N 1-cyclohexyl-n-(2-methoxyethyl)-4-oxo-n-(trifluoromethyl)-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(CCOC)C(F)(F)F)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 NGHQMYQBEKORRL-UHFFFAOYSA-N 0.000 description 1
- PNKYNAOYIOMLHD-UHFFFAOYSA-N 1-cyclohexyl-n-(2-methoxyethyl)-4-oxo-n-propan-2-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C(C)C)CCOC)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 PNKYNAOYIOMLHD-UHFFFAOYSA-N 0.000 description 1
- VGSDUJQPXBAMDJ-UHFFFAOYSA-N 1-cyclohexyl-n-(2-methoxyethyl)-4-oxo-n-propyl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(CCOC)CCC)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 VGSDUJQPXBAMDJ-UHFFFAOYSA-N 0.000 description 1
- KVYWCTXGUHTHTB-UHFFFAOYSA-N 1-cyclohexyl-n-(2-methoxyethyl)-n,3-dimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)CCOC)=CC=C3NC(=O)C2=C(C)N=C1C1CCCCC1 KVYWCTXGUHTHTB-UHFFFAOYSA-N 0.000 description 1
- PXIIKLGTSNTULZ-UHFFFAOYSA-N 1-cyclohexyl-n-(2-methoxyethyl)-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C=1C(C(=O)N(C)CCOC)=CC=C(N23)C=1NC(=O)C3=CN=C2C1CCCCC1 PXIIKLGTSNTULZ-UHFFFAOYSA-N 0.000 description 1
- MZRLBUZWOIAPJP-UHFFFAOYSA-N 1-cyclohexyl-n-(2-methoxyethyl)-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)CCOC)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 MZRLBUZWOIAPJP-UHFFFAOYSA-N 0.000 description 1
- YIZRMUVJDLYHHG-UHFFFAOYSA-N 1-cyclohexyl-n-(3-methoxypropyl)-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)CCCOC)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 YIZRMUVJDLYHHG-UHFFFAOYSA-N 0.000 description 1
- OGENQCMAHSYZPG-UHFFFAOYSA-N 1-cyclohexyl-n-[2-(dimethylamino)ethyl]-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-sulfonamide Chemical compound C=1C(S(=O)(=O)N(C)CCN(C)C)=CC=C(N23)C=1NC(=O)C3=CN=C2C1CCCCC1 OGENQCMAHSYZPG-UHFFFAOYSA-N 0.000 description 1
- JQVOOHLCAFRXCB-UHFFFAOYSA-N 1-cyclohexyl-n-[2-(dimethylamino)ethyl]-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)CCN(C)C)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 JQVOOHLCAFRXCB-UHFFFAOYSA-N 0.000 description 1
- ZFHCHCCGTGIJAX-UHFFFAOYSA-N 1-cyclohexyl-n-ethyl-8-methoxy-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound N12C=3C=C(OC)C(C(=O)N(C)CC)=CC=3NC(=O)C2=CN=C1C1CCCCC1 ZFHCHCCGTGIJAX-UHFFFAOYSA-N 0.000 description 1
- JUWPEMWQKVRKQD-UHFFFAOYSA-N 1-cyclohexyl-n-ethyl-n-(2-methoxyethyl)-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(CCOC)CC)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 JUWPEMWQKVRKQD-UHFFFAOYSA-N 0.000 description 1
- XKXIVWKERNRYRR-UHFFFAOYSA-N 1-cyclohexyl-n-ethyl-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C=1C(C(=O)N(C)CC)=CC=C(N23)C=1NC(=O)C3=CN=C2C1CCCCC1 XKXIVWKERNRYRR-UHFFFAOYSA-N 0.000 description 1
- NEZCTKGKYLGSLW-UHFFFAOYSA-N 1-cyclohexyl-n-ethyl-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)CC)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 NEZCTKGKYLGSLW-UHFFFAOYSA-N 0.000 description 1
- GWTFAAKLIYNATN-UHFFFAOYSA-N 1-cyclohexyl-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NC)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 GWTFAAKLIYNATN-UHFFFAOYSA-N 0.000 description 1
- MBQZCBJTBIYYEC-UHFFFAOYSA-N 1-cyclohexyl-n-methyl-4-oxo-n-(2-propan-2-yloxyethyl)-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)CCOC(C)C)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 MBQZCBJTBIYYEC-UHFFFAOYSA-N 0.000 description 1
- KHJNFBWXPBDZKC-UHFFFAOYSA-N 1-cyclohexyl-n-methyl-4-oxo-n-(2-propoxyethyl)-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)CCOCCC)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 KHJNFBWXPBDZKC-UHFFFAOYSA-N 0.000 description 1
- QGCHZPAJWKFAHO-UHFFFAOYSA-N 1-cyclohexyl-n-methyl-4-oxo-n-(2-pyridin-2-ylethyl)-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound C=1C=C2NC(=O)C3=CN=C(C4CCCCC4)N3C2=CC=1C(=O)N(C)CCC1=CC=CC=N1 QGCHZPAJWKFAHO-UHFFFAOYSA-N 0.000 description 1
- VETJYJVNFNCQSV-UHFFFAOYSA-N 1-cyclohexyl-n-methyl-4-oxo-n-(pyridin-2-ylmethyl)-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound C=1C=C2NC(=O)C3=CN=C(C4CCCCC4)N3C2=CC=1C(=O)N(C)CC1=CC=CC=N1 VETJYJVNFNCQSV-UHFFFAOYSA-N 0.000 description 1
- KNKRDCUIHNMPAQ-UHFFFAOYSA-N 1-cyclohexyl-n-methyl-4-oxo-n-(pyridin-3-ylmethyl)-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound C=1C=C2NC(=O)C3=CN=C(C4CCCCC4)N3C2=CC=1C(=O)N(C)CC1=CC=CN=C1 KNKRDCUIHNMPAQ-UHFFFAOYSA-N 0.000 description 1
- IJADIKGBNKCJMQ-UHFFFAOYSA-N 1-cyclohexyl-n-methyl-4-oxo-n-(pyridin-4-ylmethyl)-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound C=1C=C2NC(=O)C3=CN=C(C4CCCCC4)N3C2=CC=1C(=O)N(C)CC1=CC=NC=C1 IJADIKGBNKCJMQ-UHFFFAOYSA-N 0.000 description 1
- MOTQKIRMRADJPL-UHFFFAOYSA-N 1-cyclohexyl-n-methyl-4-oxo-n-(trifluoromethyl)-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)C(F)(F)F)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 MOTQKIRMRADJPL-UHFFFAOYSA-N 0.000 description 1
- GOIXVGLIUMMXIG-UHFFFAOYSA-N 1-cyclohexyl-n-methyl-4-oxo-n-[2-(trifluoromethoxy)ethyl]-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(CCOC(F)(F)F)C)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 GOIXVGLIUMMXIG-UHFFFAOYSA-N 0.000 description 1
- ODOUZSNCHASCDI-UHFFFAOYSA-N 1-cyclohexyl-n-methyl-4-oxo-n-propyl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C=1C(C(=O)N(C)CCC)=CC=C(N23)C=1NC(=O)C3=CN=C2C1CCCCC1 ODOUZSNCHASCDI-UHFFFAOYSA-N 0.000 description 1
- ZCIQFJUSYCXEKP-UHFFFAOYSA-N 1-cyclohexyl-n-methyl-4-oxo-n-propyl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)CCC)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 ZCIQFJUSYCXEKP-UHFFFAOYSA-N 0.000 description 1
- YYCDNRKYVWRMGB-UHFFFAOYSA-N 1-cyclohexyl-n-methyl-4-oxo-n-pyridin-2-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound C=1C=CC=NC=1N(C)C(=O)C(C=C1N23)=CC=C1NC(=O)C2=CN=C3C1CCCCC1 YYCDNRKYVWRMGB-UHFFFAOYSA-N 0.000 description 1
- QBEXHARPRVHDAT-UHFFFAOYSA-N 1-cyclohexyl-n-methyl-4-oxo-n-pyridin-3-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound C=1C=CN=CC=1N(C)C(=O)C(C=C1N23)=CC=C1NC(=O)C2=CN=C3C1CCCCC1 QBEXHARPRVHDAT-UHFFFAOYSA-N 0.000 description 1
- ILWYWCKQUWSMRF-UHFFFAOYSA-N 1-cyclohexyl-n-methyl-4-oxo-n-pyridin-4-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound C=1C=NC=CC=1N(C)C(=O)C(C=C1N23)=CC=C1NC(=O)C2=CN=C3C1CCCCC1 ILWYWCKQUWSMRF-UHFFFAOYSA-N 0.000 description 1
- ZBSKCEVKUZAUMT-UHFFFAOYSA-N 1-cyclopentyl-8-(3,5-dimethylpyrazole-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N1=C(C)C=C(C)N1C(=O)C1=CC=C(NC(=O)C=2N3C(C4CCCC4)=NC=2)C3=C1 ZBSKCEVKUZAUMT-UHFFFAOYSA-N 0.000 description 1
- ZHFHFMSABQOKLQ-UHFFFAOYSA-N 1-cyclopentyl-8-[4-(2-hydroxyethyl)piperidine-1-carbonyl]-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C1CC(CCO)CCN1C(=O)C1=CC=C(NC(=O)C=2N3C(C4CCCC4)=NC=2)C3=C1 ZHFHFMSABQOKLQ-UHFFFAOYSA-N 0.000 description 1
- UCTQULOWIJVXKC-UHFFFAOYSA-N 1-cyclopentyl-n,n-dimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)C)=CC=C3NC(=O)C2=CN=C1C1CCCC1 UCTQULOWIJVXKC-UHFFFAOYSA-N 0.000 description 1
- IPANVTYSGHAGMW-UHFFFAOYSA-N 1-cyclopentyl-n-(2-methoxyethyl)-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCCOC)=CC=C3NC(=O)C2=CN=C1C1CCCC1 IPANVTYSGHAGMW-UHFFFAOYSA-N 0.000 description 1
- DZDKYBFWMDKGKN-UHFFFAOYSA-N 1-cyclopentyl-n-(2-methoxyethyl)-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)CCOC)=CC=C3NC(=O)C2=CN=C1C1CCCC1 DZDKYBFWMDKGKN-UHFFFAOYSA-N 0.000 description 1
- YHJGHTBACUIVDG-UHFFFAOYSA-N 1-cyclopentyl-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NC)=CC=C3NC(=O)C2=CN=C1C1CCCC1 YHJGHTBACUIVDG-UHFFFAOYSA-N 0.000 description 1
- OORBDHOQLZRIQR-UHFFFAOYSA-N 1-fluoro-4-methyl-2-nitrobenzene Chemical compound CC1=CC=C(F)C([N+]([O-])=O)=C1 OORBDHOQLZRIQR-UHFFFAOYSA-N 0.000 description 1
- JKCAZPZSNMTPAK-UHFFFAOYSA-N 1-heptan-4-yl-n-(2-methoxyethyl)-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound COCCN(C)C(=O)C1=CC=C2NC(=O)C3=CN=C(C(CCC)CCC)N3C2=C1 JKCAZPZSNMTPAK-UHFFFAOYSA-N 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- GVMISRIUQFLAHU-UHFFFAOYSA-N 1-morpholin-4-yl-7-(trifluoromethyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C=1C(C(F)(F)F)=CC=C(N23)C=1NC(=O)C3=CN=C2N1CCOCC1 GVMISRIUQFLAHU-UHFFFAOYSA-N 0.000 description 1
- ZIECQGVFJKIAIF-UHFFFAOYSA-N 1-morpholin-4-yl-8-(trifluoromethyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N12C3=CC(C(F)(F)F)=CC=C3NC(=O)C2=CN=C1N1CCOCC1 ZIECQGVFJKIAIF-UHFFFAOYSA-N 0.000 description 1
- OBTMENCZUNGMCG-UHFFFAOYSA-N 1-pentan-3-yl-8-(piperidine-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound CCC(CC)C1=NC=C(C(NC2=CC=3)=O)N1C2=CC=3C(=O)N1CCCCC1 OBTMENCZUNGMCG-UHFFFAOYSA-N 0.000 description 1
- ILSMSHVGKIJYHW-UHFFFAOYSA-N 1-pentan-3-yl-8-(pyrrolidine-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound CCC(CC)C1=NC=C(C(NC2=CC=3)=O)N1C2=CC=3C(=O)N1CCCC1 ILSMSHVGKIJYHW-UHFFFAOYSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- XPCLZTMTQZBHJN-UHFFFAOYSA-N 1-piperidin-1-yl-7-(trifluoromethyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C=1C(C(F)(F)F)=CC=C(N23)C=1NC(=O)C3=CN=C2N1CCCCC1 XPCLZTMTQZBHJN-UHFFFAOYSA-N 0.000 description 1
- JYSQQZBEKDENNC-UHFFFAOYSA-N 1-piperidin-1-yl-8-(trifluoromethyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N12C3=CC(C(F)(F)F)=CC=C3NC(=O)C2=CN=C1N1CCCCC1 JYSQQZBEKDENNC-UHFFFAOYSA-N 0.000 description 1
- JNZNEPSYMKPDRD-UHFFFAOYSA-N 1-pyrrolidin-1-yl-7-(trifluoromethyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C=1C(C(F)(F)F)=CC=C(N23)C=1NC(=O)C3=CN=C2N1CCCC1 JNZNEPSYMKPDRD-UHFFFAOYSA-N 0.000 description 1
- DJINUVVMUYQOMX-UHFFFAOYSA-N 1-pyrrolidin-1-yl-8-(trifluoromethyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N12C3=CC(C(F)(F)F)=CC=C3NC(=O)C2=CN=C1N1CCCC1 DJINUVVMUYQOMX-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PUMUYOPCGPBMOI-UHFFFAOYSA-N 2,2-dimethyl-3-[2-methyl-4-oxo-7-(trifluoromethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound C1=C(C(F)(F)F)C=C2NC(=O)C3=CC(C)=C(CC(C)(C)C(O)=O)N3C2=C1 PUMUYOPCGPBMOI-UHFFFAOYSA-N 0.000 description 1
- LSBZRKYFEAOAIF-UHFFFAOYSA-N 2,2-dimethyl-3-[4-oxo-7-(trifluoromethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound C1=C(C(F)(F)F)C=C2NC(=O)C3=CC=C(CC(C)(C)C(O)=O)N3C2=C1 LSBZRKYFEAOAIF-UHFFFAOYSA-N 0.000 description 1
- OBUGJYJQJWMOQO-UHFFFAOYSA-N 2,5-dichloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC(Cl)=CN=C1Cl OBUGJYJQJWMOQO-UHFFFAOYSA-N 0.000 description 1
- WPDPLDCNQCWWEC-UHFFFAOYSA-N 2-(3-methylphenyl)-1h-imidazole Chemical compound CC1=CC=CC(C=2NC=CN=2)=C1 WPDPLDCNQCWWEC-UHFFFAOYSA-N 0.000 description 1
- YETQPLMSXLUGGT-UHFFFAOYSA-N 2-[[4-oxo-7-(trifluoromethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]methyl]butanoic acid Chemical compound C1=C(C(F)(F)F)C=C2NC(=O)C3=CC=C(CC(CC)C(O)=O)N3C2=C1 YETQPLMSXLUGGT-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- BPGIOCZAQDIBPI-UHFFFAOYSA-N 2-ethoxyethanamine Chemical compound CCOCCN BPGIOCZAQDIBPI-UHFFFAOYSA-N 0.000 description 1
- FSZCIRCHSBLAIA-UHFFFAOYSA-N 2-methyl-3-[2-methyl-4-oxo-7-(trifluoromethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound C1=C(C(F)(F)F)C=C2NC(=O)C3=CC(C)=C(CC(C)C(O)=O)N3C2=C1 FSZCIRCHSBLAIA-UHFFFAOYSA-N 0.000 description 1
- XCSNXGVWQCKJNE-UHFFFAOYSA-N 2-methyl-3-[4-oxo-7-(propoxymethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound N1C(=O)C2=CC=C(CC(C)C(O)=O)N2C2=CC=C(COCCC)C=C21 XCSNXGVWQCKJNE-UHFFFAOYSA-N 0.000 description 1
- UBKKNWJGYLSDSJ-UHFFFAOYSA-N 2-methylpyridine-3-carbonitrile Chemical compound CC1=NC=CC=C1C#N UBKKNWJGYLSDSJ-UHFFFAOYSA-N 0.000 description 1
- FPLOWPOUHNRUMN-UHFFFAOYSA-N 2-pentan-3-yl-1H-imidazole Chemical compound CCC(CC)C1=NC=CN1 FPLOWPOUHNRUMN-UHFFFAOYSA-N 0.000 description 1
- KUAONFHCNNRNHF-UHFFFAOYSA-N 3-(1-cyclohexyl-4-oxo-5h-imidazo[1,5-a]quinoxalin-8-yl)-n,n-dimethylpropanamide Chemical compound N12C3=CC(CCC(=O)N(C)C)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 KUAONFHCNNRNHF-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- DUEISLONTHDRBW-UHFFFAOYSA-N 3-(4-oxo-7-propyl-5h-pyrrolo[1,2-a]quinoxalin-1-yl)propanoic acid Chemical compound N1C(=O)C2=CC=C(CCC(O)=O)N2C2=CC=C(CCC)C=C21 DUEISLONTHDRBW-UHFFFAOYSA-N 0.000 description 1
- PZLZTBGPFWIEPM-UHFFFAOYSA-N 3-(7,8-dimethyl-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl)propanoic acid Chemical compound N1C(=O)C2=CC=C(CCC(O)=O)N2C2=C1C=C(C)C(C)=C2 PZLZTBGPFWIEPM-UHFFFAOYSA-N 0.000 description 1
- ZEDCCDVXWIERFN-UHFFFAOYSA-N 3-(7-bromo-4-oxo-5h-imidazo[1,5-a]quinoxalin-1-yl)propanoic acid Chemical compound C1=C(Br)C=C2NC(=O)C3=CN=C(CCC(=O)O)N3C2=C1 ZEDCCDVXWIERFN-UHFFFAOYSA-N 0.000 description 1
- NEGLTPJVJRBSJM-UHFFFAOYSA-N 3-(7-chloro-4-oxo-5h-imidazo[1,5-a]quinoxalin-1-yl)propanoic acid Chemical compound C1=C(Cl)C=C2NC(=O)C3=CN=C(CCC(=O)O)N3C2=C1 NEGLTPJVJRBSJM-UHFFFAOYSA-N 0.000 description 1
- SCUBVOAHJYQBKU-UHFFFAOYSA-N 3-(7-chloro-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl)propanoic acid Chemical compound C1=C(Cl)C=C2NC(=O)C3=CC=C(CCC(=O)O)N3C2=C1 SCUBVOAHJYQBKU-UHFFFAOYSA-N 0.000 description 1
- JBFRPQOOMRKXJF-UHFFFAOYSA-N 3-(7-ethoxy-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl)propanoic acid Chemical compound N1C(=O)C2=CC=C(CCC(O)=O)N2C2=CC=C(OCC)C=C21 JBFRPQOOMRKXJF-UHFFFAOYSA-N 0.000 description 1
- PKAAQRQMANZTPV-UHFFFAOYSA-N 3-(7-ethyl-4-oxo-5h-imidazo[1,5-a]quinoxalin-1-yl)propanoic acid Chemical compound N1C(=O)C2=CN=C(CCC(O)=O)N2C2=CC=C(CC)C=C21 PKAAQRQMANZTPV-UHFFFAOYSA-N 0.000 description 1
- IGHABSGIFVLZGE-UHFFFAOYSA-N 3-(7-ethyl-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl)propanoic acid Chemical compound N1C(=O)C2=CC=C(CCC(O)=O)N2C2=CC=C(CC)C=C21 IGHABSGIFVLZGE-UHFFFAOYSA-N 0.000 description 1
- RDYJSPDOVOOEEM-UHFFFAOYSA-N 3-(7-fluoro-4-oxo-5h-imidazo[1,5-a]quinoxalin-1-yl)propanoic acid Chemical compound C1=C(F)C=C2NC(=O)C3=CN=C(CCC(=O)O)N3C2=C1 RDYJSPDOVOOEEM-UHFFFAOYSA-N 0.000 description 1
- PHXASJZCRNYKTG-UHFFFAOYSA-N 3-(7-methoxy-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl)propanoic acid Chemical compound N1C(=O)C2=CC=C(CCC(O)=O)N2C2=CC=C(OC)C=C21 PHXASJZCRNYKTG-UHFFFAOYSA-N 0.000 description 1
- HOORJIJUUNCVDG-UHFFFAOYSA-N 3-(7-methyl-4-oxo-5h-imidazo[1,5-a]quinoxalin-1-yl)propanoic acid Chemical compound N1C(=O)C2=CN=C(CCC(O)=O)N2C2=CC=C(C)C=C21 HOORJIJUUNCVDG-UHFFFAOYSA-N 0.000 description 1
- WLUGNTHKUNRACM-UHFFFAOYSA-N 3-(7-methyl-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl)propanoic acid Chemical compound N1C(=O)C2=CC=C(CCC(O)=O)N2C2=CC=C(C)C=C21 WLUGNTHKUNRACM-UHFFFAOYSA-N 0.000 description 1
- KAWKVGAIOWUJLZ-UHFFFAOYSA-N 3-(8-chloro-2-methyl-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl)propanoic acid Chemical compound ClC1=CC=C2NC(=O)C3=CC(C)=C(CCC(O)=O)N3C2=C1 KAWKVGAIOWUJLZ-UHFFFAOYSA-N 0.000 description 1
- KTSUIVHENNPUDM-UHFFFAOYSA-N 3-(8-chloro-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl)propanoic acid Chemical compound ClC1=CC=C2NC(=O)C3=CC=C(CCC(=O)O)N3C2=C1 KTSUIVHENNPUDM-UHFFFAOYSA-N 0.000 description 1
- RLVIVPNAWZCJJJ-UHFFFAOYSA-N 3-[2,3-dimethyl-4-oxo-7-(trifluoromethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound C1=C(C(F)(F)F)C=C2NC(=O)C3=C(C)C(C)=C(CCC(O)=O)N3C2=C1 RLVIVPNAWZCJJJ-UHFFFAOYSA-N 0.000 description 1
- ABOMLFFJFZOXPQ-UHFFFAOYSA-N 3-[2-ethyl-3-methyl-4-oxo-7-(trifluoromethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound C1=C(C(F)(F)F)C=C2NC(=O)C3=C(C)C(CC)=C(CCC(O)=O)N3C2=C1 ABOMLFFJFZOXPQ-UHFFFAOYSA-N 0.000 description 1
- ODIINGKMXVSFTO-UHFFFAOYSA-N 3-[2-ethyl-4-oxo-7-(trifluoromethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound C1=C(C(F)(F)F)C=C2NC(=O)C3=CC(CC)=C(CCC(O)=O)N3C2=C1 ODIINGKMXVSFTO-UHFFFAOYSA-N 0.000 description 1
- OEJVLYUQRLGKTA-UHFFFAOYSA-N 3-[2-methyl-4-oxo-7-(propoxymethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound N1C(=O)C2=CC(C)=C(CCC(O)=O)N2C2=CC=C(COCCC)C=C21 OEJVLYUQRLGKTA-UHFFFAOYSA-N 0.000 description 1
- FRTZFAMOOIUHTL-UHFFFAOYSA-N 3-[2-methyl-4-oxo-8-(trifluoromethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound FC(F)(F)C1=CC=C2NC(=O)C3=CC(C)=C(CCC(O)=O)N3C2=C1 FRTZFAMOOIUHTL-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- YRZZXOLCXIFJST-UHFFFAOYSA-N 3-[3-methyl-4-oxo-7-(trifluoromethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound FC(F)(F)C1=CC=C2N3C(CCC(O)=O)=CC(C)=C3C(=O)NC2=C1 YRZZXOLCXIFJST-UHFFFAOYSA-N 0.000 description 1
- VYSIIRFBNBGEKW-UHFFFAOYSA-N 3-[4-oxo-7-(propoxymethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound N1C(=O)C2=CC=C(CCC(O)=O)N2C2=CC=C(COCCC)C=C21 VYSIIRFBNBGEKW-UHFFFAOYSA-N 0.000 description 1
- UFPCPUIJYWTAEM-UHFFFAOYSA-N 3-[4-oxo-7-(trifluoromethyl)-5h-imidazo[1,5-a]quinoxalin-1-yl]propanoic acid Chemical compound C1=C(C(F)(F)F)C=C2NC(=O)C3=CN=C(CCC(=O)O)N3C2=C1 UFPCPUIJYWTAEM-UHFFFAOYSA-N 0.000 description 1
- QHLBJMOZVVEURV-UHFFFAOYSA-N 3-[4-oxo-8-(trifluoromethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound FC(F)(F)C1=CC=C2NC(=O)C3=CC=C(CCC(=O)O)N3C2=C1 QHLBJMOZVVEURV-UHFFFAOYSA-N 0.000 description 1
- KRUPBSIVSHQNGC-UHFFFAOYSA-N 3-[7-(butoxymethyl)-2-methyl-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound N1C(=O)C2=CC(C)=C(CCC(O)=O)N2C2=CC=C(COCCCC)C=C21 KRUPBSIVSHQNGC-UHFFFAOYSA-N 0.000 description 1
- WYQKSRLROQOSFH-UHFFFAOYSA-N 3-[7-(butoxymethyl)-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl]-2-methylpropanoic acid Chemical compound N1C(=O)C2=CC=C(CC(C)C(O)=O)N2C2=CC=C(COCCCC)C=C21 WYQKSRLROQOSFH-UHFFFAOYSA-N 0.000 description 1
- DTDIPQUCVZQFRA-UHFFFAOYSA-N 3-[7-(butoxymethyl)-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound N1C(=O)C2=CC=C(CCC(O)=O)N2C2=CC=C(COCCCC)C=C21 DTDIPQUCVZQFRA-UHFFFAOYSA-N 0.000 description 1
- VSCOYVRIOCTJNN-UHFFFAOYSA-N 3-[7-(ethoxymethyl)-2-methyl-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound N1C(=O)C2=CC(C)=C(CCC(O)=O)N2C2=CC=C(COCC)C=C21 VSCOYVRIOCTJNN-UHFFFAOYSA-N 0.000 description 1
- KEMNPCAFLYDYCS-UHFFFAOYSA-N 3-[7-(ethoxymethyl)-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl]-2-methylpropanoic acid Chemical compound N1C(=O)C2=CC=C(CC(C)C(O)=O)N2C2=CC=C(COCC)C=C21 KEMNPCAFLYDYCS-UHFFFAOYSA-N 0.000 description 1
- UPUKMGGMJZRJOZ-UHFFFAOYSA-N 3-[7-(ethoxymethyl)-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound N1C(=O)C2=CC=C(CCC(O)=O)N2C2=CC=C(COCC)C=C21 UPUKMGGMJZRJOZ-UHFFFAOYSA-N 0.000 description 1
- PZUCHFQVQHFUJR-UHFFFAOYSA-N 3-[7-(methoxymethyl)-2-methyl-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound N1C(=O)C2=CC(C)=C(CCC(O)=O)N2C2=CC=C(COC)C=C21 PZUCHFQVQHFUJR-UHFFFAOYSA-N 0.000 description 1
- UHCNCAJUXAABDF-UHFFFAOYSA-N 3-[7-(methoxymethyl)-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl]-2-methylpropanoic acid Chemical compound N1C(=O)C2=CC=C(CC(C)C(O)=O)N2C2=CC=C(COC)C=C21 UHCNCAJUXAABDF-UHFFFAOYSA-N 0.000 description 1
- DAHGIXXXTRZGCK-UHFFFAOYSA-N 3-[7-(methoxymethyl)-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl]propanoic acid Chemical compound N1C(=O)C2=CC=C(CCC(O)=O)N2C2=CC=C(COC)C=C21 DAHGIXXXTRZGCK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- GJWBZPLNBGDWMP-UHFFFAOYSA-N 3-chloro-9-cyclohexylimidazo[1,5-a]pyrido[3,2-e]pyrazin-6 (5h)-one Chemical compound C=1C(Cl)=CN=C(N23)C=1NC(=O)C3=CN=C2C1CCCCC1 GJWBZPLNBGDWMP-UHFFFAOYSA-N 0.000 description 1
- HGINADPHJQTSKN-UHFFFAOYSA-M 3-ethoxy-3-oxopropanoate Chemical compound CCOC(=O)CC([O-])=O HGINADPHJQTSKN-UHFFFAOYSA-M 0.000 description 1
- RBIGKSZIQCTIJF-UHFFFAOYSA-N 3-formylthiophene Chemical compound O=CC=1C=CSC=1 RBIGKSZIQCTIJF-UHFFFAOYSA-N 0.000 description 1
- UQEANKGXXSENNF-UHFFFAOYSA-N 4-bromo-1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Br)=CC=C1F UQEANKGXXSENNF-UHFFFAOYSA-N 0.000 description 1
- SEWNAJIUKSTYOP-UHFFFAOYSA-N 4-chloro-3-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC(S(Cl)(=O)=O)=CC=C1Cl SEWNAJIUKSTYOP-UHFFFAOYSA-N 0.000 description 1
- RUQAPQLDPWSAQM-UHFFFAOYSA-N 4-ethyl-2-nitroaniline Chemical compound CCC1=CC=C(N)C([N+]([O-])=O)=C1 RUQAPQLDPWSAQM-UHFFFAOYSA-N 0.000 description 1
- TTZOLDXHOCCNMF-UHFFFAOYSA-N 4-fluoro-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1O TTZOLDXHOCCNMF-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- ULPFXSKFRXORLX-UHFFFAOYSA-N 4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C1=C(C(N)=O)C=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 ULPFXSKFRXORLX-UHFFFAOYSA-N 0.000 description 1
- LXGVZQSKCKZTAI-UHFFFAOYSA-N 4-oxo-1-pentan-3-yl-n-propyl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N1C(=O)C2=CN=C(C(CC)CC)N2C2=CC(C(=O)NCCC)=CC=C21 LXGVZQSKCKZTAI-UHFFFAOYSA-N 0.000 description 1
- KQCMDMFAVPQHQV-UHFFFAOYSA-N 5-[4-oxo-7-(trifluoromethyl)-5h-pyrrolo[1,2-a]quinoxalin-1-yl]pentanoic acid Chemical compound C1=C(C(F)(F)F)C=C2NC(=O)C3=CC=C(CCCCC(=O)O)N3C2=C1 KQCMDMFAVPQHQV-UHFFFAOYSA-N 0.000 description 1
- JYZUDVSNYNWXHM-UHFFFAOYSA-N 5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound O=C1NC2=CC=CC=C2N2C1=CN=C2 JYZUDVSNYNWXHM-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- DEGMAOOEYMHXOX-UHFFFAOYSA-N 7-(4-acetylpiperazine-1-carbonyl)-8-chloro-1-cyclohexyl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C1CN(C(=O)C)CCN1C(=O)C(C(=C1)Cl)=CC2=C1N1C(C3CCCCC3)=NC=C1C(=O)N2 DEGMAOOEYMHXOX-UHFFFAOYSA-N 0.000 description 1
- CBWVIDRYZIIXLK-UHFFFAOYSA-N 7-(4-acetylpiperazine-1-carbonyl)-8-chloro-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound CCC(CC)C1=NC=C(C(NC2=C3)=O)N1C2=CC(Cl)=C3C(=O)N1CCN(C(C)=O)CC1 CBWVIDRYZIIXLK-UHFFFAOYSA-N 0.000 description 1
- UXRNJIJZFCMDSW-UHFFFAOYSA-N 7-acetyl-1-cyclohexyl-8-methoxy-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C1=C(C(C)=O)C(OC)=CC(N23)=C1NC(=O)C3=CN=C2C1CCCCC1 UXRNJIJZFCMDSW-UHFFFAOYSA-N 0.000 description 1
- UYNMJOAAICLHGR-UHFFFAOYSA-N 7-chloro-1-(3-hydroxypropyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C1=C(Cl)C=C2NC(=O)C3=CN=C(CCCO)N3C2=C1 UYNMJOAAICLHGR-UHFFFAOYSA-N 0.000 description 1
- CKVWVUJFBLKURF-UHFFFAOYSA-N 7-chloro-1-cyclohexyl-8-(morpholine-4-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N12C=3C=C(C(=O)N4CCOCC4)C(Cl)=CC=3NC(=O)C2=CN=C1C1CCCCC1 CKVWVUJFBLKURF-UHFFFAOYSA-N 0.000 description 1
- ROFPIBFKTZWUMB-UHFFFAOYSA-N 7-chloro-1-cyclohexyl-n,n-dimethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound C1=C(Cl)C(C(=O)N(C)C)=CC(N23)=C1NC(=O)C3=CN=C2C1CCCCC1 ROFPIBFKTZWUMB-UHFFFAOYSA-N 0.000 description 1
- RSHIEVWTEQCVMU-UHFFFAOYSA-N 7-chloro-1-cyclohexyl-n-(2-methoxyethyl)-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound C1=C(Cl)C(C(=O)N(C)CCOC)=CC(N23)=C1NC(=O)C3=CN=C2C1CCCCC1 RSHIEVWTEQCVMU-UHFFFAOYSA-N 0.000 description 1
- VJVYCJIULNTODR-UHFFFAOYSA-N 7-chloro-1-propan-2-yl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C1=C(Cl)C=C2NC(=O)C3=CN=C(C(C)C)N3C2=C1 VJVYCJIULNTODR-UHFFFAOYSA-N 0.000 description 1
- WCDLPFNDEAHBJB-UHFFFAOYSA-N 7-methoxy-n,n-dimethyl-4-oxo-1-piperidin-1-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C=3C=C(C(=O)N(C)C)C(OC)=CC=3NC(=O)C2=CN=C1N1CCCCC1 WCDLPFNDEAHBJB-UHFFFAOYSA-N 0.000 description 1
- JZVGYWUUYPBDIC-UHFFFAOYSA-N 7-methoxy-n,n-dimethyl-4-oxo-1-pyrrolidin-1-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C=3C=C(C(=O)N(C)C)C(OC)=CC=3NC(=O)C2=CN=C1N1CCCC1 JZVGYWUUYPBDIC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- MDJRBQFGDIOMFB-UHFFFAOYSA-N 8-(4-methylpiperazine-1-carbonyl)-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound CCC(CC)C1=NC=C(C(NC2=CC=3)=O)N1C2=CC=3C(=O)N1CCN(C)CC1 MDJRBQFGDIOMFB-UHFFFAOYSA-N 0.000 description 1
- VXLRWGOXPSHOSS-UHFFFAOYSA-N 8-(morpholine-4-carbonyl)-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound CCC(CC)C1=NC=C(C(NC2=CC=3)=O)N1C2=CC=3C(=O)N1CCOCC1 VXLRWGOXPSHOSS-UHFFFAOYSA-N 0.000 description 1
- DDZALZGBUKRDOC-UHFFFAOYSA-N 8-[4-(2-hydroxyethyl)piperidine-1-carbonyl]-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound CCC(CC)C1=NC=C(C(NC2=CC=3)=O)N1C2=CC=3C(=O)N1CCC(CCO)CC1 DDZALZGBUKRDOC-UHFFFAOYSA-N 0.000 description 1
- GBXACVQTOMYWKV-UHFFFAOYSA-N 8-acetyl-1-(azepin-1-yl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N12C3=CC(C(=O)C)=CC=C3NC(=O)C2=CN=C1N1C=CC=CC=C1 GBXACVQTOMYWKV-UHFFFAOYSA-N 0.000 description 1
- VQCZMWAJUDPGCG-UHFFFAOYSA-N 8-acetyl-1-(oxan-4-yl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N12C3=CC(C(=O)C)=CC=C3NC(=O)C2=CN=C1C1CCOCC1 VQCZMWAJUDPGCG-UHFFFAOYSA-N 0.000 description 1
- TZNUIMSPNHLNPJ-UHFFFAOYSA-N 8-acetyl-1-cyclohexyl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N12C3=CC(C(=O)C)=CC=C3NC(=O)C2=CN=C1C1CCCCC1 TZNUIMSPNHLNPJ-UHFFFAOYSA-N 0.000 description 1
- NHFDSVSRCHNULJ-UHFFFAOYSA-N 8-acetyl-1-morpholin-4-yl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N12C3=CC(C(=O)C)=CC=C3NC(=O)C2=CN=C1N1CCOCC1 NHFDSVSRCHNULJ-UHFFFAOYSA-N 0.000 description 1
- MCHBORUJUXHAFW-UHFFFAOYSA-N 8-acetyl-1-piperidin-1-yl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N12C3=CC(C(=O)C)=CC=C3NC(=O)C2=CN=C1N1CCCCC1 MCHBORUJUXHAFW-UHFFFAOYSA-N 0.000 description 1
- WWZSJJHEADNUQK-UHFFFAOYSA-N 8-acetyl-1-pyrrolidin-1-yl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N12C3=CC(C(=O)C)=CC=C3NC(=O)C2=CN=C1N1CCCC1 WWZSJJHEADNUQK-UHFFFAOYSA-N 0.000 description 1
- MESNTSLELBRUIV-UHFFFAOYSA-N 8-chloro-1-cyclohexyl-7-(3-methyl-1,2,4-oxadiazol-5-yl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound CC1=NOC(C=2C(=CC=3N4C(C5CCCCC5)=NC=C4C(=O)NC=3C=2)Cl)=N1 MESNTSLELBRUIV-UHFFFAOYSA-N 0.000 description 1
- ZPQGPDNGZZTKPJ-UHFFFAOYSA-N 8-chloro-1-cyclohexyl-7-(4-hydroxypiperidine-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C1CC(O)CCN1C(=O)C(C(=C1)Cl)=CC2=C1N1C(C3CCCCC3)=NC=C1C(=O)N2 ZPQGPDNGZZTKPJ-UHFFFAOYSA-N 0.000 description 1
- WSDJQUHXLXVUBO-UHFFFAOYSA-N 8-chloro-1-cyclohexyl-7-(4-methylpiperazine-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C1CN(C)CCN1C(=O)C(C(=C1)Cl)=CC2=C1N1C(C3CCCCC3)=NC=C1C(=O)N2 WSDJQUHXLXVUBO-UHFFFAOYSA-N 0.000 description 1
- HPHIZRZVXKLYCN-UHFFFAOYSA-N 8-chloro-1-cyclohexyl-7-(morpholine-4-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound ClC1=CC(N2C(C3CCCCC3)=NC=C2C(=O)N2)=C2C=C1C(=O)N1CCOCC1 HPHIZRZVXKLYCN-UHFFFAOYSA-N 0.000 description 1
- AWNIMOQHSSBABZ-UHFFFAOYSA-N 8-chloro-1-cyclohexyl-7-(piperidine-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound ClC1=CC(N2C(C3CCCCC3)=NC=C2C(=O)N2)=C2C=C1C(=O)N1CCCCC1 AWNIMOQHSSBABZ-UHFFFAOYSA-N 0.000 description 1
- LYYNAYXUTFWPJB-UHFFFAOYSA-N 8-chloro-1-cyclohexyl-7-(pyrrolidine-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound ClC1=CC(N2C(C3CCCCC3)=NC=C2C(=O)N2)=C2C=C1C(=O)N1CCCC1 LYYNAYXUTFWPJB-UHFFFAOYSA-N 0.000 description 1
- HEKFKHONEGWJMR-UHFFFAOYSA-N 8-chloro-1-cyclohexyl-7-[4-(2-hydroxyethyl)piperazine-1-carbonyl]-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C1CN(CCO)CCN1C(=O)C(C(=C1)Cl)=CC2=C1N1C(C3CCCCC3)=NC=C1C(=O)N2 HEKFKHONEGWJMR-UHFFFAOYSA-N 0.000 description 1
- DFQCIDAQUGNIKJ-UHFFFAOYSA-N 8-chloro-1-cyclohexyl-7-[4-(2-hydroxyethyl)piperidine-1-carbonyl]-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound C1CC(CCO)CCN1C(=O)C(C(=C1)Cl)=CC2=C1N1C(C3CCCCC3)=NC=C1C(=O)N2 DFQCIDAQUGNIKJ-UHFFFAOYSA-N 0.000 description 1
- SRBTXBASBPITIQ-UHFFFAOYSA-N 8-chloro-1-cyclohexyl-n,n-diethyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound N12C=3C=C(Cl)C(C(=O)N(CC)CC)=CC=3NC(=O)C2=CN=C1C1CCCCC1 SRBTXBASBPITIQ-UHFFFAOYSA-N 0.000 description 1
- QTTZFSCRHCJWJD-UHFFFAOYSA-N 8-chloro-1-cyclohexyl-n-(2-hydroxyethyl)-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound N12C=3C=C(Cl)C(C(=O)N(CCO)C)=CC=3NC(=O)C2=CN=C1C1CCCCC1 QTTZFSCRHCJWJD-UHFFFAOYSA-N 0.000 description 1
- GCHGXVQBMPXQSU-UHFFFAOYSA-N 8-chloro-1-cyclohexyl-n-ethyl-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound N12C=3C=C(Cl)C(C(=O)N(C)CC)=CC=3NC(=O)C2=CN=C1C1CCCCC1 GCHGXVQBMPXQSU-UHFFFAOYSA-N 0.000 description 1
- HIIGCSBOAIVYQD-UHFFFAOYSA-N 8-chloro-1-cyclohexyl-n-methyl-4-oxo-n-(2-phenylethyl)-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C=1C=2NC(=O)C3=CN=C(C4CCCCC4)N3C=2C=C(Cl)C=1C(=O)N(C)CCC1=CC=CC=C1 HIIGCSBOAIVYQD-UHFFFAOYSA-N 0.000 description 1
- DTOBCVCUMOQLNP-UHFFFAOYSA-N 8-chloro-1-cyclohexyl-n-methyl-4-oxo-n-(2-pyridin-2-ylethyl)-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C=1C=2NC(=O)C3=CN=C(C4CCCCC4)N3C=2C=C(Cl)C=1C(=O)N(C)CCC1=CC=CC=N1 DTOBCVCUMOQLNP-UHFFFAOYSA-N 0.000 description 1
- RTBYJIUAOLCNAA-UHFFFAOYSA-N 8-chloro-1-cyclohexyl-n-methyl-4-oxo-n-propyl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound N12C=3C=C(Cl)C(C(=O)N(C)CCC)=CC=3NC(=O)C2=CN=C1C1CCCCC1 RTBYJIUAOLCNAA-UHFFFAOYSA-N 0.000 description 1
- SGYGBDCIWNASKP-UHFFFAOYSA-N 8-chloro-1-pentan-3-yl-7-(piperidine-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound CCC(CC)C1=NC=C(C(NC2=C3)=O)N1C2=CC(Cl)=C3C(=O)N1CCCCC1 SGYGBDCIWNASKP-UHFFFAOYSA-N 0.000 description 1
- QUCXVQSDZLPDRX-UHFFFAOYSA-N 8-chloro-1-pentan-3-yl-7-(pyrrolidine-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound CCC(CC)C1=NC=C(C(NC2=C3)=O)N1C2=CC(Cl)=C3C(=O)N1CCCC1 QUCXVQSDZLPDRX-UHFFFAOYSA-N 0.000 description 1
- LZUMATFDUMKPFU-UHFFFAOYSA-N 8-chloro-7-(4-hydroxypiperidine-1-carbonyl)-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound CCC(CC)C1=NC=C(C(NC2=C3)=O)N1C2=CC(Cl)=C3C(=O)N1CCC(O)CC1 LZUMATFDUMKPFU-UHFFFAOYSA-N 0.000 description 1
- HOCQRFQGVJFXMY-UHFFFAOYSA-N 8-chloro-7-(4-methylpiperazine-1-carbonyl)-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound CCC(CC)C1=NC=C(C(NC2=C3)=O)N1C2=CC(Cl)=C3C(=O)N1CCN(C)CC1 HOCQRFQGVJFXMY-UHFFFAOYSA-N 0.000 description 1
- QJUBGVRTLGADMS-UHFFFAOYSA-N 8-chloro-7-(morpholine-4-carbonyl)-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound CCC(CC)C1=NC=C(C(NC2=C3)=O)N1C2=CC(Cl)=C3C(=O)N1CCOCC1 QJUBGVRTLGADMS-UHFFFAOYSA-N 0.000 description 1
- PNFDMKUSGCXTQX-UHFFFAOYSA-N 8-chloro-7-[4-(2-hydroxyethyl)piperazine-1-carbonyl]-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound CCC(CC)C1=NC=C(C(NC2=C3)=O)N1C2=CC(Cl)=C3C(=O)N1CCN(CCO)CC1 PNFDMKUSGCXTQX-UHFFFAOYSA-N 0.000 description 1
- IUNFUMVNDMYKHF-UHFFFAOYSA-N 8-chloro-7-[4-(2-hydroxyethyl)piperidine-1-carbonyl]-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound CCC(CC)C1=NC=C(C(NC2=C3)=O)N1C2=CC(Cl)=C3C(=O)N1CCC(CCO)CC1 IUNFUMVNDMYKHF-UHFFFAOYSA-N 0.000 description 1
- BSICUEDURCUQJH-UHFFFAOYSA-N 8-chloro-n,1-dicyclohexyl-n-methyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C=1C=2NC(=O)C3=CN=C(C4CCCCC4)N3C=2C=C(Cl)C=1C(=O)N(C)C1CCCCC1 BSICUEDURCUQJH-UHFFFAOYSA-N 0.000 description 1
- OVSUJMZZCXUQAP-UHFFFAOYSA-N 8-chloro-n,n-diethyl-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound ClC1=C(C(=O)N(CC)CC)C=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 OVSUJMZZCXUQAP-UHFFFAOYSA-N 0.000 description 1
- VWVXINXVMKOCLT-UHFFFAOYSA-N 8-chloro-n,n-dimethyl-1-(oxan-4-yl)-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound N12C=3C=C(Cl)C(C(=O)N(C)C)=CC=3NC(=O)C2=CN=C1C1CCOCC1 VWVXINXVMKOCLT-UHFFFAOYSA-N 0.000 description 1
- ZDJRHJXQOWNMIK-UHFFFAOYSA-N 8-chloro-n,n-dimethyl-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound ClC1=C(C(=O)N(C)C)C=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 ZDJRHJXQOWNMIK-UHFFFAOYSA-N 0.000 description 1
- ITBGAQXMLGFRHN-UHFFFAOYSA-N 8-chloro-n,n-dimethyl-4-oxo-1-piperidin-1-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound N12C=3C=C(Cl)C(C(=O)N(C)C)=CC=3NC(=O)C2=CN=C1N1CCCCC1 ITBGAQXMLGFRHN-UHFFFAOYSA-N 0.000 description 1
- MUQLHIGPEWBKHU-UHFFFAOYSA-N 8-chloro-n,n-dimethyl-4-oxo-1-pyrrolidin-1-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound N12C=3C=C(Cl)C(C(=O)N(C)C)=CC=3NC(=O)C2=CN=C1N1CCCC1 MUQLHIGPEWBKHU-UHFFFAOYSA-N 0.000 description 1
- LVQVXNQTFRUXKX-UHFFFAOYSA-N 8-chloro-n-(2-hydroxyethyl)-n-methyl-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound ClC1=C(C(=O)N(C)CCO)C=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 LVQVXNQTFRUXKX-UHFFFAOYSA-N 0.000 description 1
- SBVFBZQPMHMAAW-UHFFFAOYSA-N 8-chloro-n-(2-methoxyethyl)-n-methyl-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound ClC1=C(C(=O)N(C)CCOC)C=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 SBVFBZQPMHMAAW-UHFFFAOYSA-N 0.000 description 1
- OMIUESXHIWXIQK-UHFFFAOYSA-N 8-chloro-n-ethyl-n-methyl-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound ClC1=C(C(=O)N(C)CC)C=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 OMIUESXHIWXIQK-UHFFFAOYSA-N 0.000 description 1
- DONYESXRKPFSPV-UHFFFAOYSA-N 8-chloro-n-methyl-4-oxo-1-pentan-3-yl-n-propyl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound N1C(=O)C2=CN=C(C(CC)CC)N2C2=C1C=C(C(=O)N(C)CCC)C(Cl)=C2 DONYESXRKPFSPV-UHFFFAOYSA-N 0.000 description 1
- KWDCGKOPBSPGAM-UHFFFAOYSA-N 8-ethoxy-n,n-dimethyl-4-oxo-1-piperidin-1-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C1=C(C(=O)N(C)C)C(OCC)=CC(N23)=C1NC(=O)C3=CN=C2N1CCCCC1 KWDCGKOPBSPGAM-UHFFFAOYSA-N 0.000 description 1
- KXIQUHKIHMUDLF-UHFFFAOYSA-N 8-methoxy-1-pentan-3-yl-7-(piperidine-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound CCC(CC)C1=NC=C(C(NC2=C3)=O)N1C2=CC(OC)=C3C(=O)N1CCCCC1 KXIQUHKIHMUDLF-UHFFFAOYSA-N 0.000 description 1
- QKBZZYBCZXEURO-UHFFFAOYSA-N 8-methoxy-1-pentan-3-yl-7-(pyrrolidine-1-carbonyl)-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound CCC(CC)C1=NC=C(C(NC2=C3)=O)N1C2=CC(OC)=C3C(=O)N1CCCC1 QKBZZYBCZXEURO-UHFFFAOYSA-N 0.000 description 1
- PAMQGTQIRQEPML-UHFFFAOYSA-N 8-methoxy-7-(morpholine-4-carbonyl)-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound CCC(CC)C1=NC=C(C(NC2=C3)=O)N1C2=CC(OC)=C3C(=O)N1CCOCC1 PAMQGTQIRQEPML-UHFFFAOYSA-N 0.000 description 1
- WXAJKOKMDDKEOM-UHFFFAOYSA-N 8-methoxy-n,n,3-trimethyl-4-oxo-1-piperidin-1-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C1=C(C(=O)N(C)C)C(OC)=CC(N23)=C1NC(=O)C3=C(C)N=C2N1CCCCC1 WXAJKOKMDDKEOM-UHFFFAOYSA-N 0.000 description 1
- NGZQQWMCSDPKKG-UHFFFAOYSA-N 8-methoxy-n,n,3-trimethyl-4-oxo-1-pyrrolidin-1-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C1=C(C(=O)N(C)C)C(OC)=CC(N23)=C1NC(=O)C3=C(C)N=C2N1CCCC1 NGZQQWMCSDPKKG-UHFFFAOYSA-N 0.000 description 1
- XJRJQPDOZQFLNB-UHFFFAOYSA-N 8-methoxy-n,n-dimethyl-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound COC1=C(C(=O)N(C)C)C=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 XJRJQPDOZQFLNB-UHFFFAOYSA-N 0.000 description 1
- JPUJOEBXIOWXMN-UHFFFAOYSA-N 8-methoxy-n,n-dimethyl-4-oxo-1-piperidin-1-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C1=C(C(=O)N(C)C)C(OC)=CC(N23)=C1NC(=O)C3=CN=C2N1CCCCC1 JPUJOEBXIOWXMN-UHFFFAOYSA-N 0.000 description 1
- HIXMUPBYMKEAEC-UHFFFAOYSA-N 8-methoxy-n,n-dimethyl-4-oxo-1-pyrrolidin-1-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C1=C(C(=O)N(C)C)C(OC)=CC(N23)=C1NC(=O)C3=CN=C2N1CCCC1 HIXMUPBYMKEAEC-UHFFFAOYSA-N 0.000 description 1
- BSIFPTHQKRLGTA-UHFFFAOYSA-N 8-methoxy-n-(2-methoxyethyl)-n-methyl-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound COC1=C(C(=O)N(C)CCOC)C=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 BSIFPTHQKRLGTA-UHFFFAOYSA-N 0.000 description 1
- NVAABBOHSFLGNO-UHFFFAOYSA-N 8-methoxy-n-methyl-4-oxo-1-pentan-3-yl-n-(2-pyridin-2-ylethyl)-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound CCC(CC)C1=NC=C(C(NC2=C3)=O)N1C2=CC(OC)=C3C(=O)N(C)CCC1=CC=CC=N1 NVAABBOHSFLGNO-UHFFFAOYSA-N 0.000 description 1
- NFZHIJKMZPKIRW-UHFFFAOYSA-N 8-methoxy-n-methyl-4-oxo-1-pentan-3-yl-n-propyl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound N1C(=O)C2=CN=C(C(CC)CC)N2C2=C1C=C(C(=O)N(C)CCC)C(OC)=C2 NFZHIJKMZPKIRW-UHFFFAOYSA-N 0.000 description 1
- PTUAEWYKIMWZSL-UHFFFAOYSA-N 8-methylsulfonyl-1-piperidin-1-yl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N12C3=CC(S(=O)(=O)C)=CC=C3NC(=O)C2=CN=C1N1CCCCC1 PTUAEWYKIMWZSL-UHFFFAOYSA-N 0.000 description 1
- BFCVUXKZNDOKPQ-UHFFFAOYSA-N 8-methylsulfonyl-1-pyrrolidin-1-yl-5h-imidazo[1,5-a]quinoxalin-4-one Chemical compound N12C3=CC(S(=O)(=O)C)=CC=C3NC(=O)C2=CN=C1N1CCCC1 BFCVUXKZNDOKPQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- UDKQVXRSGZHNKQ-UHFFFAOYSA-N CC(C)OCCN(C)C(c(cc1-[n]2c3cnc2C2CC=CCC2)ccc1NC3=O)=O Chemical compound CC(C)OCCN(C)C(c(cc1-[n]2c3cnc2C2CC=CCC2)ccc1NC3=O)=O UDKQVXRSGZHNKQ-UHFFFAOYSA-N 0.000 description 1
- IQDLVBJMZKCNGK-UHFFFAOYSA-N CCC(CC)c1ncc2[n]1-c(cc(C)c(C(N1CCN(C)CC1)=O)c1)c1NC2=O Chemical compound CCC(CC)c1ncc2[n]1-c(cc(C)c(C(N1CCN(C)CC1)=O)c1)c1NC2=O IQDLVBJMZKCNGK-UHFFFAOYSA-N 0.000 description 1
- UJRRPPOLGPTXEW-UHFFFAOYSA-N CCC(CC)c1ncc2[n]1-c(cc(C)c(C(OCC)=O)c1)c1NC2=O Chemical compound CCC(CC)c1ncc2[n]1-c(cc(C)c(C(OCC)=O)c1)c1NC2=O UJRRPPOLGPTXEW-UHFFFAOYSA-N 0.000 description 1
- JAHAQMAQEGQQNS-UHFFFAOYSA-N CCCOCc(cc1N2)ccc1N(C(C1CC(O)=O)C1C=C1)C1C2=O Chemical compound CCCOCc(cc1N2)ccc1N(C(C1CC(O)=O)C1C=C1)C1C2=O JAHAQMAQEGQQNS-UHFFFAOYSA-N 0.000 description 1
- BRCKWSOTDPFGJN-PKNBQFBNSA-N CCOC(/C=C/c(cc1)cc(NC2=O)c1-[n]1c2cnc1C1CCCCC1)=O Chemical compound CCOC(/C=C/c(cc1)cc(NC2=O)c1-[n]1c2cnc1C1CCCCC1)=O BRCKWSOTDPFGJN-PKNBQFBNSA-N 0.000 description 1
- ZVXDJCWKRHCCDW-UHFFFAOYSA-N CCOc(cc(c(N1)c2)-[n]3c(N4CCCCCC4)ncc3C1=O)c2C(N(C)C)=O Chemical compound CCOc(cc(c(N1)c2)-[n]3c(N4CCCCCC4)ncc3C1=O)c2C(N(C)C)=O ZVXDJCWKRHCCDW-UHFFFAOYSA-N 0.000 description 1
- XJJYQVUFIZRJQR-UHFFFAOYSA-N CN(C)C(c(cc1)cc(-[n]2c(N3CCCCCC3)ncc22)c1NC2=O)=O Chemical compound CN(C)C(c(cc1)cc(-[n]2c(N3CCCCCC3)ncc22)c1NC2=O)=O XJJYQVUFIZRJQR-UHFFFAOYSA-N 0.000 description 1
- PUXRVHLGIYXUAS-UHFFFAOYSA-N CN(Cc1cccnc1)C(c(cc1)cc(-[n]2c(C3CCCCC3)ncc2)c1N)=O Chemical compound CN(Cc1cccnc1)C(c(cc1)cc(-[n]2c(C3CCCCC3)ncc2)c1N)=O PUXRVHLGIYXUAS-UHFFFAOYSA-N 0.000 description 1
- WVYMALKTGDCGKZ-UHFFFAOYSA-N CN(Cc1ccncc1)C(c(cc1-[n]2c(C3CCCCC3)ncc2)ccc1[N+]([O-])=O)=O Chemical compound CN(Cc1ccncc1)C(c(cc1-[n]2c(C3CCCCC3)ncc2)ccc1[N+]([O-])=O)=O WVYMALKTGDCGKZ-UHFFFAOYSA-N 0.000 description 1
- MWIODAOSCKOALK-UHFFFAOYSA-N COCCNC(c(cc1N(C(C2CCCCC2)=N)C2=N)ccc1NC2=O)=O Chemical compound COCCNC(c(cc1N(C(C2CCCCC2)=N)C2=N)ccc1NC2=O)=O MWIODAOSCKOALK-UHFFFAOYSA-N 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- WEVYWDAVYZHBCD-UHFFFAOYSA-N Cc(c(C(N1CCCCC1)=O)c1)cc(-[n]2c3cnc2C2CCCCC2)c1NC3=O Chemical compound Cc(c(C(N1CCCCC1)=O)c1)cc(-[n]2c3cnc2C2CCCCC2)c1NC3=O WEVYWDAVYZHBCD-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- LOKUAOIZZFQWQA-UHFFFAOYSA-O N=C1N(C(C2CCCCC2)=[NH2+])c2cc(C(N3CCC(CCO)CC3)=O)ccc2NC1=O Chemical compound N=C1N(C(C2CCCCC2)=[NH2+])c2cc(C(N3CCC(CCO)CC3)=O)ccc2NC1=O LOKUAOIZZFQWQA-UHFFFAOYSA-O 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- KQPHLCLDLHROGN-UHFFFAOYSA-N O=C1Nc(cc(C(F)(F)F)cc2)c2-[n]2c(N3CCCCCC3)ncc12 Chemical compound O=C1Nc(cc(C(F)(F)F)cc2)c2-[n]2c(N3CCCCCC3)ncc12 KQPHLCLDLHROGN-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- MXECRDXLRWECJR-UHFFFAOYSA-N [1,2,4]triazolo[4,3-a]quinoxaline-8-carboxylic acid Chemical compound N1=CC2=NN=CN2C2=CC(C(=O)O)=CC=C21 MXECRDXLRWECJR-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000004062 acenaphthenyl group Chemical group C1(CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000000748 anthracen-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C([H])=C([*])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 229940117389 dichlorobenzene Drugs 0.000 description 1
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
- 229940008406 diethyl sulfate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- YNLCKGMLCSABEZ-UHFFFAOYSA-N ethyl 1-heptan-4-yl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxylate Chemical compound CCOC(=O)C1=CC=C2NC(=O)C3=CN=C(C(CCC)CCC)N3C2=C1 YNLCKGMLCSABEZ-UHFFFAOYSA-N 0.000 description 1
- XHFJXQUWCLIYML-UHFFFAOYSA-N ethyl 2-chloro-4-fluoro-5-nitrobenzoate Chemical compound CCOC(=O)C1=CC([N+]([O-])=O)=C(F)C=C1Cl XHFJXQUWCLIYML-UHFFFAOYSA-N 0.000 description 1
- LSJCSDCZOPCWHV-UHFFFAOYSA-N ethyl 3-(7-ethyl-4-oxo-5h-imidazo[1,5-a]quinoxalin-1-yl)propanoate Chemical compound C1=C(CC)C=C2NC(=O)C3=CN=C(CCC(=O)OCC)N3C2=C1 LSJCSDCZOPCWHV-UHFFFAOYSA-N 0.000 description 1
- NHQJEOKODTZDJC-UHFFFAOYSA-N ethyl 3-(7-ethyl-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl)propanoate Chemical compound C1=C(CC)C=C2NC(=O)C3=CC=C(CCC(=O)OCC)N3C2=C1 NHQJEOKODTZDJC-UHFFFAOYSA-N 0.000 description 1
- HHGKSRUCYKOHAL-UHFFFAOYSA-N ethyl 3-(7-methoxy-4-oxo-5h-pyrrolo[1,2-a]quinoxalin-1-yl)propanoate Chemical compound C1=C(OC)C=C2NC(=O)C3=CC=C(CCC(=O)OCC)N3C2=C1 HHGKSRUCYKOHAL-UHFFFAOYSA-N 0.000 description 1
- JSEMUSFPVZYRSG-UHFFFAOYSA-N ethyl 3-(triphenyl-$l^{5}-phosphanylidene)propanoate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CCC(=O)OCC)C1=CC=CC=C1 JSEMUSFPVZYRSG-UHFFFAOYSA-N 0.000 description 1
- DVHKNVFQYWXSBY-UHFFFAOYSA-N ethyl 3-[1-(2-amino-4-fluorophenyl)imidazol-2-yl]propanoate Chemical compound CCOC(=O)CCC1=NC=CN1C1=CC=C(F)C=C1N DVHKNVFQYWXSBY-UHFFFAOYSA-N 0.000 description 1
- OZTWETAOVFFKMD-UHFFFAOYSA-N ethyl 3-[1-(4-fluoro-2-nitrophenyl)imidazol-2-yl]propanoate Chemical compound CCOC(=O)CCC1=NC=CN1C1=CC=C(F)C=C1[N+]([O-])=O OZTWETAOVFFKMD-UHFFFAOYSA-N 0.000 description 1
- AAJYCHBLTARBTA-SOFGYWHQSA-N ethyl 5-[(e)-3-ethoxy-3-oxoprop-1-enyl]-1h-pyrrole-2-carboxylate Chemical compound CCOC(=O)\C=C\C1=CC=C(C(=O)OCC)N1 AAJYCHBLTARBTA-SOFGYWHQSA-N 0.000 description 1
- YQEVRVNZIRSGRI-VOTSOKGWSA-N ethyl 5-[(e)-3-ethoxy-3-oxoprop-1-enyl]-4-methyl-1h-pyrrole-2-carboxylate Chemical compound CCOC(=O)\C=C\C=1NC(C(=O)OCC)=CC=1C YQEVRVNZIRSGRI-VOTSOKGWSA-N 0.000 description 1
- NJOCLQRXCADRBX-UHFFFAOYSA-N ethyl 5-formyl-3-methyl-1h-pyrrole-2-carboxylate Chemical compound CCOC(=O)C=1NC(C=O)=CC=1C NJOCLQRXCADRBX-UHFFFAOYSA-N 0.000 description 1
- LUELUPOYASSGSU-UHFFFAOYSA-N ethyl 6-(1,3-dioxolan-2-yl)-4-oxohexanoate Chemical compound CCOC(=O)CCC(=O)CCC1OCCO1 LUELUPOYASSGSU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- UUUBBRFTQCZTIV-UHFFFAOYSA-N methyl 1-cyclopentyl-4-oxo-5h-imidazo[1,5-a]quinoxaline-8-carboxylate Chemical compound N12C3=CC(C(=O)OC)=CC=C3NC(=O)C2=CN=C1C1CCCC1 UUUBBRFTQCZTIV-UHFFFAOYSA-N 0.000 description 1
- LHAVJVZNGLTPCY-UHFFFAOYSA-N methyl 4-fluoro-2-methoxy-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=C(F)C=C1OC LHAVJVZNGLTPCY-UHFFFAOYSA-N 0.000 description 1
- PRCYHYGREGWAAN-UHFFFAOYSA-N methyl 5-formyl-1h-pyrrole-2-carboxylate Chemical compound COC(=O)C1=CC=C(C=O)N1 PRCYHYGREGWAAN-UHFFFAOYSA-N 0.000 description 1
- DBSINFUKBIMHRJ-UHFFFAOYSA-N methyl 8-methoxy-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxylate Chemical compound COC1=C(C(=O)OC)C=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 DBSINFUKBIMHRJ-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- AEXITZJSLGALNH-UHFFFAOYSA-N n'-hydroxyethanimidamide Chemical compound CC(N)=NO AEXITZJSLGALNH-UHFFFAOYSA-N 0.000 description 1
- ZEYXSMJKEIDTCB-UHFFFAOYSA-N n,n,3-trimethyl-4-oxo-1-piperidin-1-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)C)=CC=C3NC(=O)C2=C(C)N=C1N1CCCCC1 ZEYXSMJKEIDTCB-UHFFFAOYSA-N 0.000 description 1
- MERUFILXEJTMLO-UHFFFAOYSA-N n,n,3-trimethyl-4-oxo-1-pyrrolidin-1-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)C)=CC=C3NC(=O)C2=C(C)N=C1N1CCCC1 MERUFILXEJTMLO-UHFFFAOYSA-N 0.000 description 1
- GCSAMMDMMGSUPV-UHFFFAOYSA-N n,n-diethyl-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound CCN(CC)C(=O)C1=CC=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 GCSAMMDMMGSUPV-UHFFFAOYSA-N 0.000 description 1
- ABYHLOSELCEYAH-UHFFFAOYSA-N n,n-diethyl-8-methoxy-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound COC1=C(C(=O)N(CC)CC)C=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 ABYHLOSELCEYAH-UHFFFAOYSA-N 0.000 description 1
- YPVCSNWLCQTOKG-UHFFFAOYSA-N n,n-dimethyl-1-(3-methylphenyl)-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C=1C(C(=O)N(C)C)=CC=C(N23)C=1NC(=O)C3=CN=C2C1=CC=CC(C)=C1 YPVCSNWLCQTOKG-UHFFFAOYSA-N 0.000 description 1
- MDCAEBFXMNOSGW-UHFFFAOYSA-N n,n-dimethyl-1-(4-methylphenyl)-4-oxo-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C=1C(C(=O)N(C)C)=CC=C(N23)C=1NC(=O)C3=CN=C2C1=CC=C(C)C=C1 MDCAEBFXMNOSGW-UHFFFAOYSA-N 0.000 description 1
- SNNXZWCUNPPCLW-UHFFFAOYSA-N n,n-dimethyl-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C1=C(C(=O)N(C)C)C=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 SNNXZWCUNPPCLW-UHFFFAOYSA-N 0.000 description 1
- MCHORXBCCHJMSA-UHFFFAOYSA-N n,n-dimethyl-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound CN(C)C(=O)C1=CC=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 MCHORXBCCHJMSA-UHFFFAOYSA-N 0.000 description 1
- BWGXAOBHNGIMER-UHFFFAOYSA-N n,n-dimethyl-4-oxo-1-piperidin-1-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)C)=CC=C3NC(=O)C2=CN=C1N1CCCCC1 BWGXAOBHNGIMER-UHFFFAOYSA-N 0.000 description 1
- AMPVKPFOYDLLCK-UHFFFAOYSA-N n,n-dimethyl-4-oxo-1-propan-2-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C1=C(C(=O)N(C)C)C=C2NC(=O)C3=CN=C(C(C)C)N3C2=C1 AMPVKPFOYDLLCK-UHFFFAOYSA-N 0.000 description 1
- CKHGYPLTHLYKBZ-UHFFFAOYSA-N n,n-dimethyl-4-oxo-1-pyrrolidin-1-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)C)=CC=C3NC(=O)C2=CN=C1N1CCCC1 CKHGYPLTHLYKBZ-UHFFFAOYSA-N 0.000 description 1
- SZKDJNBUJXNFBZ-UHFFFAOYSA-N n,n-dimethyl-4-oxo-1-thiophen-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound C=1C(C(=O)N(C)C)=CC=C(N23)C=1NC(=O)C3=CN=C2C=1C=CSC=1 SZKDJNBUJXNFBZ-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- TVLJVIDLXIDWOJ-UHFFFAOYSA-N n-(2-methoxyethyl)-n,3-dimethyl-4-oxo-1-piperidin-1-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)CCOC)=CC=C3NC(=O)C2=C(C)N=C1N1CCCCC1 TVLJVIDLXIDWOJ-UHFFFAOYSA-N 0.000 description 1
- DJDKOKIBDCYUSY-UHFFFAOYSA-N n-(2-methoxyethyl)-n,3-dimethyl-4-oxo-1-pyrrolidin-1-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)CCOC)=CC=C3NC(=O)C2=C(C)N=C1N1CCCC1 DJDKOKIBDCYUSY-UHFFFAOYSA-N 0.000 description 1
- UOXYCQZVYPIRKH-UHFFFAOYSA-N n-(2-methoxyethyl)-n-methyl-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound COCCN(C)C(=O)C1=CC=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 UOXYCQZVYPIRKH-UHFFFAOYSA-N 0.000 description 1
- GZPHWFGGVMETRB-UHFFFAOYSA-N n-(2-methoxyethyl)-n-methyl-4-oxo-1-piperidin-1-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)CCOC)=CC=C3NC(=O)C2=CN=C1N1CCCCC1 GZPHWFGGVMETRB-UHFFFAOYSA-N 0.000 description 1
- SULGTQAFTJDBJH-UHFFFAOYSA-N n-(2-methoxyethyl)-n-methyl-4-oxo-1-pyrrolidin-1-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)N(C)CCOC)=CC=C3NC(=O)C2=CN=C1N1CCCC1 SULGTQAFTJDBJH-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- YGSDBGSFOMUXTH-UHFFFAOYSA-N n-butyl-8-chloro-n-methyl-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound N1C(=O)C2=CN=C(C(CC)CC)N2C2=C1C=C(C(=O)N(C)CCCC)C(Cl)=C2 YGSDBGSFOMUXTH-UHFFFAOYSA-N 0.000 description 1
- FJJNQFBPQWXTPZ-UHFFFAOYSA-N n-cyclohexyl-8-methoxy-n-methyl-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound CCC(CC)C1=NC=C(C(NC2=C3)=O)N1C2=CC(OC)=C3C(=O)N(C)C1CCCCC1 FJJNQFBPQWXTPZ-UHFFFAOYSA-N 0.000 description 1
- YBHIOOJLCOQUAF-UHFFFAOYSA-N n-ethyl-8-methoxy-n-methyl-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-7-carboxamide Chemical compound COC1=C(C(=O)N(C)CC)C=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 YBHIOOJLCOQUAF-UHFFFAOYSA-N 0.000 description 1
- VTEQNHLFOAFVEN-UHFFFAOYSA-N n-ethyl-n-methyl-4-oxo-1-pentan-3-yl-5h-imidazo[1,5-a]quinoxaline-8-carboxamide Chemical compound CCN(C)C(=O)C1=CC=C2NC(=O)C3=CN=C(C(CC)CC)N3C2=C1 VTEQNHLFOAFVEN-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000005880 oxathiolanyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003585 oxepinyl group Chemical group 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- APSYYKGWNWKKOC-UHFFFAOYSA-N quinoxaline-5-carboxamide Chemical compound C1=CN=C2C(C(=O)N)=CC=CC2=N1 APSYYKGWNWKKOC-UHFFFAOYSA-N 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 1
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
R1及びR2はそれぞれ独立に水素原子;ハロゲン原子;場合によりヒドロキシ基、ハロゲン原子、C1-6アルコキシ基、1〜9個のハロゲン原子を有するC1-6ハロアルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、C1-6アルカノイル基、アミノ基、アミド基、カルバモイル基、オキソ基、炭素環式基もしくは複素環式基によって置換されていてもよいC1-6アルキル基又はC1-6アルコキシ基;場合によりヒドロキシ基、C1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、1〜9個のハロゲン原子を有するC1-6ハロアルキル基、C1-6アルコキシ基、1〜9個のハロゲン原子を有するC1-6ハロアルコキシ基、アミノ基、炭素環式基もしくは複素環式基によって置換されていてもよいアシル基;場合によりC1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、アルカノイル基、炭素環式基及び複素環式基から選ばれる1〜2個の置換基によって置換されていてもよいアミノ基;ヒドロキシ基;又は場合によりハロゲン原子、C1-6アルキル基、C1-6アルコキシ基、1〜9個のハロゲン原子を有するC1-6ハロアルコキシ基、ニトロ基もしくはアミノ基によって置換されていてもよいピリミジニル基を表し、
R3は場合によりヒドロキシ基、ハロゲン原子、C1-6アルコキシ基、1〜9個のハロゲン原子を有するC1-6ハロアルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、アルカノイル基、アミノ基(ここで、該アミノ基は場合によりC1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、1〜9個のハロゲン原子を有するC1-6ハロアルキル基、アルカノイル基、炭素環式基及び複素環式基から選ばれる1〜2個の置換基によってさらに置換されていてもよい)、アミド基、カルバモイル基、オキソ基、炭素環式基もしくは複素環式基(ここで、該炭素環式基及び複素環式基は場合によりそれぞれさらにヒドロキシ基、ハロゲン原子、C1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、C1-6アルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、アミノ基、アミド基もしくはカルバモイル基によって置換されていてもよい)によって置換されていてもよいC1-9アルキル基、C2-9アルケニル基又はC2-9アルキニル基;場合によりハロゲン原子、ヒドロキシ基、C1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、C1-6アルコキシ基(ここで、該C1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基及びC1-6アルコキシ基はそれぞれ独立に場合によりハロゲン原子、ヒドロキシ基、C1-6アルコキシ基、1〜9個のハロゲン原子を有するC1-6ハロアルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、アルカノイル基、アミノ基、アミド基、カルバモイル基、炭素環式基もしくは複素環式基によってさらに置換されていてもよい)、1〜9個のハロゲン原子を有するC1-6ハロアルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、アルカノイル基、アミノ基、アミド基、カルバモイル基、炭素環式基もしくは複素環式基によって置換されていてもよいアリール基、飽和炭素環式基又は飽和複素環式基;カルボキシ基;C1-6アルコキシカルボニル基(ここで、該C1-6アルコキシカルボニル基におけるC1-6アルコキシ部分は場合によりヒドロキシ基、ハロゲン原子、C1-6アルコキシ基、1〜9個のハロゲン原子を有するC1-6ハロアルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、アミノ基、アミド基、カルバモイル基、炭素環式基もしくは複素環式基によってさらに置換されていてもよい);アミド基(ここで、該アミド基におけるアミノ部分は場合によりC1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、1〜9個のハロゲン原子を有するC1-6ハロアルキル基、アルカノイル基、炭素環式基及び複素環式基から選ばれる1〜2個の置換基によってさらに置換されていてもよい);又はカルバモイル基(ここで、該カルバモイル基におけるアミノ部分は場合によりC1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、1〜9個のハロゲン原子を有するC1-6ハロアルキル基、アルカノイル基、炭素環式基及び複素環式基から選ばれる1〜2個の置換基によってさらに置換されていてもよい)を表し、
R4は水素原子;ヒドロキシ基;場合によりヒドロキシ基、ハロゲン原子、C1-6アルコキシ基、1〜9個のハロゲン原子を有するC1-6ハロアルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、アルカノイル基、アミノ基、アミド基、カルバモイル基もしくはオキソ基によって置換されていてもよいC1-6アルキル基;又は場合によりC1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、1〜9個のハロゲン原子を有するC1-6ハロアルキル基、アルカノイル基、炭素環式基及び複素環式基から選ばれる1〜2個の置換基によって置換されていてもよいアミノ基を表し、
R5及びR8はそれぞれ独立に水素原子;ハロゲン原子;場合によりヒドロキシ基、ハロゲン原子、C1-6アルコキシ基、1〜9個のハロゲン原子を有するC1-6ハロアルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、アルカノイル基、アミノ基、アミド基、カルバモイル基もしくはオキソ基によって置換されていてもよいC1-6アルキル基、C2-6アルケニル基又はC1-6アルコキシ基;シアノ基;又はニトロ基を表し、
R6及びR7はそれぞれ独立に水素原子;ハロゲン原子;場合によりヒドロキシ基、ハロゲン原子、C1-6アルコキシ基、1〜9個のハロゲン原子を有するC1-6ハロアルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、アルカノイル基、アミノ基(ここで、該アミノ基は場合によりC1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、1〜9個のハロゲン原子を有するC1-6ハロアルキル基、アルカノイル基、炭素環式基及び複素環式基から選ばれる1〜2個の置換基によってさらに置換されていてもよい)、アミド基、カルバモイル基、オキソ基、炭素環式基もしくは複素環式基(ここで、該炭素環式基及び複素環式基は場合によりそれぞれさらにヒドロキシ基、ハロゲン原子、C1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、C1-6アルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、アミノ基、アミド基もしくはカルバモイル基によって置換されていてもよい)によって置換されていてもよいC1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基又はC1-6アルコキシ基;シアノ基;場合によりC1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基(ここで、該C1-6アルキル基、C2-6アルケニル基及びC2-6アルキニル基はそれぞれ独立に場合によりヒドロキシ基、ハロゲン原子、C1-6アルコキシ基、1〜9個のハロゲン原子を有するC1-6ハロアルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、C1-6アルカノイル基、アミノ基、アミド基、カルバモイル基、オキソ基、炭素環式基もしくは複素環式基によってさらに置換されていてもよい)、アルカノイル基、炭素環式基及び複素環式基(ここで、該炭素環式基及び複素環式基は場合によりそれぞれさらにヒドロキシ基、ハロゲン原子、C1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、C1-6アルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、アミノ基、アミド基もしくはカルバモイル基によって置換されていてもよい)から選ばれる1〜2個の置換基によって置換されていてもよいアミノ基;場合によりヒドロキシ基、ハロゲン原子、C1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、C1-6アルコキシ基(ここで、該C1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基及びC1-6アルコキシ基はそれぞれ独立に場合によりヒドロキシ基、ハロゲン原子、C1-6アルコキシ基、1〜9個のハロゲン原子を有するC1-6ハロアルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、C1-6アルカノイル基、アミノ基、アミド基、カルバモイル基、オキソ基、炭素環式基もしくは複素環式基によってさらに置換されていてもよい)、1〜9個のハロゲン原子を有するC1-6ハロアルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、アミノ基、アミド基もしくはカルバモイル基によって置換されていてもよい炭素環式基又は複素環式基;COR9;又はSO2R9を表し、
R9は水素原子;ヒドロキシ基;場合によりヒドロキシ基、ハロゲン原子、C1-6アルコキシ基、1〜9個のハロゲン原子を有するC1-6ハロアルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、アルカノイル基、アミノ基(ここで、該アミノ基は場合によりC1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、1〜9個のハロゲン原子を有するC1-6ハロアルキル基、アルカノイル基、炭素環式基及び複素環式基から選ばれる1〜2個の置換基によってさらに置換されていてもよい)、アミド基、オキソ基、炭素環式基もしくは複素環式基(ここで、該炭素環式基及び複素環式基は場合によりそれぞれさらにヒドロキシ基、ハロゲン原子、C1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、C1-6アルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、アミノ基、アミド基もしくはカルバモイル基によって置換されていてもよい)によって置換されていてもよいC1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基又はC1-6アルコキシ基;場合によりC1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、C1-6アルコキシ基(ここで、該C1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基及びC1-6アルコキシ基はそれぞれ独立に場合によりヒドロキシ基、ハロゲン原子、C1-6アルコキシ基、1〜9個のハロゲン原子を有するC1-6ハロアルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、アルカノイル基、アミノ基、アミド基、カルバモイル基、オキソ基、炭素環式基もしくは複素環式基によってさらに置換されていてもよい)、1〜9個のハロゲン原子を有するC1-6ハロアルキル基、アルカノイル基、炭素環式基及び複素環式基(ここで、該炭素環式基及び複素環式基は場合によりそれぞれさらにヒドロキシ基、ハロゲン原子、C1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、C1-6アルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、アミノ基、アミド基もしくはカルバモイル基によって置換されていてもよい)から選ばれる1〜2個の置換基によって置換されていてもよいアミノ基;又は場合によりヒドロキシ基、ハロゲン原子、C1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、C1-6アルコキシ基(ここで、該C1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基及びC1-6アルコキシ基はそれぞれ独立に場合によりヒドロキシ基、ハロゲン原子、C1-6アルコキシ基、1〜9個のハロゲン原子を有するC1-6ハロアルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、アルカノイル基、アミノ基、アミド基、カルバモイル基、オキソ基、炭素環式基もしくは複素環式基によってさらに置換されていてもよい)、1〜9個のハロゲン原子を有するC1-6ハロアルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、アルカノイル基、アミノ基(ここで、該アミノ基は場合によりC1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、1〜9個のハロゲン原子を有するC1-6ハロアルキル基、アルカノイル基、炭素環式基及び複素環式基から選ばれる1〜2個の置換基によってさらに置換されていてもよい)、アミド基、カルバモイル基、オキソ基、炭素環式基及び複素環式基(ここで、該炭素環式基及び複素環式基は場合によりそれぞれさらにヒドロキシ基、ハロゲン原子、C1-6アルキル基、C2-6アルケニル基、C2-6アルキニル基、C1-6アルコキシ基、カルボキシ基、C1-6アルコキシカルボニル基、アミノ基、アミド基もしくはカルバモイル基によって置換されていてもよい)から選ばれる1〜2個の置換基によって置換されていてもよいアジリジン−1−イル基、アゼチジン−1−イル基、ピロリジン−1−イル基、ピペリジン−1−イル基、ピペラジン−1−イル基、モルホリン−1−イル基もしくはピラゾール−1−イル基を表し、
XはS又はOを表し、
A1、A2及びA3はそれぞれ独立にN又はCを表す、但し、A1、A2及びA3がそれぞれNを表す場合、R1、R2及びR8はそれぞれ存在しない、
で示されるキノキサリン誘導体又はその塩が提供される。
R3はカルボキシ基もしくはC1-6アルコキシカルボニル基によって置換されたC1-9アルキル基又はC2-9アルケニル基、好ましくは、カルボキシ基によって置換されたC1-6アルキル基又はC2-6アルケニル基を表し、
R4は水素原子を表し、
R5及びR8はそれぞれ水素原子を表し、
R6及びR7はそれぞれ独立に水素原子;場合によりハロゲン原子によって置換されていてもよいC1-6アルキル基又はC1-6アルコキシ基を表し、好ましくは、R6はフッ素原子によって置換されたC1-6アルキル基を表し、R7は水素原子を表し、
XはOを表し、そして
A1、A2及びA3はそれぞれCを表す。
3−(4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸(実施例191)、
3−(2−メチル−4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸(実施例197)、
2−メチル−3−(4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸(実施例202)、又は
3−(7−ブチル−4−オキソ−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸(実施例210)
「C3-8シクロアルキル基」には、シクロプロピル、シクロブチル、シクロペンチル、シクロヘキシル、シクロヘプチル及びシクロオクチル基が包含され、その中、シクロペンチル及びシクロヘキシル基が好ましい。また、「C5-7シクロアルキル基」には、シクロペンチル、シクロヘキシル及びシクロヘプチル基が包含される。
前記式(I)においてA1がCを表し、A2がNを表す場合の化合物、すなわち、下記式
で示されるイミダゾキノキサリン誘導体は、例えば、式
の化合物を式
のイミダゾール化合物と反応させて、式
の化合物を得、ついで、得られる式(IV)の化合物のニトロ基をアミノ基に還元し、必要に応じて単離した後、カルボニルジイミダゾールを用いた閉環反応に付し、さらに必要に応じて、水素原子以外のR4を導入することにより製造することができる。
前記式(I)においてA1及びA2がNを表す場合の化合物、すなわち、下記式
で示されるトリアゾロキノキサリン誘導体は、例えば、式
で示されるトリアゾロキノキサリン骨格を有する化合物を得、ついで、得られる式(VI)の化合物におけるメトキシ基を加水分解してアミド構造に変換し、さらに必要に応じて、水素原子以外のR4を導入することにより製造することができる。
前記式(I)においてA1及びA2がCを表す場合の化合物、すなわち、下記式
で示されるピロロキノキサリン誘導体は、例えば、式
で示される化合物を式
で示される化合物と反応させて、式
のピロール環を有する化合物を得、ついで、得られる式(IX)の化合物のニトロ基をアミノ基に還元し、必要に応じて単離した後、カルボニルジイミダゾールを用いた閉環反応に付し、さらに必要に応じて、水素原子以外のR4を導入することにより製造することができる。
1)ヒトリコンビナントPDE9タンパクの調製
GenBankデータベースに登録されているhsPDE9A1の塩基配列(Accession No.: AF048837)を基に、以下の配列(アマシャム・ファルマシア・バイオテク社)をプライマーとして、また、Human Prostate MATCHMAKER cDNAライブラリー(CLONTECH社)を鋳型DNAとして、Pfu Turbo DNA polymerase(STRATAGENE社)を用いて、以下の条件のポリメラーゼチェーンリアクションによりhsPDE9A1フラグメントを増幅した。
[3H]−cGMP(比活性=244.2GBq/mmol)を33.3nmol/Lの濃度で含むバッファーB(70 mmol/L Tris-HCl pH 7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) 溶液150μLに、氷冷下にて、評価化合物溶液(化合物をDMSOに溶解し、DMSOの濃度が5%となるように蒸留水にて希釈したもの)50μL及び上記で調製したPDE9タンパク溶液をバッファーC (40 mmol/L Tris-HCl pH 7.5, 15 mmol/L Benzamidine, 15 mmol/L 2-Mercaptoethanol, 1 μg/mL Pepstatin A, 1 μg/mL Leupeptin) にて1,500倍に希釈した溶液50μLを加えた。この混合溶液を30℃にて30分間インキュベートした後、沸騰水中で90秒間加熱することによりPDE9の酵素反応を停止させた。次に、室温に戻して、Snake venom(SIGMA社:1mg/mL)を50μL加え、30℃にて10分間インキュベートすることにより、先の反応で生成した[3H]−5’−GMPを[3H]−guanosineに変換した。この反応液を、0.5mol/L塩酸で活性化した陽イオン交換樹脂(Bio-Rad AG50W-X4 resin, mesh size 200-400)1mLを充填したカラムに通し、12mLの蒸留水で未反応基質([3H]−cGMP)を溶出分離後、3mol/Lアンモニア水3mLで[3H]−guanosineを溶出させ、液体シンチレーションカウンターで放射活性を測定した。
1)ヒトリコンビナントPDE5タンパクの調製
GenBankデータベースに登録されているhsPDE5A1の塩基配列(Accession No.: NM-001083)を基に、以下の配列(SIGMA GENOSYS社)をプライマーとして、また、Human Prostate MATCHMAKER cDNAライブラリー(CLONTECH社)を鋳型DNAとして、KDD plus DNA polymerase(TOYOBO社)を用いて、以下の条件のポリメラーゼチェーンリアクション(PCR)によりhsPDE5A1フラグメントを増幅した。
上記のPDE9阻害作用の測定と同様の方法により、評価化合物のPDE5阻害活性を測定し、その抑制率を算出して、各化合物のPDE5に対するIC50値を求めた。その結果を、PDE9に対する阻害作用と合わせて下記表Aに示す。なお、下記表A及び後記表Bにおける参考例1の化合物は、PCT国際公開WO03/37432パンフレットにおいて薬理活性値が記載されているただ一つの化合物である。
3〜4週齢の雌性Hartley系モルモット(日本SLC社)をpentobarbital(30 mg/kg i.p.)麻酔下にて開腹し、膀胱頚部より1〜2mm末梢側の尿道に幅1.4mm、内径2.0mmのポリエチレンチューブを装着した。これを閉創後、3週間以上飼育することにより、排尿を伴わない膀胱内圧上昇(無抑制収縮)の発生及び残尿の発生が認められるモルモット尿道部分閉塞モデルを作製した。
N,N−ジメチル−4−オキソ−1−m−トリル−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 346(M+).
N,N−ジメチル−4−オキソ−1−p−トリル−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 346(M+).
7−クロロ−1−[3−(2−メチル)ピリジル]イミダゾ[1,5−a]キノキサリン−4(5H)−オン
MS(m/z): 309(M+-1).
N,N−ジメチル−4−オキソ−1−(3−チエニル)−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 338(M+).
1−(3−クロロフェニル)−N,N−ジメチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 368(M++2), 366(M+).
7−クロロ−1−イソプロピル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン
MS(m/z): 263(M++2), 261(M+).
1−イソプロピル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボン酸エチル
MS(m/z): 299(M+).
1−イソプロピル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボン酸
MS(m/z): 271(M+).
1−イソプロピル−N,N−ジメチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 298(M+).
1−(1−エチルプロピル)−N,N−ジメチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 326(M+).
8−クロロ−1−(1−エチルプロピル)−N,N−ジメチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 362(M++2), 360(M+).
1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボン酸エチル
MS(m/z): 327(M+).
1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボン酸
MS(m/z): 299(M+).
1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 298(M+).
8−クロロ−1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボン酸エチル
MS(m/z): 361(M+).
8−クロロ−1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボン酸
MS(m/z): 333(M+).
8−クロロ−N−エチル−1−(1−エチルプロピル)−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 374(M+).
8−クロロ−1−(1−エチルプロピル)−N−メチル−4−オキソ−N−プロピル−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 388(M+).
1−{[8−クロロ−1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル]カルボニル}ピペリジン
MS(m/z): 400(M+).
8−クロロ−1−(1−エチルプロピル)−N−(2−メトキシエチル)−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 404(M+).
1−{[8−クロロ−1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル]カルボニル}−4−ヒドロキシピペリジン
MS(m/z): 416(M+).
1−{[8−クロロ−1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル]カルボニル}ピロリジン
MS(m/z): 386(M+).
1−{[8−クロロ−1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル]カルボニル}−4−メチルピペラジン
MS(m/z): 415(M+).
N−ブチル−8−クロロ−1−(1−エチルプロピル)−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 402(M+).
1−{[8−クロロ−1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル]カルボニル}−4−(2−ヒドロキシエチル)ピペリジン
MS(m/z): 443(M+-1).
8−クロロ−N,N−ジエチル−1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 388(M+).
1−アセチル−4−{[8−クロロ−1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル]カルボニル}ピペラジン
MS(m/z): 443(M+).
8−クロロ−1−(1−エチルプロピル)−N−(2−ヒドロキシエチル)−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 390(M+).
4−{[8−クロロ−1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル]カルボニル}モルホリン
MS(m/z): 402(M+).
1−{[8−クロロ−1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル]カルボニル}−4−(2−ヒドロキシエチル)ピペラジン
MS(m/z): 445(M+).
1−(1−エチルプロピル)−8−メトキシ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボン酸メチル
MS(m/z): 343(M+).
1−(1−エチルプロピル)−8−メトキシ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボン酸
MS(m/z): 329(M+).
1−(1−エチルプロピル)−8−メトキシ−N,N−ジメチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 356(M+).
N−エチル−1−(1−エチルプロピル)−8−メトキシ−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 370(M+).
N,N−ジエチル−1−(1−エチルプロピル)−8−メトキシ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 384(M+).
1−(1−エチルプロピル)−8−メトキシ−N−(2−メトキシエチル)−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 400(M+).
1−{[1−(1−エチルプロピル)−8−メトキシ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル]カルボニル}ピロリジン
MS(m/z): 382(M+).
1−{[1−(1−エチルプロピル)−8−メトキシ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル]カルボニル}ピペリジン
MS(m/z): 396(M+).
1−{[1−(1−エチルプロピル)−8−メトキシ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル]カルボニル}−4−メチルピペラジン
MS(m/z): 411(M+).
4−{[1−(1−エチルプロピル)−8−メトキシ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル]カルボニル}モルホリン
MS(m/z): 398(M+).
1−(1−エチルプロピル)−8−メトキシ−N−メチル−4−オキソ−N−プロピル−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 384(M+).
1−(1−エチルプロピル)−8−メトキシ−N−メチル−4−オキソ−N−[2−(2−ピリジル)エチル]−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 447(M+).
N−シクロヘキシル−1−(1−エチルプロピル)−8−メトキシ−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 424(M+).
1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボン酸エチル
MS(m/z): 327(M+).
1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボン酸
MS(m/z): 299(M+).
1−(1−エチルプロピル)−N,N−ジメチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 326(M+).
4−{[1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル]カルボニル}モルホリン
MS(m/z): 368(M+).
1−{[1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル]カルボニル}−4−メチルピペラジン
MS(m/z): 381(M+).
1−(1−エチルプロピル)−N−(2−メトキシエチル)−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 370(M+).
1−{[1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル]カルボニル}ピペリジン
MS(m/z): 366(M+).
1−{[1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル]カルボニル}ピロリジン
MS(m/z): 352(M+).
N,N−ジエチル−1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 354(M+).
N−エチル−1−(1−エチルプロピル)−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 340(M+).
1−(1−エチルプロピル)−4−オキソ−N−プロピル−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 340(M+).
1−{[1−(1−エチルプロピル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル]カルボニル}−4−(2−ヒドロキシエチル)ピペリジン
MS(m/z): 410(M+).
1−シクロヘキシル−N,N−ジメチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 338(M+).
1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボン酸エチル
MS(m/z): 339(M+).
1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボン酸
MS(m/z): 311(M+).
1−[(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル)カルボニル]−4−メチルピペラジン
MS(m/z): 393(M+).
1−[(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル)カルボニル]ピロリジン
MS(m/z): 364(M+).
1−[(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル)カルボニル]ピペリジン
MS(m/z): 378(M+).
4−[(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル)カルボニル]モルホリン
MS(m/z): 380(M+).
1−シクロヘキシル−N−エチル−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 352(M+).
1−シクロヘキシル−N−(2−ヒドロキシエチル)−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 368(M+).
1−シクロヘキシル−N−(2−メトキシエチル)−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 382(M+).
1−シクロヘキシル−N,N−ジエチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 366(M+).
1−シクロヘキシル−N−メチル−4−オキソ−N−プロピル−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 366(M+).
1−シクロヘキシル−8−メトキシ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボン酸メチル
MS(m/z): 355(M+).
1−シクロヘキシル−8−メトキシ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボン酸
MS(m/z): 341(M+).
1−シクロヘキシル−8−メトキシ−N,N−ジメチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 368(M+).
1−シクロヘキシル−N−エチル−8−メトキシ−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 382(M+).
1−シクロヘキシル−8−メトキシ−N−(2−メトキシエチル)−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 412(M+).
1−[(1−シクロヘキシル−8−メトキシ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル)カルボニル]ピロリジン
MS(m/z): 394(M+).
1−シクロヘキシル−N,N−ジエチル−8−メトキシ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 396(M+).
1−シクロヘキシル−8−メトキシ−N−メチル−4−オキソ−N−プロピル−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 396(M+).
1−[(1−シクロヘキシル−8−メトキシ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル)カルボニル]ピペリジン
MS(m/z): 408(M+).
1−シクロヘキシル−8−メトキシ−3−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボン酸メチル
MS(m/z): 369(M+).
1−シクロヘキシル−8−メトキシ−3−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボン酸
MS(m/z): 355(M+).
1−シクロヘキシル−8−メトキシ−N,N,3−トリメチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 382(M+).
1−シクロヘキシル−8−エトキシ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボン酸エチル
MS(m/z): 383(M+).
1−シクロヘキシル−8−エトキシ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボン酸
MS(m/z): 355(M+).
1−シクロヘキシル−8−エトキシ−N,N−ジメチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 382(M+).
8−クロロ−1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボン酸エチル
MS(m/z): 375(M++2), 373(M+).
8−クロロ−1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボン酸
MS(m/z): 347(M++2), 345(M+).
8−クロロ−1−シクロヘキシル−N,N−ジメチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 374(M++2), 372(M+).
1−[(8−クロロ−1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル)カルボニル]−4−(2−ヒドロキシエチル)ピペラジン
MS(m/z): 457(M+).
4−[(8−クロロ−1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル)カルボニル]モルホリン
MS(m/z): 416(M++2), 414(M+).
8−クロロ−1−シクロヘキシル−N−エチル−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 388(M++2), 386(M+).
8−クロロ−1−シクロヘキシル−N−(2−ヒドロキシエチル)−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 404(M++2), 402(M+).
1−[(8−クロロ−1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル)カルボニル]ピロリジン
MS(m/z): 400(M++2), 398(M+).
8−クロロ−1−シクロヘキシル−N−(2−メトキシエチル)−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 418(M++2), 416(M+).
1−[(8−クロロ−1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル)カルボニル]−4−メチルピペラジン
MS(m/z): 429(M++2), 427(M+).
1−[(8−クロロ−1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル)カルボニル]−4−ヒドロキシピペリジン
MS(m/z): 430(M++2), 428(M+).
1−[(8−クロロ−1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル)カルボニル]−4−(2−ヒドロキシエチル)ピペリジン
MS(m/z): 458(M++2), 456(M+).
1−アセチル−4−[(8−クロロ−1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル)カルボニル]ピペラジン
MS(m/z): 457(M++2), 455(M+).
8−クロロ−1−シクロヘキシル−N,N−ジエチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 402(M++2), 400(M+).
8−クロロ−1−シクロヘキシル−N−メチル−4−オキソ−N−プロピル−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 402(M++2), 400(M+).
1−[(8−クロロ−1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル)カルボニル]ピペリジン
MS(m/z): 414(M++2), 412(M+).
1−シクロヘキシル−N,N−ジメチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−スルホンアミド
MS(m/z): 374(M+).
1−[(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル)スルホニル]−4−メチルピペラジン
MS(m/z): 429(M+).
1−シクロヘキシル−N−(2−ジメチルアミノエチル)−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−スルホンアミド
MS(m/z): 430(M+-1).
1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボン酸エチル
MS(m/z): 339(M+).
1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボン酸
MS(m/z): 311(M+).
1−シクロヘキシル−N,N−ジメチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 338(M+).
1−シクロヘキシル−N−(2−メトキシエチル)−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 382(M+).
4−[(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル)カルボニル]モルホリン
MS(m/z): 380(M+).
1−シクロヘキシル−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 324(M+).
1−シクロヘキシル−N−(2−メトキシエチル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 368(M+).
1−[(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル)カルボニル]−4−メチルピペラジン
MS(m/z): 393(M+).
1−[(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル)カルボニル]ピペリジン
MS(m/z): 378(M+).
1−[(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル)カルボニル]ピロリジン
MS(m/z): 364(M+).
1−シクロヘキシル−N,N−ジエチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 366(M+).
1−シクロヘキシル−N−エチル−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 352(M+).
1−シクロヘキシル−N−メチル−4−オキソ−N−プロピル−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 366(M+).
1−[(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル)カルボニル]−4−(2−ヒドロキシエチル)ピペリジン
MS(m/z): 422(M+).
1−シクロヘキシル−4−オキソ−N−(2−ピリジル)−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 266(M+-121).
1−シクロヘキシル−4−オキソ−N−(3−ピリジル)−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 387(M+).
1−シクロヘキシル−4−オキソ−N−(2−ピリジルメチル)−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 401(M+).
1−シクロヘキシル−4−オキソ−N−(3−ピリジルメチル)−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 401(M+).
1−シクロヘキシル−N−エチル−N−(2−メトキシエチル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 396(M+).
1−シクロヘキシル−N−イソプロピル−N−(2−メトキシエチル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 410(M+).
1−シクロヘキシル−N−(2−メトキシエチル)−4−オキソ−N−プロピル−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 410(M+).
1−シクロヘキシル−N−(2−エトキシエチル)−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 396(M+).
1−シクロヘキシル−N−(3−メトキシプロピル)−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 396(M+).
1−シクロヘキシル−N−メチル−4−オキソ−N−(3−ピリジルメチル)−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 415(M+).
1−シクロヘキシル−N−メチル−4−オキソ−N−(2−ピリジルメチル)−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 415(M+).
1−シクロヘキシル−N−メチル−4−オキソ−N−(4−ピリジルメチル)−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 415(M+).
1−シクロヘキシル−N−メチル−4−オキソ−N−[2−(2−ピリジル)エチル]−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 429(M+).
1−シクロヘキシル−N−(2−ジメチルアミノエチル)−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 395(M+).
1−シクロヘキシル−8−(1−ヒドロキシ−1−メチルエチル)イミダゾ[1,5−a]キノキサリン−4(5H)−オン
MS(m/z): 325(M+).
(E)−3−(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル)アクリル酸エチル
MS(m/z): 365(M+).
(E)−3−(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル)アクリル酸
MS(m/z): 337(M+).
7−アセチル−1−シクロヘキシル−8−メトキシイミダゾ[1,5−a]キノキサリン−4(5H)−オン
MS(m/z): 339(M+).
7−クロロ−1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボン酸エチル
MS(m/z): 375(M++2), 373(M+).
7−クロロ−1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボン酸
MS(m/z): 347(M++2), 345(M+).
7−クロロ−1−シクロヘキシル−N,N−ジメチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 374(M++2), 372(M+).
7−クロロ−1−シクロヘキシル−N−(2−メトキシエチル)−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 418(M++2), 416(M+).
4−[(7−クロロ−1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル)カルボニル]モルホリン
MS(m/z): 416(M++2), 414(M+).
1−シクロヘキシル−3−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボン酸エチル
MS(m/z): 353(M+).
1−シクロヘキシル−3−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボン酸
MS(m/z): 325(M+).
1−シクロヘキシル−N−(2−メトキシエチル)−N,3−ジメチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 396(M+).
1−シクロヘキシル−N,O−ジメチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−ヒドロキサム酸
MS(m/z): 354(M+).
8−アセチル−1−シクロヘキシルイミダゾ[1,5−a]キノキサリン−4(5H)−オン
MS(m/z): 309(M+).
1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボニトリル
MS(m/z): 291(M+-1).
7−ブロモ−1−シクロヘキシルイミダゾ[1,5−a]キノキサリン−4(5H)−オン
MS(m/z): 346(M++1), 344(M+-1).
1−シクロヘキシル−7−(ピラゾール−1−イル)イミダゾ[1,5−a]キノキサリン−4(5H)−オン
MS(m/z): 333(M+).
1−シクロヘキシル−7−(3,5−ジメチルピラゾール−1−イル)イミダゾ[1,5−a]キノキサリン−4(5H)−オン
MS(m/z): 361(M+).
8−クロロ−1−シクロヘキシル−N−メチル−4−オキソ−N−フェネチル−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 462(M+).
8−クロロ−N,1−ジシクロヘキシル−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 440(M+).
8−クロロ−1−シクロヘキシル−N−メチル−4−オキソ−N−[2−(2−ピリジル)エチル]−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−カルボキサミド
MS(m/z): 463(M+).
1−[(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−7−イル)カルボニル]−3,5−ジメチルピラゾール
MS(m/z): 388(M+-1).
1−シクロヘキシル−7−(3−メチル−[1,2,4]−オキサジアゾール−5−イル)イミダゾ[1,5−a]キノキサリン−4(5H)−オン
MS(m/z): 348(M+-1).
8−クロロ−1−シクロヘキシル−7−(3−メチル−[1,2,4]−オキサジアゾール−5−イル)イミダゾ[1,5−a]キノキサリン−4(5H)−オン
MS(m/z): 383(M+).
(E)−3−(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル)アクリル酸メチル
MS(m/z): 351(M+).
(E)−3−(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル)アクリル酸
MS(m/z): 337(M+).
(E)−3−(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル)−N,N−ジメチルアクリルアミド
MS(m/z): 364(M+).
(E)−3−(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル)−N−メチルアクリルアミド
MS(m/z): 350(M+).
3−(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル)プロパン酸メチル
MS(m/z): 353(M+).
3−(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル)プロパン酸
MS(m/z): 339(M+).
3−(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル)−N,N−ジメチルプロパン酸アミド
MS(m/z): 366(M+).
1−[3−(1−シクロヘキシル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル)プロパノイル]−4−メチルピペラジン
MS(m/z): 421(M+).
1−シクロペンチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボン酸メチル
MS(m/z): 310(M+-1).
1−シクロペンチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボン酸
MS(m/z): 296(M+-1).
1−シクロペンチル−N―(2−メトキシエチル)−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 354(M+).
1−シクロペンチル−N―メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 310(M+).
1−シクロペンチル−N―(2−メトキシエチル)−N−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 368(M+).
1−シクロペンチル−N,N―ジメチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 324(M+).
1−[(1−シクロペンチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル)カルボニル]−4−(2−ヒドロキシエチル)ピペリジン
MS(m/z): 407(M+-1).
1−[(1−シクロペンチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−イル)カルボニル]−3,5−ジメチルピラゾール
MS(m/z): 375(M+).
4−オキソ−1−(1−プロピルブチル)−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボン酸エチル
MS(m/z): 355(M+).
4−オキソ−1−(1−プロピルブチル)−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボン酸
MS(m/z): 327 (M+).
N−(2−メトキシエチル)−N−メチル−4−オキソ−1−(1−プロピルブチル)−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−8−カルボキサミド
MS(m/z): 398(M+).
1−(テトラヒドロピラン−4−イル)−7−トリフルオロメチルイミダゾ[1,5−a]キノキサリン−4(5H)−オン
MS(m/z): 337(M+).
3−(7−フルオロ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−1−イル)プロパン酸エチル
MS(m/z): 303(M+), 230(base).
3−(7−フルオロ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−1−イル)プロパン酸
MS(m/z): 275(M+), 230(base).
3−(7−クロロ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−1−イル)プロパン酸エチル
MS(m/z): 321(M++2), 319(M+).
3−(7−クロロ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−1−イル)プロパン酸
MS(m/z): 293(M++2), 291(M+), 248, 246.
7−クロロ−1−(3−ヒドロキシプロピル)イミダゾ[1,5−a]キノキサリン−4(5H)−オン
MS(m/z): 279(M++2), 277(M+).
3−(7−ブロモ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−1−イル)プロパン酸エチル
MS(m/z): 365(M+2), 363(M+).
3−(7−ブロモ−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−1−イル)プロパン酸
MS(m/z): 337(M++2), 335(M+).
3−(7−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−1−イル)プロパン酸エチル
3−(7−メチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−1−イル)プロパン酸
MS(m/z): 271(M+), 226(base).
3−(7−アセチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−1−イル)プロパン酸エチル
MS(m/z): 327(M+), 254(base).
3−(7−エチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−1−イル)プロパン酸エチル
MS(m/z): 313(M+), 240(base).
3−(7−エチル−4−オキソ−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−1−イル)プロパン酸
MS(m/z): 285(M+), 240(base).
3−(4−オキソ−7−トリフルオロメチル−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−1−イル)プロパン酸エチル
MS(m/z): 353(M+), 280(base).
3−(4−オキソ−7−トリフルオロメチル−4,5−ジヒドロイミダゾ[1,5−a]キノキサリン−1−イル)プロパン酸
MS(m/z): 325(M+), 280(base).
(E)−3−(4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)アクリル酸エチル
MS(m/z): 350 (M+), 277(base).
(E)−3−(4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)アクリル酸
MS(m/z): 322 (M+), 277(base).
3−(4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸エチル
MS(m/z): 352(M+), 265(base).
3−(4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸
MS(m/z): 324(M+), 265(base).
(E)−3−(3−メチル−4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)アクリル酸エチル
MS(m/z): 364(M+), 291(base).
3−(3−メチル−4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸エチル
MS(m/z): 366(M+), 279(base).
3−(3−メチル−4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸
MS(m/z): 338(M+), 279(base).
(E)−3−(2−メチル−4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)アクリル酸エチル
MS(m/z): 364(M+), 291(base).
3−(2−メチル−4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸エチル
MS(m/z): 366(M+), 279(base).
3−(2−メチル−4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸
MS(m/z): 338(M+), 279(base).
(E)−3−(2,3−ジメチル−4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)アクリル酸エチル
MS(m/z): 378(M+), 305(base).
3−(2,3−ジメチル−4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸エチル
MS(m/z): 380(M+), 293(base).
3−(2,3−ジメチル−4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸
MS(m/z): 352(M+), 293(base).
2−メチル−3−(4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸エチル
MS(m/z): 366(M+), 265(base).
2−メチル−3−(4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸
MS(m/z): 338(M+), 265(base).
3−(7−エチル−4−オキソ−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸エチル
MS(m/z): 312 (M+), 225(base).
3−(7−エチル−4−オキソ−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸
MS(m/z): 284(M+), 225(base).
3−(7−メチル−4−オキソ−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸エチル
MS(m/z): 298 (M+), 211(base).
3−(7−メチル−4−オキソ−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸
MS(m/z): 270(M+), 211(base).
3−(4−オキソ−7−プロピル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸エチル
MS(m/z): 326 (M+), 239(base).
3−(4−オキソ−7−プロピル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸
MS(m/z): 298 (M+), 239(base).
3−(7−ブチル−4−オキソ−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸エチル
MS(m/z): 340 (M+), 253(base).
3−(7−ブチル−4−オキソ−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸
MS(m/z): 312(M+), 253(base).
3−(7,8−ジメチル−4−オキソ−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸エチル
MS(m/z): 312 (M+), 225(base).
3−(7,8−ジメチル−4−オキソ−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸
MS(m/z): 284(M+), 225(base).
3−(7−メトキシ−4−オキソ−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸エチル
MS(m/z): 314(M+), 227(base).
3−(7−メトキシ−4−オキソ−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸
MS(m/z): 286(M+), 227(base).
3−(7−エトキシ−4−オキソ−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸エチル
MS(m/z): 328(M+), 241(base).
3−(7−エトキシ−4−オキソ−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸
MS(m/z): 300(M+), 241(base).
3−クロロ−9−シクロヘキシルイミダゾ[1,5−a]ピリド[3,2−e]ピラジン−6(5H)−オン
MS(m/z): 304(M++2), 302(M+), 234(base).
3−(1H−イミダゾール−2−イル)−2−メチルピリジン
MS(m/z): 159(M+).
2−(3−チエニル)−1H−イミダゾール
MS(m/z): 150(M+).
N,N−ジメチル−3−ニトロ−4−[2−(3−チエニル)−1H−イミダゾール−1−イル]ベンズアミド
MS(m/z): 342(M+).
3−アミノ−N,N−ジメチル−4−[2−(3−チエニル)−1H−イミダゾール−1−イル]ベンズアミド
MS(m/z): 312(M+).
4−[2−(3−クロロフェニル)−1H−イミダゾール−1−イル]−N,N−ジメチル−3−ニトロベンズアミド
3−アミノ−4−[2−(3−クロロフェニル)−1H−イミダゾール−1−イル]−N,N−ジメチルベンズアミド
1−(4−クロロ−2−ニトロフェニル)−2−イソプロピル−1H−イミダゾール
MS(m/z): 267(M++2), 265(M+).
5−クロロ−2−(2−イソプロピル−1H−イミダゾール−1−イル)アニリン
MS(m/z): 237(M++2), 235(M+).
4−(2−イソプロピル−1H−イミダゾール−1−イル)−3−ニトロ安息香酸エチル
MS(m/z): 303(M+).
3−アミノ−4−(2−イソプロピル−1H−イミダゾール−1−イル)安息香酸エチル
MS(m/z): 273(M+).
4−[2−(1−エチルプロピル)−1H−イミダゾール−1−イル]−N,N−ジメチル−3−ニトロベンズアミド
MS(m/z): 330(M+).
3−アミノ−4−[2−(1−エチルプロピル)−1H−イミダゾール−1−イル]−N,N−ジメチルベンズアミド
MS(m/z): 300(M+).
2−クロロ−4−[2−(1−エチルプロピル)−1H−イミダゾール−1−イル]−N,N−ジメチル−5−ニトロベンズアミド
MS(m/z): 366(M++2), 364(M+).
5−アミノ−2−クロロ−4−[2−(1−エチルプロピル)−1H−イミダゾール−1−イル]−N,N−ジメチルベンズアミド
MS(m/z): 336(M++2), 334(M+).
4−[2−(1−エチルプロピル)−1H−イミダゾール−1−イル]−3−ニトロ安息香酸エチル
MS(m/z): 331(M+).
3−アミノ−4−[2−(1−エチルプロピル)−1H−イミダゾール−1−イル]安息香酸エチル
MS(m/z): 301(M+).
2−クロロ−4−[2−(1−エチルプロピル)−1H−イミダゾール−1−イル]−5−ニトロ安息香酸エチル
MS(m/z): 365(M+).
MS(m/z): 335(M+).
4−[2−(1−エチルプロピル)−1H−イミダゾール−1−イル]−2−メトキシ−5−ニトロ安息香酸メチル
MS(m/z): 347(M+).
5−アミノ−4−[2−(1−エチルプロピル)−1H−イミダゾール−1−イル]−2−メトキシ安息香酸メチル
MS(m/z): 317(M+).
3−[2−(1−エチルプロピル)−1H−イミダゾール−1−イル]−4−ニトロ安息香酸エチル
MS(m/z): 331(M+).
4−アミノ−3−[2−(1−エチルプロピル)−1H−イミダゾール−1−イル]安息香酸エチル
MS(m/z): 301(M+).
4−(2−シクロヘキシル−1H−イミダゾール−1−イル)−N,N−ジメチル−3−ニトロベンズアミド
MS(m/z): 342(M+).
3−アミノ−4−(2−シクロヘキシル−1H−イミダゾール−1−イル)−N,N−ジメチルベンズアミド
MS(m/z): 312(M+).
4−(2−シクロヘキシル−1H−イミダゾール−1−イル)−3−ニトロ安息香酸エチル
MS(m/z): 343(M+).
3−アミノ−4−(2−シクロヘキシル−1H−イミダゾール−1−イル)安息香酸エチル
MS(m/z): 313(M+).
4−(2−シクロヘキシル−1H−イミダゾール−1−イル)−2−メトキシ−5−ニトロ安息香酸メチル
MS(m/z): 359(M+).
5−アミノ−4−(2−シクロヘキシル−1H−イミダゾール−1−イル)−2−メトキシ安息香酸メチル
MS(m/z): 329(M+).
4−(2−シクロヘキシル−4−メチル−1H−イミダゾール−1−イル)−2−メトキシ−5−ニトロ安息香酸メチル
MS(m/z): 373(M+).
5−アミノ−4−(2−シクロヘキシル−4−メチル−1H−イミダゾール−1−イル)−2−メトキシ安息香酸メチル
MS(m/z): 343(M+).
2−エトキシ−4−フルオロ安息香酸エチル
MS(m/z): 212(M+).
2−エトキシ−4−フルオロ−5−ニトロ安息香酸エチル
MS(m/z): 257(M+).
4−(2−シクロヘキシル−1H−イミダゾール−1−イル)−2−エトキシ−5−ニトロ安息香酸エチル
MS(m/z): 387(M+).
5−アミノ−4−(2−シクロヘキシル−1H−イミダゾール−1−イル)−2−エトキシ安息香酸エチル
MS(m/z): 357(M+).
2−クロロ−4−(2−シクロヘキシル−1H−イミダゾール−1−イル)−5−ニトロ安息香酸エチル
MS(m/z): 379(M++2), 377(M+).
5−アミノ−2−クロロ−4−(2−シクロヘキシル−1H−イミダゾール−1−イル)安息香酸エチル
MS(m/z): 349(M++2), 347(M+).
4−(2−シクロヘキシル−1H−イミダゾール−1−イル)−N,N−ジメチル−3−ニトロベンゼンスルホンアミド
MS(m/z): 378(M+).
3−アミノ−4−(2−シクロヘキシル−1H−イミダゾール−1−イル)−N,N−ジメチルベンゼンスルホンアミド
MS(m/z): 348(M+).
1−(4−クロロ−3−ニトロベンゼンスルホニル)−4−メチルピペラジン
MS(m/z): 321(M++2), 319(M+).
1−[4−(2−シクロヘキシル−1H−イミダゾール−1−イル)−3−ニトロベンゼンスルホニル]−4−メチルピペラジン
MS(m/z): 433(M+).
1−[3−アミノ−4−(2−シクロヘキシル−1H−イミダゾール−1−イル)ベンゼンスルホニル]−4−メチルピペラジン
MS(m/z): 403(M+).
4−(2−シクロヘキシル−1H−イミダゾール−1−イル)−N−(2−ジメチルアミノエチル)−N−メチル−3−ニトロベンゼンスルホンアミド
MS(m/z): 434(M+-1).
3−アミノ−4−(2−シクロヘキシル−1H−イミダゾール−1−イル)−N−(2−ジメチルアミノエチル)−N−メチルベンゼンスルホンアミド
MS(m/z): 404(M+-1).
3−フルオロ−4−ニトロ安息香酸エチル
MS(m/z): 213(M+).
3−(2−シクロヘキシル−1H−イミダゾール−1−イル)−4−ニトロ安息香酸エチル
MS(m/z): 343(M+).
4−アミノ−3−(2−シクロヘキシル−1H−イミダゾール−1−イル)安息香酸エチル
MS(m/z): 313(M+).
N−(2−エトキシエチル)−3−フルオロ−4−ニトロベンズアミド
MS(m/z): 257(M++1).
3−(2−シクロヘキシル−1H−イミダゾール−1−イル)−N−(2−エトキシエチル)−4−ニトロベンズアミド
MS(m/z): 386(M+).
3−(2−シクロヘキシル−1H−イミダゾール−1−イル)−N−(2−エトキシエチル)−N−メチル−4−ニトロベンズアミド
MS(m/z): 400(M+).
4−アミノ−3−(2−シクロヘキシル−1H−イミダゾール−1−イル)−N−(2−エトキシエチル)−N−メチルベンズアミド
MS(m/z): 370(M+).
3−フルオロ−N−(3−メトキシプロピル)−4−ニトロベンズアミド
MS(m/z): 256(M+).
3−(2−シクロヘキシル−1H−イミダゾール−1−イル)−N−(3−メトキシプロピル)−4−ニトロベンズアミド
MS(m/z): 386(M+).
3−(2−シクロヘキシル−1H−イミダゾール−1−イル)−N−(3−メトキシプロピル)−N−メチル−4−ニトロベンズアミド
MS(m/z): 400(M+).
4−アミノ−3−(2−シクロヘキシル−1H−イミダゾール−1−イル)−N−(3−メトキシプロピル)−N−メチルベンズアミド
MS(m/z): 370(M+).
3−フルオロ−4−ニトロ−N−(3−ピリジルメチル)ベンズアミド
MS(m/z): 275(M+).
3−(2−シクロヘキシル−1H−イミダゾール−1−イル)−4−ニトロ−N−(3−ピリジルメチル)ベンズアミド
MS(m/z): 405(M+).
3−(2−シクロヘキシル−1H−イミダゾール−1−イル)−N−メチル−4−ニトロ−N−(3−ピリジルメチル)ベンズアミド
MS(m/z): 419(M+).
4−アミノ−3−(2−シクロヘキシル−1H−イミダゾール−1−イル)−N−メチル−N−(3−ピリジルメチル)ベンズアミド
MS(m/z): 389(M+).
3−フルオロ−4−ニトロ−N−(2−ピリジルメチル)ベンズアミド
MS(m/z): 275(M+).
3−(2−シクロヘキシル−1H−イミダゾール−1−イル)−4−ニトロ−N−(2−ピリジルメチル)ベンズアミド
MS(m/z): 405(M+).
3−(2−シクロヘキシル−1H−イミダゾール−1−イル)−N−メチル−4−ニトロ−N−(2−ピリジルメチル)ベンズアミド
4−アミノ−3−(2−シクロヘキシル−1H−イミダゾール−1−イル)−N−メチル−N−(2−ピリジルメチル)ベンズアミド
MS(m/z): 389(M+).
3−フルオロ−4−ニトロ−N−(4−ピリジルメチル)ベンズアミド
MS(m/z): 275(M+).
3−(2−シクロヘキシル−1H−イミダゾール−1−イル)−4−ニトロ−N−(4−ピリジルメチル)ベンズアミド
MS(m/z): 405(M+).
3−(2−シクロヘキシル−1H−イミダゾール−1−イル)−N−メチル−4−ニトロ−N−(4−ピリジルメチル)ベンズアミド
4−アミノ−3−(2−シクロヘキシル−1H−イミダゾール−1−イル)−N−メチル−N−(4−ピリジルメチル)ベンズアミド
MS(m/z): 389(M+).
(E)−3−[4−(2−シクロヘキシル−1H−イミダゾール−1−イル)−3−ニトロフェニル]アクリル酸エチル
MS(m/z): 369(M+).
(E)−3−[3−アミノ−4−(2−シクロヘキシル−1H−イミダゾール−1−イル)フェニル]アクリル酸エチル
MS(m/z): 339(M+).
1−(4−フルオロ−2−メトキシ−5−ニトロフェニル)エタノン
MS(m/z): 213(M+).
1−[4−(2−シクロヘキシル−1H−イミダゾール−1−イル)−2−メトキシ−5−ニトロフェニル]エタノン
MS(m/z): 343(M+).
1−[5−アミノ−4−(2−シクロヘキシル−1H−イミダゾール−1−イル)−2−メトキシフェニル]エタノン
MS(m/z): 313(M+).
2−クロロ−5−フルオロ−4−ニトロ安息香酸エチル
MS(m/z): 249(M++2), 247(M+).
2−クロロ−5−(2−シクロヘキシル−1H−イミダゾール−1−イル)−4−ニトロ安息香酸エチル
4−アミノ−2−クロロ−5−(2−シクロヘキシル−1H−イミダゾール−1−イル)安息香酸エチル
3−(2−シクロヘキシル−4−メチル−1H−イミダゾール−1−イル)−4−ニトロ安息香酸エチル
MS(m/z): 357(M+).
4−アミノ−3−(2−シクロヘキシル−4−メチル−1H−イミダゾール−1−イル)安息香酸エチル
MS(m/z): 327(M+).
4−(2−シクロヘキシル−1H−イミダゾール−1−イル)−3−ニトロベンゾニトリル
MS(m/z): 296(M+).
3−アミノ−4−(2−シクロヘキシル−1H−イミダゾール−1−イル)ベンゾニトリル
MS(m/z): 266(M+).
1−(4−ブロモ−2−ニトロフェニル)−2−シクロヘキシル−1H−イミダゾール
MS(m/z): 352(M++3), 350(M++1).
5−ブロモ−2−(2−シクロヘキシル−1H−イミダゾール−1−イル)アニリン
MS(m/z): 321(M++2), 319(M+).
(E)−3−[3−(2−シクロヘキシル−1H−イミダゾール−1−イル)−4−ニトロフェニル]アクリル酸メチル
MS(m/z): 355(M+).
(E)−3−[4−アミノ−3−(2−シクロヘキシル−1H−イミダゾール−1−イル)フェニル]アクリル酸メチル
MS(m/z): 325(M+).
3−(2−シクロペンチル−1H−イミダゾール−1−イル)−4−ニトロ安息香酸メチル
MS(m/z): 315(M+).
4−アミノ−3−(2−シクロペンチル−1H−イミダゾール−1−イル)安息香酸メチル
MS(m/z): 285(M+).
2−(1−プロピルブチル)イミダゾール
MS(m/z): 166(M+).
4−ニトロ−3−[2−(1−プロピルブチル)−1H−イミダゾール−1−イル]安息香酸エチル
MS(m/z): 359(M+).
4−アミノ−3−[2−(1−プロピルブチル)−1H−イミダゾール−1−イル]安息香酸エチル
MS(m/z): 329(M+).
2−(テトラヒドロピラン−4−イル)イミダゾール
MS(m/z): 152(M+).
1−(2−ニトロ−4−トリフルオロメチルフェニル)−2−(テトラヒドロピラン−4−イル)−1H−イミダゾール
MS(m/z): 341(M+).
2−[2−(テトラヒドロピラン−4−イル)−1H−イミダゾール−1−イル]−5−トリフルオロメチルアニリン
MS(m/z): 311(M+).
3−[1−(4−フルオロ−2−ニトロフェニル)−1H−イミダゾール−2−イル]プロパン酸エチル
MS(m/z): 308(M++1), 187(base).
3−[1−(2−アミノ−4−フルオロフェニル)−1H−イミダゾール−2−イル]プロパン酸エチル
MS(m/z): 277(M+), 204(base).
3−[1−(4−メチル−2−ニトロフェニル)−1H−イミダゾール−2−イル]プロパン酸エチル
MS(m/z): 304(M++1), 183(base).
3−[1−(2−アミノ−4−メチルフェニル)−1H−イミダゾール−2−イル]プロパン酸エチル
MS(m/z): 273(M+), 200(base).
3−[1−(4−アセチル−2−ニトロフェニル)−1H−イミダゾール−2−イル]プロパン酸エチル
MS(m/z): 332(M++1), 211(base).
3−[1−(4−アセチル−2−アミノフェニル)−1H−イミダゾール−2−イル]プロパン酸エチル
MS(m/z): 301(M+), 228(base).
3−[1−(2−ニトロ−4−トリフルオロメチルフェニル)−1H−イミダゾール−2−イル]プロパン酸エチル
MS(m/z): 357(M+), 81(base).
3−[1−(2−アミノ−4−トリフルオロメチルフェニル)−1H−イミダゾール−2−イル]プロパン酸エチル
MS(m/z): 327(M+), 254(base).
5−[(E)−2−エトキシカルボニルビニル]−3−メチル−1H−ピロール−2−カルボン酸エチル
MS(m/z): 251(M+), 159(base).
5−[(E)−2−エトキシカルボニルビニル]−4−メチル−1H−ピロール−2−カルボン酸エチル
MS(m/z): 251(M+), 160base).
5−[(E)−2−エトキシカルボニルビニル]−3,4−ジメチル−1H−ピロール−2−カルボン酸エチル
MS(m/z): 265(M+, base).
5−クロロ−2−(2−シクロヘキシル−1H−イミダゾール−1−イル)−3−ニトロピリジン
MS(m/z): 308(M++2), 306(M+), 55(base).
3−アミノ−5−クロロ−2−(2−シクロヘキシル−1H−イミダゾール−1−イル)ピリジン
MS(m/z): 278(M++2), 276(M+), 135(base).
mg/錠
活性成分 5.0
でん粉 10.0
乳糖 73.0
カルボキシメチルセルロースカルシウム 10.0
タルク 1.0
ステアリン酸マグネシウム 1.0
100.0
Claims (8)
- R1及びR2はそれぞれ水素原子を表し、
R7は水素原子を表す請求項1記載のキノキサリン誘導体又はその塩。 - R3はカルボキシ基によって置換されたC1-6アルキル基又はC2-6アルケニル基を表す請求項1および2のいずれかに記載のキノキサリン誘導体又はその塩。
- R6はフッ素原子によって置換されたC1-6アルキル基を表す請求項1〜3のいずれかに記載のキノキサリン誘導体又はその塩。
- (E)−3−(4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)アクリル酸、
3−(4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸、
3−(2−メチル−4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸、
2−メチル−3−(4−オキソ−7−トリフルオロメチル−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸、又は
3−(7−ブチル−4−オキソ−4,5−ジヒドロピロロ[1,2−a]キノキサリン−1−イル)プロパン酸である請求項1記載のキノキサリン誘導体又はその塩。 - 請求項1〜5のいずれかに記載のキノキサリン誘導体又はその塩を含有するPDE9阻害剤。
- 請求項1〜5のいずれかに記載のキノキサリン誘導体又はその塩及び製薬学的に許容される担体を含んでなる医薬組成物。
- 請求項1〜5のいずれかに記載のキノキサリン誘導体又はその塩を有効成分として含むことを特徴とする、過活動膀胱、頻尿、尿失禁、前立腺肥大症に伴う排尿障害、神経因性膀胱、間質性膀胱炎、尿路結石または前立腺肥大症の処置剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014115951A JP5744288B2 (ja) | 2006-12-13 | 2014-06-04 | キノキサリン誘導体 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006336215 | 2006-12-13 | ||
JP2006336215 | 2006-12-13 | ||
JP2014115951A JP5744288B2 (ja) | 2006-12-13 | 2014-06-04 | キノキサリン誘導体 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008549397A Division JP5578786B2 (ja) | 2006-12-13 | 2007-12-12 | キノキサリン誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014205686A JP2014205686A (ja) | 2014-10-30 |
JP5744288B2 true JP5744288B2 (ja) | 2015-07-08 |
Family
ID=39511782
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008549397A Active JP5578786B2 (ja) | 2006-12-13 | 2007-12-12 | キノキサリン誘導体 |
JP2014115951A Active JP5744288B2 (ja) | 2006-12-13 | 2014-06-04 | キノキサリン誘導体 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008549397A Active JP5578786B2 (ja) | 2006-12-13 | 2007-12-12 | キノキサリン誘導体 |
Country Status (9)
Country | Link |
---|---|
US (3) | US8299080B2 (ja) |
EP (3) | EP2848620B1 (ja) |
JP (2) | JP5578786B2 (ja) |
KR (2) | KR101563103B1 (ja) |
CN (1) | CN101553491B (ja) |
AU (1) | AU2007332440B2 (ja) |
CA (1) | CA2671980C (ja) |
ES (3) | ES2599054T3 (ja) |
WO (1) | WO2008072779A1 (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5271897B2 (ja) | 2006-05-31 | 2013-08-21 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | ポリ(ADP−リボース)ポリメラーゼ(PARP)の阻害剤としての、ピロロ[1,2−a]ピラジン−1(2H)−オン及びピロロ[1,2−d][1,2,4]トリアジン−1(2H)−オン誘導体 |
US7928105B2 (en) * | 2009-01-23 | 2011-04-19 | Takeda Pharmaceutical Company Limited | Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-ones |
RU2011140333A (ru) | 2009-03-05 | 2013-04-10 | Астеллас Фарма Инк. | Хиноксалиновое соединение |
EP2403857B1 (en) * | 2009-03-05 | 2013-12-04 | Takeda Pharmaceutical Company Limited | Thienopyrimidine as cdc7 kinase inhibitors |
US8541417B2 (en) | 2009-07-30 | 2013-09-24 | Takeda Pharmaceutical Company Limited | Poly (ADP-ribose) polymerase (PARP) inhibitors |
DK2615089T3 (en) * | 2010-09-07 | 2016-06-06 | Astellas Pharma Inc | Pyrazoloquinolinforbindelser |
ES2747423T3 (es) * | 2010-09-07 | 2020-03-10 | Astellas Pharma Inc | Compuesto de quinoxalina |
US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
TWI532742B (zh) * | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
IN2014CN02463A (ja) * | 2011-10-07 | 2015-06-19 | Eisai R&D Man Co Ltd | |
CN106905324B (zh) | 2011-10-10 | 2018-09-25 | H.隆德贝克有限公司 | 具有咪唑并吡嗪酮骨架的pde9抑制剂 |
SG11201403909RA (en) | 2012-01-26 | 2014-10-30 | Lundbeck & Co As H | Pde9 inhibitors with imidazo triazinone backbone |
US20140045856A1 (en) * | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
EP2982675B1 (en) | 2013-04-05 | 2017-08-16 | Eisai R&D Management Co., Ltd. | Salt of pyrazoloquinoline derivative, and crystal thereof |
AU2014250391B2 (en) * | 2013-04-05 | 2017-11-02 | Eisai R&D Management Co., Ltd. | Pyridinylpyrazoloquinoline compound |
WO2014168211A1 (ja) * | 2013-04-11 | 2014-10-16 | 宇部興産株式会社 | 2-(4-テトラヒドロピラニル)イミダゾール及び/又はその酸塩の製造方法 |
WO2016199943A1 (en) * | 2015-06-11 | 2016-12-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds |
AU2016289856B2 (en) | 2015-07-07 | 2020-11-26 | H. Lundbeck A/S | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases |
AR107456A1 (es) | 2016-02-12 | 2018-05-02 | Lilly Co Eli | Inhibidor de pde1 |
JOP20170164A1 (ar) * | 2016-08-25 | 2019-01-30 | Lilly Co Eli | مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري |
KR101851643B1 (ko) | 2017-02-20 | 2018-04-25 | 한국과학기술연구원 | 연료전지용 복합 고분자 전해질막 및 그 제조 방법 |
JP7079777B2 (ja) | 2017-06-01 | 2022-06-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤 |
CN110603039B (zh) | 2017-06-01 | 2023-02-28 | 卫材R&D管理有限公司 | 组合吡唑并喹啉衍生物和美金刚的痴呆治疗剂 |
AU2018278422B2 (en) | 2017-06-01 | 2022-03-17 | Eisai R&D Management Co., Ltd. | Lewy body disease therapeutic agent containing pyrazoloquinoline derivative |
RU2019135261A (ru) | 2017-06-01 | 2021-07-09 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Фармацевтическая композиция, содержащая ингибитор pde9 |
EP3634964B1 (en) | 2017-06-08 | 2022-02-23 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine pde9 inhibitors |
KR102059965B1 (ko) | 2017-06-28 | 2019-12-27 | 한국과학기술연구원 | 연료전지용 복합 고분자 전해질막 및 그 제조 방법 |
AR112457A1 (es) * | 2017-08-02 | 2019-10-30 | Lilly Co Eli | Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona |
AR112346A1 (es) * | 2017-08-10 | 2019-10-16 | Lilly Co Eli | Derivados de [1,2,4]triazolo |
SI3801526T1 (sl) | 2018-05-25 | 2024-05-31 | Cardurion Pharmaceuticals, Inc. | Monohidratne in kristalinične oblike 6-((3s, 4s)-4-metil-1-(pirimidin-2-ilmetil)pirolidin-3-il)-3-tetrahidropiran-4- il-7h-imidazo (1.5 - a) pirazin-8-ona |
CN109180679B (zh) * | 2018-07-31 | 2021-05-14 | 中山大学 | 一类N-取代吡唑并[3,4-d]嘧啶酮类化合物及其制备方法和应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4354027A (en) * | 1980-05-19 | 1982-10-12 | Usv Pharmaceutical Corporation | Triazoloquinoxalin-4-ones |
US4495187A (en) * | 1982-10-18 | 1985-01-22 | Pfizer Inc. | Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents |
IN160956B (ja) * | 1982-10-18 | 1987-08-22 | Pfizer | |
US4623725A (en) * | 1982-10-18 | 1986-11-18 | Pfizer Inc. | [1,2,4]Triazolo[4,3-a]quinoxaline-4-amine derivatives |
US4547501A (en) * | 1983-09-02 | 1985-10-15 | Pfizer Inc. | Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents |
US5055465A (en) * | 1989-05-31 | 1991-10-08 | Berlex Laboratories, Inc. | Imidazoquinoxalinones, their aza analogs and process for their preparation |
US5166344A (en) * | 1989-05-31 | 1992-11-24 | Berlex Laboratories, Inc. | Process for the preparation of imidazoquinoxalinones |
AU654548B2 (en) * | 1991-04-23 | 1994-11-10 | Toray Industries, Inc. | Tricyclic triazole derivative, production thereof, and use thereof |
US5683998A (en) * | 1991-04-23 | 1997-11-04 | Toray Industries, Inc. | Tricyclic triazolo derivatives, processes for producing the same and the uses of the same |
US5153196A (en) * | 1991-06-05 | 1992-10-06 | Eli Lilly And Company | Excitatory amino acid receptor antagonists and methods for the use thereof |
US5196421A (en) * | 1991-06-05 | 1993-03-23 | Eli Lilly And Company | Excitatory amino acid receptor antagonists in methods for the use thereof |
DK162491D0 (da) * | 1991-09-20 | 1991-09-20 | Novo Nordisk As | Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne |
AU3767793A (en) * | 1992-04-03 | 1993-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Fused quinoxalinone derivative and pharmaceutical composition containing the same |
DK31093D0 (ja) * | 1993-03-19 | 1993-03-19 | Novo Nordisk As | |
PL310950A1 (en) | 1993-03-31 | 1996-01-08 | Basf Ag | Novel imidazole quinoxalinones, method of obtaining them and their application |
JPH09508632A (ja) * | 1994-02-11 | 1997-09-02 | ノボ ノルディスク アクティーゼルスカブ | 複素環式化合物並びにそれらの製造及び使用 |
HUT76810A (en) * | 1994-09-16 | 1997-11-28 | Novo Nordisk As | [1,2,4]triazolo[4,3-a]quinoxalinone derivatives, process for their preparation and pharmaceutical compositions containing them |
DE19510965A1 (de) * | 1995-03-24 | 1996-09-26 | Asta Medica Ag | Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung |
IT1276167B1 (it) * | 1995-11-24 | 1997-10-27 | Foscama Biomed Chim Farma | Imidazo(1,2-alfa)chinossalin-4-ammine attivi come antagonisti adenosinici,procedimento per la loro preparazione e loro composizioni |
IL144156A0 (en) * | 1999-01-20 | 2002-05-23 | Dresden Arzneimittel | Use of imidazo [1,5-a]-pyrido [3,2-e] -pyrazinones as medicaments |
WO2002028860A2 (en) * | 2000-10-03 | 2002-04-11 | Bristol-Myers Squibb Company | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same |
US6869956B2 (en) * | 2000-10-03 | 2005-03-22 | Bristol-Myers Squibb Company | Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK) |
WO2002060386A2 (en) * | 2001-02-01 | 2002-08-08 | Bristol-Myers Squibb Company | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK) |
HN2002000317A (es) | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
US20030195205A1 (en) * | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
MXPA04004170A (es) * | 2001-11-02 | 2004-09-06 | Pfizer Prod Inc | Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9. |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
US6896956B2 (en) * | 2002-12-13 | 2005-05-24 | Exxonmobil Oil Corporation | Sealable and peelable film structure |
TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
TW200815436A (en) * | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
-
2007
- 2007-12-12 CN CN2007800456328A patent/CN101553491B/zh active Active
- 2007-12-12 ES ES14184461.3T patent/ES2599054T3/es active Active
- 2007-12-12 EP EP14184461.3A patent/EP2848620B1/en active Active
- 2007-12-12 ES ES12167114.3T patent/ES2536906T3/es active Active
- 2007-12-12 US US12/448,212 patent/US8299080B2/en active Active
- 2007-12-12 CA CA2671980A patent/CA2671980C/en active Active
- 2007-12-12 EP EP12167114.3A patent/EP2489667B1/en active Active
- 2007-12-12 KR KR1020147032341A patent/KR101563103B1/ko active IP Right Grant
- 2007-12-12 AU AU2007332440A patent/AU2007332440B2/en active Active
- 2007-12-12 ES ES07859852.1T patent/ES2566774T3/es active Active
- 2007-12-12 WO PCT/JP2007/074363 patent/WO2008072779A1/ja active Application Filing
- 2007-12-12 KR KR1020097014327A patent/KR101555384B1/ko active IP Right Grant
- 2007-12-12 EP EP07859852.1A patent/EP2103613B1/en active Active
- 2007-12-12 JP JP2008549397A patent/JP5578786B2/ja active Active
-
2012
- 2012-09-14 US US13/617,683 patent/US8829000B2/en active Active
-
2014
- 2014-06-04 JP JP2014115951A patent/JP5744288B2/ja active Active
- 2014-07-31 US US14/448,335 patent/US9040536B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JPWO2008072779A1 (ja) | 2010-04-02 |
US9040536B2 (en) | 2015-05-26 |
EP2848620B1 (en) | 2016-09-28 |
JP2014205686A (ja) | 2014-10-30 |
KR20140139631A (ko) | 2014-12-05 |
EP2103613A1 (en) | 2009-09-23 |
AU2007332440B2 (en) | 2013-05-16 |
ES2566774T3 (es) | 2016-04-15 |
CN101553491B (zh) | 2013-05-29 |
EP2489667A1 (en) | 2012-08-22 |
EP2103613B1 (en) | 2016-02-17 |
US20140336197A1 (en) | 2014-11-13 |
US20130225572A1 (en) | 2013-08-29 |
CN101553491A (zh) | 2009-10-07 |
CA2671980A1 (en) | 2008-06-19 |
KR101555384B1 (ko) | 2015-09-23 |
WO2008072779A1 (ja) | 2008-06-19 |
ES2599054T3 (es) | 2017-01-31 |
US20100048556A1 (en) | 2010-02-25 |
EP2489667B1 (en) | 2015-04-15 |
US8299080B2 (en) | 2012-10-30 |
AU2007332440A1 (en) | 2008-06-19 |
ES2536906T3 (es) | 2015-05-29 |
CA2671980C (en) | 2015-05-05 |
KR20090097919A (ko) | 2009-09-16 |
EP2103613A4 (en) | 2010-12-08 |
US8829000B2 (en) | 2014-09-09 |
KR101563103B1 (ko) | 2015-10-23 |
EP2848620A1 (en) | 2015-03-18 |
JP5578786B2 (ja) | 2014-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5744288B2 (ja) | キノキサリン誘導体 | |
EP2488519B1 (en) | Pyrazolopyridine derivatives as anticancer agent | |
AU2011288876B2 (en) | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | |
JP5560278B2 (ja) | キナーゼ阻害剤として有用なイミダゾピリダジンカルボニトリル | |
JP5140418B2 (ja) | チエノピリミジン誘導体 | |
CN113811300A (zh) | Tead转录因子的新型小分子抑制剂 | |
JP2012514044A (ja) | Rafキナーゼ阻害剤として有用なヘテロアリール化合物 | |
WO2017060488A1 (en) | New trpa1 antagonists | |
EP3444238B1 (en) | Process for preparing difluoromethylene compounds | |
US20080318949A1 (en) | Pyrazolopyrimidinone Derivatives, Their Preparation And Their Use | |
KR20190129034A (ko) | 금속효소 억제제 화합물 | |
EP2662367A1 (en) | Novel indole or indazole derivative or salt thereof | |
JP2023542845A (ja) | Rnaヘリカーゼdhx33を阻害する多環式化合物及びその応用 | |
EP4332101A1 (en) | Methionine adenosyltransferase inhibitor, preparation method therefor and application thereof | |
RU2650678C2 (ru) | Новые производные имидазолидин-2,4-дионов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150313 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150415 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150428 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5744288 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |